Patent Application
20220396819
The present invention relates to a method for producing a peptide having physiological activity, a peptide comprising a short linker, and the like.
In recent years, biopharmaceuticals such as antibody medicine, regenerative medicine, nucleic acid medicine, and the like have been studied and actually used as modality of medicines. In addition, medium molecules, especially peptides, are attracting attention as new modality of medicines. In particular, a number of peptides having a special shape (special peptides) such as cyclic peptides have been developed, and are expected to be applied to pharmaceuticals.
Under such circumstances, the development of dimer peptides and peptide complexes is expected to accelerate in the future. For example, regarding dimer peptides, APL-2 of Apellis Pharmaceuticals has been clinically studied as a therapeutic agent for age-related macular degeneration and the like and is expected to be put into practical use.
The dimer peptide generally has a structure in which two peptide chains are linked by a short linker, and the peptide complex generally has a structure in which a peptide chain and a drug are linked by a short linker. As such a short linker, a PEG linker is mainly used.
However, in the production of dimer peptides and peptide complexes, conventional chemical synthesis methods require chemical synthesis of peptide chains, addition of PEG linkers, and purification, and many production steps are required. In addition, if the peptide is a cyclic peptide, the peptide chain must be further cyclized. Therefore, in order to produce dimer peptides or peptide complexes by conventional chemical synthesis methods, it is necessary to go through complicated steps, which is very time-consuming. Moreover, in the conventional chemical synthesis methods, the synthesis of a dimer peptide obtained by binding a first peptide and a second peptide via a PEG linker yields a product in which the C-terminus of the first peptide binds to the linker and the C-terminus of the second peptide also binds to the linker, but cannot perform efficient synthesis of dimer peptides such that the C-terminus of the first peptide binds to the linker and the N-terminus of the second peptide binds to the linker.
In addition, the PEG linker mainly used is expensive, and it cannot be said that the conventional chemical synthesis methods are economically preferable.
Published Japanese Translation of PCT International Application No. 2013-531480 describes a drug conjugate comprising a biologically active protein and a random coil polypeptide containing an amino acid sequence composed of at least 50 proline and alanine amino acid residues. Patent Literature 1 states that the random coil polypeptide provides increased blood stability of the drug conjugate.
However, Published Japanese Translation of PCT International Application No. 2013-531480 does not specifically disclose the use of the random coil polypeptide in place of a short linker such as a PEG linker in a dimer peptide or peptide complex.
Further, in order to utilize a peptide molecule such as a dimer peptide as a pharmaceutical, it is desired not only to improve the stability of the peptide molecule such as a dimer peptide but also to maintain or improve the activity. As described above, the PEG linker is mainly used as a short linker for linking two peptide chains, and the use of the PEG linker poses a manufacturing problem, and from the viewpoint of the activity of peptide molecules such as dimer peptides, more useful short linkers are eagerly desired.
As described above, in the production of peptide molecules such as dimer peptides, the conventional chemical synthesis methods are not easy to operate and require high costs.
Therefore, an aspect of the present invention aims to provide a method for producing a peptide molecule such as a dimer peptide easily and inexpensively as compared with the conventional chemical synthesis methods.
As described above, as a short linker for linking two peptide chains, more useful short linkers are desired from the viewpoint of the activity of peptide molecules such as dimer peptides.
Therefore, an aspect of the present invention aims to provide a peptide molecule such as a dimer peptide having good activity containing a specific short linker.
The present invention may include, for example, the following aspects.
It is an aspect of the present invention to provide a peptide molecule comprising:
(I) a first physiologically active peptide portion;
(II) a linker portion composed of 49 or less amino acid residues; and
(III) a second physiologically active peptide portion located on the opposite side of the linker portion from the first physiologically active peptide portion, wherein
the first physiologically active peptide portion and the second physiologically active peptide portion may be the same as or different from each other, and
at least 90% of an amino acid sequence of the linker portion is composed of amino acid residues selected from alanine (A), proline (P), and serine (S).
It is a further aspect of the present invention to provide the peptide molecule as described above, wherein the first physiologically active peptide portion constitutes a cyclic peptide and/or the second physiologically active peptide portion constitutes a cyclic peptide.
It is a further aspect of the present invention to provide the peptide molecule as described above, wherein the first physiologically active peptide portion constitutes a cyclic peptide having a cyclic structure formed by a disulfide bond and/or the second physiologically active peptide portion constitutes a cyclic peptide having a cyclic structure formed by a disulfide bond.
It is a further aspect of the present invention to provide the peptide molecule as described above, wherein the first physiologically active peptide portion and the second physiologically active peptide portion each constitute a cyclic peptide that binds to a c-Met protein, and may be the same as or different from each other.
It is a further aspect of the present invention to provide the peptide molecule according to as described above, wherein the cyclic peptide is a cyclic peptide having a cyclic structure formed by a disulfide bond, containing an amino acid sequence selected from the following (a) to (i):
(g) a peptide in which one or two amino acid residues other than a cysteine residue are substituted, deleted, or added in any of the amino acid sequences (a) to (f), and which binds to a c-Met protein;
(h) a peptide which is composed of an amino acid sequence having 90% or more sequence identity with any of the amino acid sequences (a) to (f), but having cysteine residues at both ends, and which binds to a c-Met protein; and
(i) a peptide in which at least one amino acid other than the cysteine residues at both ends in any of the amino acid sequences (a) to (h) is modified (the amino acid modification is phosphorylation, methylation, acetylation, adenylylation, ADP-ribosylation, or glycosylation).
It is a further aspect of the present invention to provide the peptide molecule as described above, wherein the first physiologically active peptide portion and the second physiologically active peptide portion each constitute a cyclic peptide that binds to an erythropoietin receptor, and may be the same as or different from each other.
It is a further aspect of the present invention to provide the peptide molecule as described above, wherein the cyclic peptide is a cyclic peptide having a cyclic structure formed by a disulfide bond, containing an amino acid sequence selected from the following (j) to (n):
(l) a peptide in which one or two amino acid residues other than a cysteine residue are substituted, deleted, or added in the amino acid sequence of (j) or (k), and which binds to an erythropoietin receptor;
(m) a peptide which is composed of an amino acid sequence having 90% or more sequence identity with either the amino acid sequence of (j) or (k), but having a cysteine residue at the same position in (j) or (k), and which binds to an erythropoietin receptor; and
(n) a peptide in which at least one amino acid other than the cysteine residue in any of the amino acid sequences (j) to (m) is modified (the amino acid modification is phosphorylation, methylation, acetylation, adenylylation, ADP-ribosylation, or glycosylation).
It is a further aspect of the present invention to provide the peptide molecule as described above, wherein the first physiologically active peptide portion and the second physiologically active peptide portion are each composed of a physiologically active peptide that binds to a thrombopoietin receptor, and may be the same as or different from each other.
It is a further aspect of the present invention to provide the peptide molecule as described above, wherein the physiologically active peptide contains an amino acid sequence selected from the following (o) to (u):
(s) a peptide in which one or two amino acid residues other than a cysteine residue are substituted, deleted, or added in any of the amino acid sequences (o) to (r), and which binds to a thrombopoietin receptor;
(t) a peptide which is composed of an amino acid sequence having 90% or more sequence identity with any of the amino acid sequences (o) to (r), but having a cysteine residue at the same position in (p) or (q) when based on (p) or (q), and which binds to a thrombopoietin receptor; and
(u) a peptide in which at least one amino acid other than the cysteine residue in any of the amino acid sequences (o) to (t) is modified (the amino acid modification is phosphorylation, methylation, acetylation, adenylylation, ADP-ribosylation, or glycosylation).
It is a further aspect of the present invention to provide the peptide molecule as described above, further comprising: a functional modification portion at a position not adjacent to the linker portion (II).
It is a further aspect of the present invention to provide the peptide molecule as described above, wherein
the linker portion (II) is a first linker portion, and
the peptide molecule further comprising:
a second linker portion on the opposite side of the second physiologically active peptide portion from the first linker portion; and
a third physiologically active peptide portion located on the opposite side of the second linker portion from the second physiologically active peptide portion, wherein
the third physiologically active peptide portion may be the same as or different from the first physiologically active peptide portion and/or second physiologically active peptide portion, and the second linker portion is composed of 49 or less amino acid residues, and at least 90% of the amino acid sequence thereof is composed of amino acid residues selected from alanine (A), proline (P), and serine (S), which may be the same as or different from the first linker portion.
It is a further aspect of the present invention to provide the peptide molecule as described above, wherein the linker portion (II) repeatedly contains two or more amino acid sequences selected from the group consisting of AP, AAP, AS, ASP, and ASS, and if a second linker portion is present, the second linker portion repeatedly contains two or more amino acid sequences selected from the group consisting of AP, AAP, AS, ASP, and ASS.
It is a further aspect of the present invention to provide a method for producing a peptide molecule, comprising the steps of: producing the peptide molecule by expressing a polynucleotide in a host cell containing the polynucleotide encoding the peptide molecule or by expressing a polynucleotide encoding the peptide molecule in a cell-free expression system, wherein the peptide molecule contains (I) a first physiologically active peptide portion, (II) a linker portion composed of an amino acid residue, and (III) a second physiologically active peptide portion and/or an additional amino acid sequence composed of at least one amino acid residue, located on the opposite side of the linker portion from the first physiologically active peptide portion, the first physiologically active peptide portion and the second physiologically active peptide portion each have a molecular weight of 10,000 or less and are composed of 50 or less amino acid residues, and may be the same as or different from each other, and the additional amino acid sequence has a molecular weight of 10,000 or less and is composed of 50 or less amino acid residues.
It is a further aspect of the present invention to provide the production method as described above, wherein the first physiologically active peptide portion constitutes a cyclic peptide and/or the second physiologically active peptide portion constitutes a cyclic peptide.
It is a further aspect of the present invention to provide a method for producing a peptide molecule, comprising the steps of: producing the peptide molecule by expressing a polynucleotide in a host cell containing the polynucleotide encoding the peptide molecule or by expressing a polynucleotide encoding the peptide molecule in a cell-free expression system, wherein the peptide molecule contains (I) a first physiologically active peptide portion constituting a cyclic peptide, (II) a linker portion composed of an amino acid residue, and (III) a second physiologically active peptide portion and/or an additional amino acid sequence composed of at least one amino acid residue, located on the opposite side of the linker portion from the first physiologically active peptide portion, the first physiologically active peptide portion and the second physiologically active peptide portion may be the same as or different from each other, and the additional amino acid sequence has a molecular weight of 10,000 or less and is composed of 50 or less amino acid residues.
It is a further aspect of the present invention to provide the production method as described above, wherein the peptide molecule contains the second physiologically active peptide portion, and the second physiologically active peptide portion constitutes a cyclic peptide.
It is a further aspect of the present invention to provide the production method as described above, wherein the linker portion has a molecular weight of 10,000 or less and is composed of 50 or less amino acid residues.
It is a further aspect of the present invention to provide the production method as described above, wherein the linker portion is a linker portion having a molecular weight of 10,000 or less and composed of 49 or less amino acid residues, and at least 90% of the amino acid sequence thereof is composed of amino acid residues selected from alanine (A), proline (P), and serine (S).
It is a further aspect of the present invention to provide the production method as described above, wherein the linker portion repeatedly contains two or more amino acid sequences selected from the group consisting of AP, AAP, AS, ASP, and ASS.
According to an embodiment as described herein, it is possible to produce a peptide molecule such as a dimer peptide easily and inexpensively as compared with the conventional chemical synthesis methods.
According to an embodiment as described herein, it is possible to efficiently synthesize a dimer peptide such that the C-terminus of the first peptide binds to a linker and the N-terminus of the second peptide binds to a linker.
According to an embodiment as described herein, it is possible to provide a dimer peptide having good activity.
An embodiment as described herein relates to a peptide molecule. Such a peptide molecule is a peptide molecule comprising:
(I) a first physiologically active peptide portion;
(II) a linker portion composed of 49 or less amino acid residues; and
(III) a second physiologically active peptide portion located on the opposite side of the linker portion from the first physiologically active peptide portion, wherein
the first physiologically active peptide portion and the second physiologically active peptide portion may be the same as or different from each other, and
at least 90% of an amino acid sequence of the linker portion is composed of amino acid residues selected from alanine (A), proline (P), and serine (S).
In one embodiment as described herein, the peptide molecule may contain a first physiologically active peptide portion on the N-terminus side of the linker portion and a second physiologically active peptide portion on the C-terminus side of the linker portion, or may contain a first physiologically active peptide portion on the C-terminus side of the linker portion and a second physiologically active peptide portion on the N-terminus side of the linker portion. Further, in one embodiment as described herein, the peptide molecule may contain an arbitrary amino acid sequence as long as it does not inhibit the functions of the first physiologically active peptide and second physiologically active peptide on the N-terminus side and/or the C-terminus side of the first physiologically active peptide portion and/or second physiologically active peptide portion, or in the space with the linker portion. As such an arbitrary amino acid sequence, for example, a sequence useful for enhancing the expression or secretion of peptide molecules in a host cell, or a sequence for simply adjusting the length (such as 1, 2, 3, or 1 to 5 Gly) may be used.
In the peptide molecule, each amino acid may be an L-amino acid or a D-amino acid, and may be a natural type or an unnatural type. Further, in the peptide molecule, each amino acid includes an α-, β-, or γ-amino acid, and an α-amino acid is a particular example.
In one embodiment as described herein, the peptide molecule may be configured to have two or more linker portions, such as “first physiologically active peptide portion”-“linker portion”-“second physiologically active peptide portion”-“linker portion”−“arbitrary sequence” from the N-terminus side. Here, the arbitrary sequence may be a third physiologically active peptide portion (may be the same as or different from the first physiologically active peptide portion and/or second physiologically active peptide portion), or may be an additional amino acid sequence composed of at least one amino acid residue. Examples of the additional amino acid sequence include a sequence having a molecular weight of 10,000 or less and composed of 50 or less amino acid residues. Such additional amino acid sequences include enzyme identification sequences such as SortaseA identification signal and Butelase identification signal, tag sequences such as FLAG tag, PA tag, and histidine tag, reactive amino acids such as lysine, cysteine, glutamic acid, and aspartic acid, or sequences containing the reactive amino acids.
In one embodiment of the peptide molecule as described herein,
the linker portion (II) is a first linker portion, and
the peptide molecule further comprising:
a second linker portion on the opposite side of the second physiologically active peptide portion from the first linker portion; and
a third physiologically active peptide portion located on the opposite side of the second linker portion from the second physiologically active peptide portion, wherein
the third physiologically active peptide portion may be the same as or different from the first physiologically active peptide portion and/or second physiologically active peptide portion, and
the second linker portion is composed of 49 or less amino acid residues, and at least 90% of the amino acid sequence thereof is composed of amino acid residues selected from alanine (A), proline (P), and serine (S), which may be the same as or different from the first linker portion.
As used in the present specification, the term “physiologically active peptide” means a peptide that can exhibit physiological activity in a living body such as a human or an animal. Here, the “physiological activity” is a property that acts on the physiological functions of a living body, and may include both a property that enhances physiological functions and a property that suppresses physiological functions.
In the present specification, the “physiologically active peptide” includes not only a peptide itself that can exhibit physiological activity in a living body such as a human or an animal, but also a peptide that exhibits physiological activity by modification in vivo (that is, a precursor substance), and the “physiologically active peptide” may be composed of a naturally occurring amino acid sequence or may be composed of an unnaturally occurring amino acid sequence. Examples of the “physiologically active peptide” include, but are not limited to, a target-binding peptide, a target-inhibiting peptide, a target-activating peptide, and an enzyme-recognizing peptide.
As used in the present specification, the term “target-binding peptide” means a physiologically active peptide that binds to a target (mainly a protein) such as a receptor, enzyme, ion channel, or transporter (including those that start exhibiting binding property to a target or physiological activity by modification in vivo). Examples of the target-binding peptide include, but are not limited to, an albumin-binding cyclic peptide and an organ delivery cyclic peptide.
As used in the present specification, the term “target-inhibiting peptide” means a physiologically active peptide that has an action of inhibiting the biological reactions caused by activation of a target (mainly a protein) such as a receptor, enzyme, ion channel, or transporter or the physiological functions in which the target is involved. The “target-inhibiting peptide” includes not only a physiologically active peptide that, by binding to a target itself, inhibits the biological reactions caused by activation of the target or the physiological functions in which the target is involved, but also a physiologically active peptide that inhibits the biological reactions caused by activation of the target or the physiological functions in which the target is involved based on binding to a factor that binds to the target to alter the properties or shape of that factor.
As used in the present specification, the term “target-activating peptide” means a physiologically active peptide that has an action of activating a target (mainly a protein) such as a receptor, enzyme, ion channel, or transporter to cause biological reactions or an action of enhancing the physiological functions in which the target is involved (including those that start exhibiting activating effects or enhancing effects by modification in vivo). The “target-activating peptide” includes not only a physiologically active peptide that, by binding to a target itself, activates the target to cause biological reactions or enhances the physiological functions in which the target is involved, but also a physiologically active peptide that activates the target to cause biological reactions or enhances the physiological functions in which the target is involved based on binding to a factor to alter the properties or shape of that factor and making the factor start binding to the target.
Targets in the “target-binding peptide”, “target-inhibiting peptide”, and “target-activating peptide” can include receptors that are activated by dimerization, such as proliferation factor receptors, growth factor receptors, and cytokine receptors.
As used in the present specification, the term “enzyme-recognizing peptide” means a physiologically active peptide that is recognized as a substrate by enzymes (including those that start being recognized as a substrate by enzymes or start exhibiting physiological activity by modification in vivo).
In one embodiment of the peptide molecule, the molecular weights of the first physiologically active peptide portion and second physiologically active peptide portion are not particularly limited, but may be, for example, 250 or more, 500 or more, 800 or more, or 1,000 or more, and may be 10,000 or less, 9,000 or less, 8,000 or less, 7,000 or less, 6,000 or less, 5,000 or less, or 4,000 or less.
In one embodiment of the peptide molecule, the lengths of the first physiologically active peptide portion and second physiologically active peptide portion are not particularly limited, but may be, for example, each independently one composed of 3 or more, 6 or more, 10 or more, or 12 or more amino acid residues, and may be one composed of 50 or less, 45 or less, 40 or less, 35 or less, 30 or less, 25 or less, or 20 or less amino acid residues.
In one embodiment of the peptide molecule, the first physiologically active peptide portion and/or second physiologically active peptide portion may be a straight chain or a branched chain, and may constitute a cyclic peptide. The cyclic peptide in the first physiologically active peptide portion and/or second physiologically active peptide portion is not particularly limited in what kind of binding mode it has a cyclic structure, and it can form a cyclic structure, for example, by a disulfide bond between two cysteine residues, by a thioether bond (bond between a thiol group and a haloalkyl group), or by a bond of 1,2,3-triazole (bond between an azido group and an alkyne group). Note that the disulfide bond may be formed spontaneously inside or outside cells by culturing the cells, or by an enzymatic reaction by the cells.
In one embodiment of the peptide molecule, the first physiologically active peptide portion may contain two cysteine residues, or at least two cysteine residues.
In one embodiment of the peptide molecule, the second physiologically active peptide portion may contain two cysteine residues, or at least two cysteine residues.
In one embodiment of the peptide molecule, the first physiologically active peptide portion constitutes a cyclic peptide.
In one embodiment of the peptide molecule, the second physiologically active peptide portion constitutes a cyclic peptide.
When the peptide molecule has a cyclic peptide in the first physiologically active peptide portion and/or second physiologically active peptide portion, examples of the cyclic peptide include, but are not particularly limited to, FGFR binding peptide, c-Met (HGFR) binding peptide, erythropoietin receptor binding peptide, thrombopoietin receptor binding peptide, albumin binding peptide, EGFR binding peptide, VEGFR binding peptide, PDGFR binding peptide, Axl binding peptide, PDGFR binding peptide, SCFR binding peptide, Flt-3 binding peptide, c-Ret binding peptide, ROR binding peptide, Tie binding peptide, NGFR binding peptide, Insulin receptor binding peptide, EphR binding peptide, Alk binding peptide, DDR binding peptide, TGFBR binding peptide, Activin receptor binding peptide, BMP receptor binding peptide, interleukin receptor binding peptide, T-cell receptor binding peptide, transferrin receptor binding peptide, lipoprotein receptor binding peptide, ubiquitin ligase binding peptide, antibody binding peptide, complement binding peptide, GPCR binding peptide, ion channel binding peptide, virus binding peptide, and the like.
In one embodiment of the peptide molecule, the first physiologically active peptide portion and the second physiologically active peptide portion each constitute a cyclic peptide that binds to a c-Met (also referred to simply as Met) protein and may be the same as or different from each other. The cyclic peptide that binds to the c-Met protein includes, but is not limited to, a cyclic peptide having a cyclic structure formed by a disulfide bond, containing or composed of an amino acid sequence selected from the following (a) to (i):
(g) a peptide in which one or two amino acid residues other than a cysteine residue are substituted, deleted, or added in any of the amino acid sequences (a) to (f), and which binds to a c-Met protein;
(h) a peptide which is composed of an amino acid sequence having 90% or more sequence identity with any of the amino acid sequences (a) to (f), but having cysteine residues at both ends, and which binds to a c-Met protein. For example, the sequence identity may be 92% or higher, 95% or higher, or 98% or higher. Note that in the present specification, the amino acid sequence homology may be calculated by using a known analysis tool, and may be calculated, for example, by using the National Center for Biotechnology Information (NCBI) homology algorithm BLAST (Basic local alignment search tool). In addition, the default (initial setting) parameters in the analysis tool may be used to calculate the amino acid sequence homology.
(i) A peptide in which at least one amino acid other than the cysteine residues at both ends in any of the amino acid sequences (a) to (h) is modified. Here, the amino acid modification is phosphorylation, methylation, acetylation, adenylylation, ADP-ribosylation, or glycosylation.
Note that it is known Met is an HGF receptor, a tyrosine kinase type receptor, and a cyclic peptide that binds to such Met (HGFR) functions as a Met (HGFR) agonist by dimerization.
As used in the present specification, in the expression “substituted, deleted, or added”, substitution means substitution with a known amino acid, including a conservative amino acid substitution. A “conservative amino acid substitution” is a substitution in which an amino acid residue is substituted with another amino acid residue having a side chain R group with similar chemical properties (for example, charge or hydrophobicity). Examples of the amino acid groups having side chains with similar chemical properties include glycine, alanine, valine, leucine, and isoleucine having aliphatic side chains, serine and threonine having aliphatic hydroxyl side chains, asparagine and glutamine having amide-containing side chains, phenylalanine, tyrosine, and tryptophan having aromatic side chains, lysine, arginine, and histidine having basic side chains, and aspartic acid and glutamic acid having acidic side chains. Each amino acid introduced by substitution may be an L-amino acid or a D-amino acid, and may be a natural type amino acid or an unnatural type amino acid, or an amino acid that constitutes a protein in humans and animals.
As used in the present specification, in the expression “substituted, deleted, or added”, addition means that a known amino acid is added to the terminus of the amino acid sequence, or that a known amino acid is inserted between amino acid residues of the amino acid sequence. Each amino acid introduced by addition may be an L-amino acid or a D-amino acid, and may be a natural type amino acid or an unnatural type amino acid, or an amino acid that constitutes a protein in humans and animals.
In one embodiment of the peptide molecule, the first physiologically active peptide portion and the second physiologically active peptide portion each constitute a cyclic peptide that binds to an erythropoietin receptor and may be the same as or different from each other. The cyclic peptides that binds to an erythropoietin receptor includes, but is not limited to, a cyclic peptide having a cyclic structure formed by a disulfide bond, containing or composed of an amino acid sequence selected from the following (j) to (n):
(l) a peptide in which one or two amino acid residues other than a cysteine residue are substituted, deleted, or added in the amino acid sequence of (j) or (k), and which binds to an erythropoietin receptor;
(m) a peptide which is composed of an amino acid sequence having 90% or more sequence identity with either the amino acid sequence of (j) or (k), but having a cysteine residue at the same position in (j) or (k), and which binds to an erythropoietin receptor. For example, the sequence identity may be 92% or higher, 95% or higher, or 98% or higher.
(n) a peptide in which at least one amino acid other than the cysteine residue in any of the amino acid sequences (j) to (m) is modified. Here, the amino acid modification is phosphorylation, methylation, acetylation, adenylylation, ADP-ribosylation, or glycosylation.
In one embodiment of the peptide molecule, the first physiologically active peptide portion and the second physiologically active peptide portion are each composed of a physiologically active peptide that binds to a thrombopoietin receptor and may be the same as or different from each other. The physiologically active peptide that binds to a thrombopoietin receptor includes, but is not limited to, a peptide containing or composed of an amino acid sequence selected from the following (o) to (u):
(s) a peptide in which one or two amino acid residues other than a cysteine residue are substituted, deleted, or added in any of the amino acid sequences (o) to (r), and which binds to a thrombopoietin receptor;
(t) a peptide which is composed of an amino acid sequence having 90% or more sequence identity with any of the amino acid sequences (o) to (r), but having a cysteine residue at the same position in (p) or (q) when based on (p) or (q), and which binds to a thrombopoietin receptor. For example, the sequence identity may be 92% or higher, 95% or higher, or 98% or higher.
(u) a peptide in which at least one amino acid other than the cysteine residue in any of the amino acid sequences (o) to (t) is modified. Here, the amino acid modification is phosphorylation, methylation, acetylation, adenylylation, ADP-ribosylation, or glycosylation.
The peptides set forth in SEQ ID NO: 68 and SEQ ID NO: 69 are each a cyclic peptide having a cyclic structure formed by a disulfide bond.
In one embodiment of the peptide molecule, the first physiologically active peptide portion and the second physiologically active peptide portion each constitute a cyclic peptide that binds to a vascular endothelial growth factor receptor (VEGFR) and may be the same or different from each other. The cyclic peptide that binds to VEGFR includes, but is not limited to, a cyclic peptide having a cyclic structure formed by a disulfide bond, containing or composed of an amino acid sequence selected from the following (aa) to eff):
(dd) a peptide in which one or two amino acid residues other than a cysteine residue are substituted, deleted, or added in any of the amino acid sequences (aa) to (cc), and which binds to VEGFR.
(ee) a peptide which is composed of an amino acid sequence having 90% or more sequence identity with any of the amino acid sequences of (aa) to (cc), but having a cysteine residue at the same position in (aa) or (cc), and which binds to VEGFR. For example, the sequence identity may be 92% or higher, 95% or higher, or 98% or higher.
(f) a peptide in which at least one amino acid other than the cysteine residue in any of the amino acid sequences (aa) to (ee) is modified. Here, the amino acid modification is phosphorylation, methylation, acetylation, adenylylation, ADP-ribosylation, or glycosylation.
In one embodiment of the peptide molecule, the linker portion may have a molecular weight of 10,000 or less.
In one embodiment of the peptide molecule, for the linker portion, at least 90%, at least 95%, or 100% of the amino acid sequence thereof may be composed of amino acid residues selected from alanine (A), proline (P) and serine (S). The proline residues may constitute more than 4% and less than 40% in the amino acid sequence of the linker portion. For example, in the amino acid sequence of the linker portion, the proline residues may constitute more than about 4%, more than about 5%, more than about 6%, more than about 8%, more than about 10%, more than about 15%, or more than about 20%, and may constitute less than about 40% or less than about 35%. Further, the alanine residues and the serine residue may each independently constitute more than about 4%, more than about 10%, or more than about 20%, and may constitute less than about 50%.
As used in the present specification, the term “about X %” is not limited to the number X, but also includes values of additional 10% to 20% more residues, or 10% to 20% less residues. For example, the term “about 10%” also relates to 11% or 12% and 9% or 8%.
In the amino acid sequence of the linker portion, amino acid residues different from alanine, serine, and proline may be selected from, for example, the group consisting of Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Thr, Trp, Tyr, and Val as well as ones obtained by modifying these amino acids and ones obtained by adding functional groups or protecting groups to these amino acids (such as chloroacetylated amino acids, homocysteine, mercapto norvaline, mercapto norleucine, 2-amino-7-mercaptoheptanoic acid, and 2-amino-8-mercaptooctanoic acid, as well as amino acids whose protecting groups have been deprotected after the SH groups of these amino acids have been protected once, propargylglycine, homopropargylglycine, 2-amino-6-heptynoic acid, 2-amino-7-octynoic acid, 2-amino-8-nonynoic acid, 4-pentynoylated and 5-hexynoylated amino acids, azidoalanine, 2-amino-4-azidobutanoic acid, azidoptonorvaline, azidonorleucine, 2-amino-7-azidoheptanoic acid, 2-amino-8-azidooctanoic acid, azidoacetylated and 3-azidopentanoylated amino acids, N-(4-aminomethyl-benzoyl)-phenylalanine (AMBF), 4-3-aminomethyltyrosine, 5-hydroxytryptophan (WOH), N-3-chloromethylbenzoyl-L-phenylalanine, N-3-chloromethylbenzoyl-L-tyrosine, N-3-chloromethylbenzoyl-L-tryptophane). Further, each amino acid may be an L-amino acid or a D-amino acid. Such amino acid residues different from alanine, serine, and proline include ones without a hydrophobic side chain such as Val, Ile, Leu, Met, Phe, Tyr, or Trp, and/or ones without a charged side chain such as Lys, Arg, Asp, or Glu.
In one embodiment of the peptide molecule, for the linker portion, at least 90%, at least 95%, or 100% of the amino acid sequence thereof may be composed of amino acid residues selected from alanine (A) and proline (P). In this case, proline residues may constitute more than 10% and less than 75% in the amino acid sequence of the linker portion. For example, in the amino acid sequence of the linker portion, the proline residues may constitute more than about 10%, more than about 12%, more than about 14%, more than about 18%, more than about 20%, more than about 22%, more than about 23%, more than about 24%, or more than about 25%, and may constitute less than about 75%, less than about 70%, less than about 65%, less than about 60%, less than about 55%, less than about 50%, less than about 48%, less than about 46%, less than about 44%, less than about 42%, less than about 41%, less than about 40%, less than about 39%, less than about 38%, less than about 37%, less than about 36%, or less than about 35%. Further, the alanine residues may constitute more than about 25%, more than about 30%, more than about 35%, more than about 40%, more than about 45%, more than about 50%, more than about 52%, more than about 54%, more than about 56%, more than about 58%, more than about 59%, more than about 60%, more than about 61%, more than about 62%, more than about 63%, more than about 64%, or more than about 65%, and may constitute less than about 90%, less than about 88%, less than about 86%, less than about 84%, less than about 82%, less than about 80%, less than about 79%, less than about 78%, less than about 77%, less than about 76%, or less than about 75%.
In the amino acid sequence of the linker portion, the amino acid residues different from alanine, serine and proline may be selected from the group consisting of Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Thr, Trp, Tyr, and Val. Such amino acid residues different from alanine, serine, and proline include ones without a hydrophobic side chain such as Val, Ile, Leu, Met, Phe, Tyr, or Trp, and/or ones without a charged side chain such as Lys, Arg, Asp, or Glu.
In one embodiment of the peptide molecule, the linker portion contains multiple amino acid repeats, the amino acid repeats are composed of alanine (A), proline (P), and serine (S), and in the amino acid repeats, the number of consecutive identical amino acid residues may be 6 residues or less, 5 residues or less, 4 residues or less, or 3 residues or less.
In one embodiment of the peptide molecule, the linker portion contains multiple amino acid repeats, the amino acid repeats are composed of alanine (A) and proline (P), and in the amino acid repeats, the number of consecutive identical amino acid residues may be 6 residues or less, 5 residues or less, 4 residues or less, or 3 residues or less.
In one embodiment of the peptide molecule, the linker portion may repeatedly contain two or more amino acid sequences selected from the group consisting of AP, AAP, AS, ASP, and ASS.
In one embodiment of the peptide molecule, the linker portion may be composed of, for example, 5 or more, 6 or more, 7 or more, or 8 or more amino acid residues.
In one embodiment of the peptide molecule, specific examples of the linker portion include, but are not limited to, those containing any of the following amino acid sequences and those consisting of any of the following amino acid sequences: AAPAAPAP (SEQ ID NO: 74), AAPAAPAPAAPAAPAP (SEQ ID NO: 75), AAPAAPAPAAPAAPAPAAPAAPAPAAPAAPAPAAPAAPAPAAPAAPAPA (SEQ ID NO: 76), SAPSPSSAPASASAPASPASASASASPASSPASASSASPAASSASPASS (SEQ ID NO: 77), AAPAAPAPAAPAAPAPAAPA (SEQ ID NO: 7), AAPAAPAPAAPAAPAPAAPAAP (SEQ ID NO: 8), AAPAAPAPAAPAAP (SEQ ID NO: 9), AAPAAAPAPAAPAAPAPAAP (SEQ ID NO 10), AAAPAAAPAAAPAAAPAAAP (SEQ ID NO 11), AAPAAPAAPAAPAAPAAPAAPAAP (SEQ ID NO 12), APAAAPAPAAAPAPAAAPAPAAAP (SEQ ID NO 13), AAAPAAPAAPPAAAAPAAPAAPPA (SEQ ID NO 14), and APAPAPAPAPAPAPAPAPAP (SEQ ID NO 15), ASPAAPAPASPAAPAPSAPA (SEQ ID NO 16), AAPASPAPAAPSAPAPAAPS (SEQ ID NO 17), APSSPSPSAPSSPSPASPSS (SEQ ID NO 18), SAPSSPSPSAPSSPSPASPS (SEQ ID NO 19), SSPSAPSPSSPASPSPSSPA (SEQ ID NO 20), AASPAAPSAPPAAASPAAPSAPPA (SEQ ID NO 21), and ASAAAPAAASAAASAPSAAA (SEQ ID NO 22), as well as circular permutation mutant sequences thereof.
Taking AAPAAPAPAAPAAPAPAAPA (SEQ ID NO: 7) as an example, a circular permutation mutant sequence may be easily prepared, for example, by removing the first alanine of the above sequence and adding another alanine to the terminus of the above sequence. Such a circular permutation mutant sequence for SEQ ID NO: 7 is APAAPAPAAPAAPAPAAPAA (SEQ ID NO: 23). Furthermore, non-limited examples of the circular permutation mutant sequence with circularly permutated amino acid residues for SEQ ID NO: 7 include the following.
In one embodiment of the peptide molecule, the peptide molecule may further contain a functional modification portion at a position not adjacent to the linker portion.
As used in the present specification, the term “functional modification portion” means a portion in a peptide molecule that imparts some function to the peptide molecule in addition to the functions of the physiologically active peptide, and can be composed of an amino acid sequence. Examples of the functional modification portion include, but are not limited to, a stabilized sequence, a water-solubility improved sequence, an enzyme identification sequence, a tag sequence, a target binding sequence, and the like.
Specific examples of the stabilized sequence or water-solubility improved sequence include, but are not limited to, a random coil polypeptide containing an amino acid sequence composed of at least 50 proline and alanine amino acid residues as described in Published Japanese Translation of PCT International Application No. 2013-531480 (cited herein by reference to the content of that document as constituting part of the present specification), a random coil polypeptide containing an amino acid sequence composed of proline, alanine, and serine amino acid residues as described in Published Japanese Translation of PCT International Application No. 2010-531139 (cited herein by reference to the content of that document as constituting part of the present specification), and the like.
Specific examples of the enzyme identification sequence include, but are not limited to, SortaseA identification signal, Butelase identification signal, Transglutaminase identification signal, and the like.
Specific examples of the tag sequence include, but are not limited to, FLAG tags, PA tags, histidine tags, and the like.
Specific examples of the target binding sequence include, but are not limited to, small molecule antibodies such as VHH and scFv.
In one embodiment of the peptide molecule, the functional modification portion may be composed of, for example, 3 or more, 6 or more, 10 or more, or 12 or more amino acid residues, and may be composed of 1000 or less, 500 or less, 300 or less, or 150 or less amino acid residues.
An embodiment as described herein relates to a method for producing a peptide molecule. The peptide molecule produced by the production method may contain
(I) a first physiologically active peptide portion,
(II) a linker portion composed of an amino acid residue, and
(III) a second physiologically active peptide portion or an additional amino acid sequence composed of at least one amino acid residue, located on the opposite side of the linker portion from the first physiologically active peptide portion.
In one embodiment of the production method, the peptide molecule may have, but is not limited to, a structure “first physiologically active peptide portion”−“linker portion”-“second physiologically active peptide portion” from the N-terminus side or a structure “first physiologically active peptide portion”-“linker portion”-“additional amino acid sequence” from the N-terminus side, for example. In addition, the peptide molecule may be configured to have two or more linker portions, such as “first physiologically active peptide portion”-“linker portion”-“second physiologically active peptide portion”-“linker portion”-“arbitrary sequence” from the N-terminus side (so as to link three or more additional amino acid sequences in tandem, composed of the first physiologically active peptide portion as well as the second physiologically active peptide portion and/or at least one amino acid residue, via two or more linker portions). Here, the arbitrary sequence may be a physiologically active peptide portion (may be the same as the first physiologically active peptide portion and/or second physiologically active peptide portion), or may be an additional amino acid sequence composed of at least one amino acid residue.
A specific example of such a produced peptide molecule may be the above-mentioned peptide molecule comprising:
(I) a first physiologically active peptide portion;
(II) a linker portion composed of 49 or less amino acid residues; and
(III) a second physiologically active peptide portion located on the opposite side of the linker portion from the first physiologically active peptide portion, wherein
the first physiologically active peptide portion and the second physiologically active peptide portion may be the same as or different from each other, and
at least 90% of an amino acid sequence of the linker portion is composed of amino acid residues selected from alanine (A), proline (P), and serine (S).
In the peptide molecule produced by the production method, the first physiologically active peptide portion and second physiologically active peptide portion each may have a molecular weight of 10,000 or less and may be composed of 50 or less amino acid residues, and may be the same as or different from each other. Examples of the first physiologically active peptide portion and/or second physiologically active peptide portion include, but are not limited to, FGFR binding peptide, c-Met (HGFR) binding peptide, erythropoietin receptor binding peptide, thrombopoietin receptor binding peptide, albumin binding peptide, EGFR binding peptide, VEGFR binding peptide, PDGFR binding peptide, Axl binding peptide, PDGFR binding peptide, SCFR binding peptide, Flt-3 binding peptide, c-Ret binding peptide, ROR binding peptide, Tie binding peptide, NGFR binding peptide, Insulin receptor binding peptide, EphR binding peptide, Alk binding peptide, DDR binding peptide, TGFBR binding peptide, Activin receptor binding peptide, BMP receptor binding peptide, interleukin receptor binding peptide, T-cell receptor binding peptide, transferrin receptor binding peptide, lipoprotein receptor binding peptide, ubiquitin ligase binding peptide, antibody binding peptide, complement binding peptide, GPCR binding peptide, ion channel binding peptide, virus binding peptide, and the like.
In one embodiment of the production method, the molecular weights of the first physiologically active peptide portion and second physiologically active peptide portion may be, for example, 9,000 or less, 8,000 or less, 7,000 or less, 6,000 or less, 5,000 or less, or 4,000 or less, and 250 or more, 500 or more, 800 or more, or 1,000 or more.
In one embodiment of the production method, the lengths of the first physiologically active peptide portion and second physiologically active peptide portion may be, for example, each independently composed of 45 or less, 40 or less, 35 or less, 30 or less, 25 or less, or 20 or less amino acid residues, and may be composed of 3 or more, 6 or more, 10 or more, or 12 or more amino acid residues.
In one embodiment of the production method, the first physiologically active peptide portion and/or second physiologically active peptide portion may be a straight chain or a branched chain, and may constitute a cyclic peptide. The cyclic peptide in the first physiologically active peptide portion and/or second physiologically active peptide portion is not particularly limited in what kind of binding mode it has a cyclic structure, and it can form a cyclic structure, for example, by a disulfide bond between two cysteine residues, by a thioether bond (bond between a thiol group and a haloalkyl group), or by a bond of 1,2,3-triazole (bond between an azido group and an alkyne group). Note that the disulfide bond may be formed spontaneously inside or outside cells by culturing the cells, or by an enzymatic reaction by the cells.
In one embodiment of the production method, the first physiologically active peptide portion may contain two cysteine residues, or at least two cysteine residues.
In one embodiment of the production method, the second physiologically active peptide portion may contain two cysteine residues, or at least two cysteine residues.
It is considered that various cyclic peptides exist, but what kind of cyclic peptide is constituted in the first physiologically active peptide portion and/or second physiologically active peptide portion is not particularly limited.
In one embodiment of the production method, when the peptide molecule is a dimer peptide, there may be one having higher physiological activity than a monomer peptide. For example, if the peptide molecule produced by the production method is one obtained by binding two FGFR-binding cyclic peptides via a linker portion, it may have higher FGFR inhibitory activity than the case of one FGFR-binding cyclic peptide.
Specific examples of the cyclic peptide include cyclic peptides that bind to c-Met (also referred to simply as Met), but the cyclic peptide is not limited to this in the peptide molecule obtained by the production method.
cyclic peptide having a cyclic structure formed by a disulfide bond, containing or composed of an amino acid sequence selected from the following (a) to (i):
(g) a peptide in which one or two amino acid residues other than a cysteine residue are substituted, deleted, or added in any of the amino acid sequences (a) to (f), and which binds to a c-Met protein;
(h) a peptide which is composed of an amino acid sequence having 90% or more sequence identity with any of the amino acid sequences (a) to (f), but having cysteine residues at both ends, and which binds to a c-Met protein. For example, the sequence identity may be 92% or higher, 95% or higher, or 98% or higher. In the present specification, the amino acid sequence homology may be calculated by using a known analysis tool, and may be calculated, for example, by using the National Center for Biotechnology Information (NCBI) homology algorithm BLAST (Basic local alignment search tool). In addition, the default (initial setting) parameters in the analysis tool may be used to calculate the amino acid sequence homology.
(i) A peptide in which at least one amino acid other than the cysteine residues at both ends in any of the amino acid sequences (a) to (h) is modified. Here, the amino acid modification is phosphorylation, methylation, acetylation, adenylylation, ADP-ribosylation, or glycosylation.
Note that it is known Met is an HGF receptor, a tyrosine kinase type receptor, and a cyclic peptide that binds to such Met (HGFR) functions as a Met (HGFR) agonist by dimerization.
In one embodiment of the production method, the first physiologically active peptide portion and/or second physiologically active peptide portion of the peptide molecule produced may constitute a cyclic peptide that binds to an erythropoietin receptor. If both the first physiologically active peptide portion and the second physiologically active peptide portion constitute a cyclic peptide that binds to an erythropoietin receptor, the cyclic peptides may be the same as or different from each other. The cyclic peptide that binds to an erythropoietin receptor includes, but is not limited to, a cyclic peptide having a cyclic structure formed by a disulfide bond, containing or composed of an amino acid sequence selected from the following (j) to (n).
(l) a peptide in which one or two amino acid residues other than a cysteine residue are substituted, deleted, or added in the amino acid sequence of (j) or (k), and which binds to an erythropoietin receptor;
(m) a peptide which is composed of an amino acid sequence having 90% or more sequence identity with either the amino acid sequence of (j) or (k), but having a cysteine residue at the same position in (j) or (k), and which binds to an erythropoietin receptor. For example, the sequence identity may be 92% or higher, 95% or higher, or 98% or higher.
(n) A peptide in which at least one amino acid other than the cysteine residue in any of the amino acid sequences (j) to (m) is modified. Here, the amino acid modification is phosphorylation, methylation, acetylation, adenylylation, ADP-ribosylation, or glycosylation.
In one embodiment of the production method, the first physiologically active peptide portion and/or second physiologically active peptide portion of the peptide molecule produced may be composed of a physiologically active peptide that binds to a thrombopoietin receptor. If both the first physiologically active peptide portion and the second physiologically active peptide portion are composed of a physiologically active peptide that binds to a thrombopoietin receptor, the physiologically active peptides may be the same as or different from each other. The physiologically active peptide that binds to a thrombopoietin receptor includes, but is not limited to, a peptide containing or composed of an amino acid sequence selected from the following (o) to (u).
(s) a peptide in which one or two amino acid residues other than a cysteine residue are substituted, deleted, or added in any of the amino acid sequences (o) to (r), and which binds to a thrombopoietin receptor;
(t) a peptide which is composed of an amino acid sequence having 90% or more sequence identity with any of the amino acid sequences (o) to (r), but having a cysteine residue at the same position in (p) or (q) when based on (p) or (q), and which binds to a thrombopoietin receptor. For example, the sequence identity may be 92% or higher, 95% or higher, or 98% or higher.
(u) A peptide in which at least one amino acid other than the cysteine residue in any of the amino acid sequences (o) to (t) is modified. Here, the amino acid modification is phosphorylation, methylation, acetylation, adenylylation, ADP-ribosylation, or glycosylation.
The peptides set forth in SEQ ID NO: 68 and SEQ ID NO: 69 are each a cyclic peptide having a cyclic structure formed by a disulfide bond.
In one embodiment of the production method, the first physiologically active peptide portion and/or second physiologically active peptide portion of the peptide molecule produced may constitute a cyclic peptide that binds to a vascular endothelial growth factor receptor (VEGFR). If both the first physiologically active peptide portion and the second physiologically active peptide portion constitute a cyclic peptide that binds to VEGFR, the cyclic peptides may be the same as or different from each other. The cyclic peptide that binds to VEGFR includes, but is not limited to, a cyclic peptide having a cyclic structure formed by a disulfide bond, containing or composed of an amino acid sequence selected from the following (aa) to (ff).
(dd) a peptide in which one or two amino acid residues other than a cysteine residue are substituted, deleted, or added in any of the amino acid sequences (aa) to (cc), and which binds to VEGFR;
(ee) a peptide which is composed of an amino acid sequence having 90% or more sequence identity with any of the amino acid sequences of (aa) to (cc), but having a cysteine residue at the same position in (aa) or (cc), and which binds to VEGFR. For example, the sequence identity may be 92% or higher, 95% or higher, or 98% or higher.
(f) A peptide in which at least one amino acid other than the cysteine residue in any of the amino acid sequences (aa) to (ee) is modified. Here, the amino acid modification is phosphorylation, methylation, acetylation, adenylylation, ADP-ribosylation, or glycosylation.
In one embodiment of the production method, the linker portion has a molecular weight of 10,000 or less and may be composed of 50 or less amino acid residues.
Further, in one embodiment of the production method, the linker portion may be a linker portion having a molecular weight of 10,000 or less and composed of 50 or less or 49 or less amino acid residues, and at least 90%, at least 95%, or at least 100% of the amino acid sequence is composed of amino acid residues selected from alanine (A), proline (P), and serine (S). In this case, the proline residues may constitute more than 4% and less than 40% in the amino acid sequence of the linker portion. For example, in the amino acid sequence of the linker portion, the proline residues may constitute more than about 4%, more than about 5%, more than about 6%, more than about 8%, more than about 10%, more than about 15%, or more than about 20%, and may constitute less than about 40% or less than about 35%. Further, the alanine residues and the serine residue may each independently constitute more than about 4%, more than about 10%, or more than about 20%, and may constitute less than about 50%.
As used in the present specification, the term “about X %” is not limited to a concise number of percentages, but also includes values of additional 10% to 20% more residues, or 10% to 20% less residues. For example, the term “about 10%” also relates to 110% or 12% and 9% or 8%.
In the amino acid sequence of the linker portion, amino acid residues different from alanine, serine, and proline may be selected from the group consisting of Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Thr, Trp, Tyr, and Val. Such amino acid residues different from alanine, serine, and proline include ones without a hydrophobic side chain such as Val, Ile, Leu, Met, Phe, Tyr, or Trp, and/or ones without a charged side chain such as Lys, Arg, Asp, or Glu.
In one embodiment of the production method, the linker portion may be a linker portion having a molecular weight of 10,000 or less and composed of 50 or less or 49 or less amino acid residues, and at least 90%, at least 95%, or at least 100% of the amino acid sequence is composed of amino acid residues selected from alanine (A) and proline (P). In this case, proline residues may constitute more than 10% and less than 75% in the amino acid sequence of the linker portion. For example, in the amino acid sequence of the linker portion, the proline residues may constitute more than about 10%, more than about 12%, more than about 14%, more than about 18%, more than about 20%, more than about 22%, more than about 23%, more than about 24%, or more than about 25%, and may constitute less than about 75%, less than about 70%, less than about 65%, less than about 60%, less than about 55%, less than about 50%, less than about 48%, less than about 46%, less than about 44%, less than about 42%, less than about 41%, less than about 40%, less than about 39%, less than about 38%, less than about 37%, less than about 36%, or less than about 35%. Further, the alanine residues may constitute more than about 25%, more than about 30%, more than about 35%, more than about 40%, more than about 45%, more than about 50%, more than about 52%, more than about 54%, more than about 56%, more than about 58%, more than about 59%, more than about 60%, more than about 61%, more than about 62%, more than about 63%, more than about 64%, or more than about 65%, and may constitute less than about 90%, less than about 88%, less than about 86%, less than about 84%, less than about 82%, less than about 80%, less than about 79%, less than about 78%, less than about 77%, less than about 76%, or less than about 75%.
In the amino acid sequence of the linker portion, the amino acid residues different from alanine, serine and proline may be selected from the group consisting of Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Thr, Trp, Tyr, and Val. Such amino acid residues different from alanine, serine, and proline include ones without a hydrophobic side chain such as Val, Ile, Leu, Met, Phe, Tyr, or Trp, and/or ones without a charged side chain such as Lys, Arg, Asp, or Glu.
In one embodiment of the production method, the linker portion contains multiple amino acid repeats, the amino acid repeats are composed of alanine (A), proline (P), and serine (S), and in the amino acid repeats, the number of consecutive identical amino acid residues may be 6 residues or less, 5 residues or less, 4 residues or less, or 3 residues or less.
In one embodiment of the production method, the linker portion contains multiple amino acid repeats, the amino acid repeats are composed of alanine (A) and proline (P), and in the amino acid repeats, the number of consecutive identical amino acid residues may be 6 residues or less, 5 residues or less, 4 residues or less, or 3 residues or less.
In one embodiment of the production method, the linker portion may repeatedly contain two or more amino acid sequences selected from the group consisting of AP, AAP, AS, ASP, and ASS.
In one embodiment of the production method, the linker portion may contain a sequence composed of glycine (G) and serine (S). In this case, the linker portion may repeatedly contain an amino acid sequence selected from the group consisting of GGGGS, GGGS, GGS, and GS.
In one embodiment of the production method, the linker portion may repeatedly contain glycine or may be composed solely of glycine.
In one embodiment of the production method, the linker portion may repeatedly contain the amino acid sequence represented by EAAAK.
In one embodiment of the production method, the amino acid sequence of the linker portion can be, but is not limited to, one composed of A, P, and S, one composed of A and P, or one composed of a repetition of the sequence represented by GGGGS.
In one embodiment of the production method, the length of the linker portion may be composed of 50 or less amino acid residues, and for example, the linker portion may be composed of 49 or less, 40 or less, 35 or less, 30 or less, or 25 or less amino acid residues.
In one embodiment of the production method, the linker portion may be composed of 1 or more amino acid residues, and for example, the linker portion may be composed of 4 or more, 8 or more, 12 or more, or 16 or more amino acid residues.
In one embodiment of the production method, specific examples of the linker portion include, but are not limited to, those containing any of the following amino acid sequences and those consisting of any of the following amino acid sequences: AAPAAPAP (SEQ ID NO: 74), AAPAAPAPAAPAAPAP (SEQ ID NO: 75), AAPAAPAPAAPAAPAPAAPAAPAPAAPAAPAPAAPAAPAPAAPAAPAPA (SEQ ID NO: 76), SAPSPSSAPASASAPASPASASASASPASSPASASSASPAASSASPASS (SEQ ID NO: 77), AAPAAPPAAPAAPAAPAAPAPAAPAAPAPAAPAAPAPAAPAAPAPAAPAAPAPAAPAAP APAAPAAPAPAAPAAPAPAAPAAPAPAAPAAPAPAAPA (SEQ ID NO: 78), SAPSPSSAPASASAPASPASASASASPASSPASASSASPAASSASPASSSASPSAPAAPSASA APSASPASSSPAPASAPSPAAAASSPSPAPSSASSAA (SEQ ID NO: 79), AAPAAPAPAAPAAPAPAAPAAPAPAAPAAPAPAAPAAPAPAAPAAPAPAAPAAPAPAAPAAP APAAPAAPAPAAPAAPAPAAPAAPAPAAPAAPAPAAPAAPAPAAPAAPAPAAPAAPAPAAPA APAPAAPAAPAPAAPAAPAPAAPAAPAPAAPAAPAPAAPAAPAPAAPAAPAPAAPAAPAPAA PAAPAPAAPAAPAP (SEQ ID NO: 80), AAPAAPAPAAPAAPAPAAPA (SEQ ID NO: 7), AAPAAPAPAAPAAPAPAAPAAP (SEQ ID NO: 8), AAPAAPAPAAPAAP (SEQ ID NO: 9), AAPAAAPAPAAPAAPAPAAP (SEQ ID NO 10), AAAPAAAPAAAPAAAPAAAP (SEQ ID NO 11), AAPAAPAAPAAPAAPAAPAAPAAP (SEQ ID NO 12), APAAAPAPAAAPAPAAAPAPAAAP (SEQ ID NO 13), AAAPAAPAAPPAAAAPAAPAAPPA (SEQ ID NO 14), and APAPAPAPAPAPAPAPAPAP (SEQ ID NO 15), ASPAAPAPASPAAPAPSAPA (SEQ ID NO 16), AAPASPAPAAPSAPAPAAPS (SEQ ID NO 17), APSSPSPSAPSSPSPASPSS (SEQ ID NO 18), SAPSSPSPSAPSSPSPASPS (SEQ ID NO 19), SSPSAPSPSSPASPSPSSPA (SEQ ID NO 20), AASPAAPSAPPAAASPAAPSAPPA (SEQ ID NO 21), and ASAAAPAAASAAASAPSAAA (SEQ ID NO 22), as well as circular permutation mutant sequences thereof.
Taking AAPAAPAPAAPAAPAPAAPA (SEQ ID NO: 7) as an example, a circular permutation mutant sequence may be easily prepared, for example, by removing the first alanine of the above sequence and adding another alanine to the terminus of the above sequence. Such a circular permutation mutant sequence for SEQ ID NO: 7 is APAAPAPAAPAAPAPAAPAA (SEQ ID NO: 23). Furthermore, non-limited examples of the circular permutation mutant sequence with circularly permutated amino acid residues for SEQ ID NO: 7 include the following.
In one embodiment of the production method, the peptide molecule produced by the production method may contain an additional amino acid sequence composed of at least one amino acid residue on the opposite side of the linker portion from the first physiologically active peptide portion. This additional amino acid sequence has a molecular weight of 10,000 or less and is composed of 50 or less amino acid residues. Such additional amino acid sequences include enzyme identification sequences such as SortaseA identification signal and Butelase identification signal, tag sequences such as FLAG tag, PA tag, and histidine tag, reactive amino acids such as lysine, cysteine, glutamic acid, and aspartic acid, or sequences containing the reactive amino acids.
If the peptide molecule produced by the production method contains an additional amino acid sequence composed of at least one amino acid residue on the opposite side of the linker portion from the first physiologically active peptide portion, and the additional amino acid sequence is a sequence composed of a reactive amino acid or containing a reactive amino acid, the peptide molecule may be used as a conjugate reagent for preparing a physiologically active peptide-drug conjugate or the like.
The peptide molecule produced by the production method may contain a second physiologically active peptide portion and an additional amino acid sequence composed of at least one amino acid residue, on the opposite side of the linker portion from the first physiologically active peptide portion.
The peptide molecule produced by the production method may contain a first physiologically active peptide portion on the N-terminus side of the linker portion and a second physiologically active peptide portion and/or an additional amino acid sequence on the C-terminus side of the linker portion. Further, the peptide molecule produced by the production method may contain a first physiologically active peptide portion on the C-terminus side of the linker portion and a second physiologically active peptide portion and/or an additional amino acid sequence on the N-terminus side of the linker portion. Moreover, the peptide molecule produced by the production method may contain an arbitrary amino acid sequence as long as it does not inhibit the functions of the first physiologically active peptide and second physiologically active peptide on the N-terminus side and/or the C-terminus side of the first physiologically active peptide portion and/or second physiologically active peptide portion, or in the space with the linker portion. As such an arbitrary amino acid sequence, for example, a sequence useful for enhancing the expression or secretion of peptide molecules in a host cell may be used.
In one embodiment of the production method, the peptide molecule produced may further contain a functional modification portion at a position not adjacent to the linker portion. The functional modification portion is as described above.
The production method can include the step of producing the peptide molecule by expressing a polynucleotide in a host cell containing the polynucleotide encoding the peptide molecule or by expressing a polynucleotide encoding the peptide molecule in a cell-free expression system. Host cells containing polynucleotides encoding the peptide molecule may be prepared by known techniques. For example, a host cell containing a polynucleotide encoding the peptide molecule may be prepared by, e.g., introducing a recombinant vector containing the polynucleotide into the host cell.
In one embodiment of the production method, examples of host cells include, but are not limited to, prokaryotic cells (bacteria) such as genus Escherichia (such as Escherichia coli) and genus Corynebacterium (such as Corynebacterium glutamicum), fungal cells (fungi) such as yeast, plant cells, insect cells, and animal cells. As for the bacteria of the genus Corynebacterium as host cells, the ones described in WO2016/171224 can be used.
In one embodiment of the production method, expression of the polynucleotide in a host cell may be transient or stable. The conditions for culturing the host cells may be appropriately selected by those skilled in the art based on common general technical knowledge according to the type of host cells used. For example, the temperature, humidity, carbon dioxide concentration, and other conditions of the culture environment may be such that polynucleotide expression is possible in the host cells, and the culture medium used is not limited to ones suitable for each host cell and may be selected from conventionally known ones.
In one embodiment of the production method, the synthesis of the peptide molecule in the cell-free expression system may be carried out using a cell extract or using a commercially available cell-free expression reagent, and may be carried out based on a technique known to those skilled in the art. The components contained in the cell-free expression system include nucleic acids encoding the desired polypeptide as a template (DNA or mRNA), proteins required for transcription, translation, energy regeneration, and post-translational modification (such as RNA polymerase, ribosome, aminoacyl-tRNA synthetase, translation initiation factor, translation elongation factor, translation termination factor, ribosome recycling factor, nucleoside diphosphate kinase, adenosine kinase, creatine kinase, prolyl isomerase, disulfide-binding isomerase, and chaperone), tRNA, aminoacyl tRNA, natural amino acids, unnatural amino acids, NTP, buffer, and the like.
Examples of commercially available cell-free expression reagents include PUREfrex 2.0 (GeneFrontier Corporation) and PURExpress In Vitro Protein Synthesis Kit (New England BioLabs).
In producing a peptide molecule, the production method may include the steps of introducing into a host cell a polynucleotide encoding a peptide molecule or a recombinant vector containing the polynucleotide, and expressing the polynucleotide in the host cell to generate a peptide molecule. The introduction means in the introduction step may be appropriately selected by those skilled in the art based on common general technical knowledge according to the type of host cells used. The vector usable may be one capable of functionally inserting a polynucleotide encoding a peptide molecule and carrying the fragments into the host cells to result in replication and/or expression of heterologous nucleic acid fragments in the host cells, and examples thereof include plasmids, phages, cosmids, and viruses. The vector can be appropriately selected by those skilled in the art according to the type of host cells used.
In one embodiment of the production method, a polynucleotide encoding the peptide molecule may be appropriately synthesized by those skilled in the art using a conventional polynucleotide synthesis technique based on the amino acid sequence of that peptide molecule. Examples of the polynucleotide encoding the peptide molecule include one encoding a peptide molecule having a structure “first physiologically active peptide portion”-“linker portion”-“second physiologically active peptide portion” or “first physiologically active peptide portion”-“linker portion”-“additional amino acid sequence”. Peptide molecules may be easily and inexpensively produced from such polynucleotides.
In one embodiment of the production method, the polynucleotide encoding the peptide molecule may appropriately contain a promoter sequence or a signal sequence on the N-terminus side thereof. In addition, the polynucleotide may contain a restriction enzyme recognition sequence on the N-terminus side and/or the C-terminus side. Such promoter sequences, signal sequences, and restriction enzyme recognition sequences may be appropriately selected by those skilled in the art according to the type of host cells or vectors used.
In one embodiment of the production method, the produced peptide molecule may be appropriately isolated from host cells, and may be purified and/or recovered based on the common general technical knowledge of those skilled in the art.
In one embodiment of the production method, the produced peptide molecule may be appropriately isolated after being secreted from host cells, and may be purified and/or recovered based on the common general technical knowledge of those skilled in the art.
In one embodiment of the production method, a desired peptide molecule such as a dimer peptide may be expressed from a single polynucleotide chain, and a desired peptide molecule such as a dimer peptide may be produced easily and inexpensively as compared with conventional chemical synthesis methods.
In one embodiment of the production method, if the first physiologically active peptide portion and/or second physiologically active peptide portion constitutes a cyclic peptide, a straight chain peptide molecule is generated from a single polynucleotide chain, and it is possible to construct a cyclic peptide from the straight chain peptide molecule in the host cells or after secretion from the host cells. Therefore, regarding the synthesis of a peptide molecule containing a cyclic peptide, the conventional chemical synthesis methods require a large number of steps resulting in complexity, but according to the production method, a peptide molecule containing a cyclic peptide may be produced easily and inexpensively. Regarding the composition of the cyclic peptide, a cyclic structure may be formed by a disulfide bond between two cysteine residues, but is not limited thereto.
An embodiment as described herein relates to a polynucleotide for encoding a peptide molecule. The peptide molecule produced by the expression of this polynucleotide may contain (I) a first physiologically active peptide portion, (II) a linker portion composed of an amino acid residue, and (III) a second physiologically active peptide portion and/or an additional amino acid sequence composed of at least one amino acid residue, located on the opposite side of the linker portion from the first physiologically active peptide portion. Here, the first physiologically active peptide portion and second physiologically active peptide portion may be the same as or different from each other. Such polynucleotides may be appropriately synthesized by those skilled in the art using conventional polynucleotide synthesis techniques based on the amino acid sequence of the peptide molecule produced.
One embodiment of the polynucleotide may be the same as that described in relation to the production method as described herein.
In one embodiment of the polynucleotide, the polynucleotide may be for use in the production method as described above.
In one embodiment of the polynucleotide, the first physiologically active peptide portion, the linker portion composed of amino acid residues, the second physiologically active peptide portion, and the additional amino acid sequence composed of at least one amino acid residue in the peptide molecule produced by the expression of the polynucleotide may be the same as those described in relation to the production method as described above.
An embodiment as described herein relates not only to the above-mentioned peptide molecules but also to the following peptide molecules. This peptide molecule may contain (I) a first physiologically active peptide portion, (II) a linker portion composed of an amino acid residue, and (III) a second physiologically active peptide portion located on the opposite side of the linker portion from the first physiologically active peptide portion.
In one embodiment of the peptide molecule, it may contain a first physiologically active peptide portion on the N-terminus side of the linker portion and a second physiologically active peptide portion on the C-terminus side of the linker portion, or may contain a first physiologically active peptide portion on the C-terminus side of the linker portion and a second physiologically active peptide portion on the N-terminus side of the linker portion. Further, in one embodiment, the peptide molecule may contain an arbitrary amino acid sequence as long as it does not inhibit the functions of the first physiologically active peptide and second physiologically active peptide on the N-terminus side and/or the C-terminus side of the first physiologically active peptide portion and/or second physiologically active peptide portion, or in the space with the linker portion. As such an arbitrary amino acid sequence, for example, a sequence useful for enhancing the expression or secretion of peptide molecules in a host cell may be used.
In one embodiment of the peptide molecule, the first physiologically active peptide portion and second physiologically active peptide portion each constitute a cyclic peptide that binds to a c-Met protein, and may be the same as or different from each other. Such cyclic peptide that binds to a c-Met (also referred to simply as Met) protein includes a cyclic peptide having a cyclic structure formed by a disulfide bond, containing an amino acid sequence selected from the following (a) to (i).
(g) a peptide in which one or two amino acid residues other than a cysteine residue are substituted, deleted, or added in any of the amino acid sequences (a) to (f), and which binds to a c-Met protein;
(h) a peptide which is composed of an amino acid sequence having 90% or more sequence identity with any of the amino acid sequences (a) to (f), but having cysteine residues at both ends, and which binds to a c-Met protein. For example, the sequence identity may be 92% or higher, 95% or higher, or 98% or higher. In the present specification, the amino acid sequence homology may be calculated by using a known analysis tool, and may be calculated, for example, by using the National Center for Biotechnology Information (NCBI) homology algorithm BLAST (Basic local alignment search tool). In addition, the default (initial setting) parameters in the analysis tool may be used to calculate the amino acid sequence homology.
A peptide in which at least one amino acid other than the cysteine residues at both ends in any of the amino acid sequences (a) to (h) is modified. Here, the amino acid modification is phosphorylation, methylation, acetylation, adenylylation, ADP-ribosylation, or glycosylation.
Note that it is known a cyclic peptide that binds to such Met (HGFR) functions as a Met (HGFR) agonist by dimerization.
In one embodiment of the peptide molecule, the linker portion has a molecular weight of 10,000 or less and may be composed of 50 or less amino acid residues.
Further, in one embodiment of the peptide molecule, the linker portion may be a linker portion having a molecular weight of 10,000 or less and composed of 50 or less or 49 or less amino acid residues, and at least 90%, at least 95%, or at least 100% of the amino acid sequence is composed of amino acid residues selected from alanine (A), proline (P), and serine (S). In this case, the proline residues may constitute more than 4% and less than 40% in the amino acid sequence of the linker portion. For example, in the amino acid sequence of the linker portion, the proline residues may constitute more than about 4%, more than about 5%, more than about 6%, more than about 8%, more than about 10%, more than about 15%, or more than about 20%, and may constitute less than about 40% or less than about 35%. Further, the alanine residues and the serine residue may each independently constitute more than about 4%, more than about 10%, or more than about 20%, and may constitute less than about 50%.
In the amino acid sequence of the linker portion, amino acid residues different from alanine, serine, and proline may be selected from the group consisting of Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Thr, Trp, Tyr, and Val. Such amino acid residues different from alanine, serine, and proline include ones without a hydrophobic side chain such as Val, Ile, Leu, Met, Phe, Tyr, or Trp, and/or ones without a charged side chain such as Lys, Arg, Asp, or Glu.
In one embodiment of the peptide molecule, the linker portion may be a linker portion having a molecular weight of 10,000 or less and composed of 50 or less or 49 or less amino acid residues, and at least 90%, at least 95%, or at least 100% of the amino acid sequence is composed of amino acid residues selected from alanine (A) and proline (P). In this case, proline residues may constitute more than 10% and less than 75% in the amino acid sequence of the linker portion. For example, in the amino acid sequence of the linker portion, the proline residues may constitute more than about 10%, more than about 12%, more than about 14%, more than about 18%, more than about 20%, more than about 22%, more than about 23%, more than about 24%, or more than about 25%, and may constitute less than about 75%, less than about 70%, less than about 65%, less than about 60%, less than about 55%, less than about 50%, less than about 48%, less than about 46%, less than about 44%, less than about 42%, less than about 41%, less than about 40%, less than about 39%, less than about 38%, less than about 37%, less than about 36%, or less than about 35%. Further, the alanine residues may constitute more than about 25%, more than about 30%, more than about 35%, more than about 40%, more than about 45%, more than about 50%, more than about 52%, more than about 54%, more than about 56%, more than about 58%, more than about 59%, more than about 60%, more than about 61%, more than about 62%, more than about 63%, more than about 64%, or more than about 65%, and may constitute less than about 90%, less than about 88%, less than about 86%, less than about 84%, less than about 82%, less than about 80%, less than about 79%, less than about 78%, less than about 77%, less than about 76%, or less than about 75%.
In the amino acid sequence of the linker portion, the amino acid residues different from alanine, serine and proline may be selected from the group consisting of Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Thr, Trp, Tyr, and Val. Such amino acid residues different from alanine, serine, and proline include ones without a hydrophobic side chain such as Val, Ile, Leu, Met, Phe, Tyr, or Trp, and/or ones without a charged side chain such as Lys, Arg, Asp, or Glu.
In one embodiment of the peptide molecule, the linker portion contains multiple amino acid repeats, the amino acid repeats are composed of alanine (A), proline (P), and serine (S), and in the amino acid repeats, the number of consecutive identical amino acid residues may be 6 residues or less, 5 residues or less, 4 residues or less, or 3 residues or less.
In one embodiment of the peptide molecule, the linker portion contains multiple amino acid repeats, the amino acid repeats are composed of alanine (A) and proline (P), and in the amino acid repeats, the number of consecutive identical amino acid residues may be 6 residues or less, 5 residues or less, 4 residues or less, or 3 residues or less.
In one embodiment of the peptide molecule, the linker portion may repeatedly contain two or more amino acid sequences selected from the group consisting of AP, AAP, AS, ASP, and ASS.
In one embodiment of the peptide molecule, the linker portion may contain a sequence composed of glycine (G) and serine (S). In this case, the linker portion may repeatedly contain an amino acid sequence selected from the group consisting of GGGGS, GGGS, GGS, and GS.
In one embodiment of the peptide molecule, the linker portion may repeatedly contain glycine or may be composed solely of glycine.
In one embodiment of the peptide molecule, the linker portion may repeatedly contain the amino acid sequence represented by EAAAK.
In one embodiment of the peptide molecule, the amino acid sequence of the linker portion can be, but is not limited to, one composed of A, P, and S, one composed of A and P, or one composed of a repetition of the sequence represented by GGGGS.
In one embodiment of the peptide molecule, the length of the linker portion may be composed of 50 or less amino acid residues, and for example, the linker portion may be composed of 49 or less, 40 or less, 35 or less, 30 or less, or 25 or less amino acid residues.
In one embodiment of the peptide molecule, the linker portion may be composed of 1 or more amino acid residues, and for example, the linker portion may be composed of 4 or more, 8 or more, 12 or more, or 16 or more amino acid residues.
In one embodiment of the peptide molecule, specific examples of the linker portion include, but are not limited to, those containing any of the following amino acid sequences and those consisting of any of the following amino acid sequences: AAPAAPAP (SEQ ID NO: 74), AAPAAPAPAAPAAPAP (SEQ ID NO: 75), AAPAAPAPAAPAAPAPAAPAAPAPAAPAAPAPAAPAAPAPAAPAAPAPA (SEQ ID NO: 76), SAPSPSSAPASASAPASPASASASASPASSPASASSASPAASSASPASS (SEQ ID NO: 77), AAPAAPPAAPAAPAAPAAPAPAAPAAPAPAAPAAPAPAAPAAPAPAAPAAPAPAAPAAP APAAPAAPAPAAPAAPAPAAPAAPAPAAPAAPAPAAPA (SEQ ID NO: 78), SAPSPSSAPASASAPASPASASASASPASSPASASSASPAASSASPASSSASPSAPAAPSASA APSASPASSSPAPASAPSPAAAASSPSPAPSSASSAA (SEQ ID NO: 79), AAPAAPAPAAPAAPAPAAPAAPAPAAPAAPAPAAPAAPAPAAPAAPAPAAPAAPAPAAPAAP APAAPAAPAPAAPAAPAPAAPAAPAPAAPAAPAPAAPAAPAPAAPAAPAPAAPAAPAPAAPA APAPAAPAAPAPAAPAAPAPAAPAAPAPAAPAAPAPAAPAAPAPAAPAAPAPAAPAAPAPAA PAAPAPAAPAAPAP (SEQ ID NO: 80), AAPAAPAPAAPAAPAPAAPA (SEQ ID NO: 7), AAPAAPAPAAPAAPAPAAPAAP (SEQ ID NO: 8), AAPAAPAPAAPAAP (SEQ ID NO: 9), AAPAAAPAPAAPAAPAPAAP (SEQ ID NO 10), AAAPAAAPAAAPAAAPAAAP (SEQ ID NO 11), AAPAAPAAPAAPAAPAAPAAPAAP (SEQ ID NO 12), APAAAPAPAAAPAPAAAPAPAAAP (SEQ ID NO 13), AAAPAAPAAPPAAAAPAAPAAPPA (SEQ ID NO 14), and APAPAPAPAPAPAPAPAPAP (SEQ ID NO 15), ASPAAPAPASPAAPAPSAPA (SEQ ID NO 16), AAPASPAPAAPSAPAPAAPS (SEQ ID NO 17), APSSPSPSAPSSPSPASPSS (SEQ ID NO 18), SAPSSPSPSAPSSPSPASPS (SEQ ID NO 19), SSPSAPSPSSPASPSPSSPA (SEQ ID NO 20), AASPAAPSAPPAAASPAAPSAPPA (SEQ ID NO 21), and ASAAAPAAASAAASAPSAAA (SEQ ID NO 22), as well as circular permutation mutant sequences thereof.
Taking AAPAAPAPAAPAAPAPAAPA (SEQ ID NO: 7) as an example, a circular permutation mutant sequence may be easily prepared, for example, by removing the first alanine of the above sequence and adding another alanine to the terminus of the above sequence. Such a circular permutation mutant sequence for SEQ ID NO: 7 is APAAPAPAAPAAPAPAAPAA (SEQ ID NO: 23). Furthermore, non-limited examples of the circular permutation mutant sequence with circularly permutated amino acid residues for SEQ ID NO: 7 include the following.
Hereinafter, the present invention will be described in more detail by way of examples, but the present invention is not limited thereto.
Note that the HGF used in the examples are all recombinant human HGF (rhHGF, R&D Systems), and the recombinant human HGF is simply referred to as HGF in the present specification and the drawings.
The pPK6 vector described in WO2016/171224 is a vector for amplifying the tatABC gene encoding the Tat secretion system. By removing unnecessary sequences from pPK6, a shortened vector was constructed as follows.
First, pPK6 was used as a template to amplify the 5′-side of the removed region with the primers set forth in SEQ ID NO: 33 and SEQ ID NO: 34, and the 3′-side with the primers set forth in SEQ ID NO: 35 and SEQ ID NO: 36. The two amplified DNA fragments were introduced into the Sall-Sall site of pPK6 by an infusion reaction to obtain a plasmid with 548 bases removed from pPK6. This plasmid was named pPK6b.
Next, pPK6b was used as a template to amplify the 5′-side of the removed region with the primers set forth in SEQ ID NO: 37 and SEQ ID NO: 38, and the 3′-side with the primers set forth in SEQ ID NO: 39 and SEQ ID NO: 40. The two amplified DNA fragments were introduced into the ClaI-SpeI site of pPK6b by an infusion reaction to construct plasmids with 310 bases further removed from pPK6b. For the infusion reaction, In-Fusion (registered trademark) HD Cloning Kit (Takara Bio) was used, and the reaction conditions were according to the protocol recommended by the manufacturer.
In this way, an unnecessary sequence of 858 bases was removed from the pPK6 vector to construct a shortened plasmid. This vector was named pPK10.
(1-1) Outline of FBP-PAS Dimer Peptide Design
A peptide molecule with two FGFR1 binding cyclic peptides (FBPs) bound with a PAS linker is expressed as one polypeptide in C. glutamicum. Therefore, the peptide sequence was designed to be “first FBP”-“PAS linker”-“second FBP (same sequence as the above first FBP)”. That is, the C-terminus of the first FBP and the N-terminus of the PAS linker are linked to the N-terminus of the second FBP and the C-terminus of the PAS linker by an amide bond, and may be expressed in C. glutamicum as a single polypeptide chain.
(1-2) Preparation of FBP-PAS Dimer Peptide
The prepared FBP-PAS dimer peptide is as follows.
(1-3) Expression of FBP-PAS Dimer Peptide
Corynex (registered trademark) was used to examine the expression of FBP-PAS dimer peptide. Hereinafter, examples of expression examinations using Corynex (registered trademark) will be described.
(1-4) Construction of Secretory Expression Plasmid of FBP-PAS Dimer Peptide Using TorA Signal Sequence
As the FBP-PAS dimer peptide, the amino acid sequence of the above (a) FBP-PAS (which may be hereinafter referred to as “FBP-PAS”) was designed, and the base sequence encoding this protein was designed in consideration of the codon usage frequency of C. glutamicum. Furthermore, the following expression cassette was designed to enable secretion expression by C. glutamicum.
FBP-PAS was secretory-expressed as a fusion protein of FBP-PAS and a signal peptide 39 amino acid residue of TorA derived from E. coli (hereinafter referred to as “TorAss-FBP-PAS”). The base sequence and amino acid sequence encoding the designed TorAss-FBP-PAS are set forth in SEQ ID NOs: 42 and 43, respectively.
The promoter of the cspB gene derived from the C. glutamicum ATCC 13869 strain was linked upstream of the base sequence set forth in TorAss-FBP-PAS, and furthermore, an expression cassette of TorAss-FBP-PAS having a KpnI site on the 5′-side and an ApaI site on the 3′-side was designed and totally synthesized. The totally synthesized DNA fragment (TorAss-FBP-PAS expression cassette) was inserted into the KpnI-ApaI site of pPK10 described in Reference Example 1 to construct pPK10_TorAss-FBP-PAS, a secretory expression plasmid for the FBP-PAS dimer peptide using the TorA signal sequence. As a result of determining the base sequence of the inserted fragment, it was confirmed that the TorAss-FBP-PAS expression cassette as designed had been constructed. Base sequences were determined using BigDye (registered trademark) Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) and 3130 Genetic Analyzer (Applied Biosystems).
(1-5) Secretory Expression of FBP-PAS Dimer Peptide in C. glutamicum
The pPK10_TorAss-FBP-PAS constructed above was used to transform the C. glutamicum YDK0107 strain described in WO2016/171224 to obtain the YDK0107/pPK10_TorAss-FBP-PAS strain.
The obtained transformants were cultured in MMTG liquid medium containing 25 mg/L kanamycin (glucose at 120 g, magnesium sulfate heptahydrate at 3 g, ammonium sulfate at 30 g, potassium dihydrogen phosphate at 1.5 g, iron heptahydrate at 0.03 g, manganese sulfate pentahydrate at 0.03 g, thiamine hydrochloride at 0.45 mg, biotin at 0.45 mg, DL-methionine at 0.15 g, soybean hydrochloric acid hydrolyzate (total nitrogen amount at 0.2 g), calcium carbonate at 50 g, adjusted to pH 7.0 with 1 L of water) at 30° C. for 72 hours.
After completion of the culture, 6.5 μL of the culture supernatant obtained by centrifuging each culture solution was subjected to reduced SDS-PAGE using NuPAGE (registered trademark) 12% Bis-Tirs Gel (Thermo Fisher Scientific), and then stained with Quick-CBB (Wako). As a result, a protein band presumed to be FBP-PAS was detected in the culture supernatant of the YDK0107/pPK10_TorAss-FBP-PAS strain (
(1-6) Purification of FBP-PAS Dimer Peptide
The culture supernatant containing FBP-PAS obtained above was purified by dialysis in PBS (Mg—/Ca—) buffer for 2 days using a dialysis membrane (MWCO=3.5 kDa, Spectrum).
Disulfide bonds were reduced by adding 5 mM Tris(2-carboxyethyl)phosphine Hydrochloride (TCEP-HCl) to the FBP-PAS dimer peptide solution and incubating at room temperature for 48 hours. The FBP-PAS dimer peptides treated with FBP-PAS and TCEP-HCl were each mixed with α-Cyano-4-hydroxycinnamic Acid (CHCA), and the molecular weight was measured with MALDI-TOF-MS (Shimadzu, AXIMA-TOF 2).
As shown in
From these results, it was confirmed that the FBP-PAS dimer peptide expressed by Corynex (registered trademark) had a peptide sequence as designed and had a structure containing two disulfide bonds in the molecule.
The inhibitory activity of the FBP monomer peptide chemically synthesized with the FBP-PAS dimer peptide on FGFR was evaluated by luciferase assay. To 25 μL of Opti-MEM medium (Thermo Fisher Scientific), 0.6 μL of Attractene Transfection Reagent (QIAGEN) was added, and the mixture was incubated at room temperature for 5 minutes. To the above mixed solution, a mixed solution of 25 μL of Opti-MEM and 1 μL of SRE reporter vector (QIAGEN) was added, and the mixture was incubated at room temperature for 20 minutes. This mixed solution was added to a 96-well plate, over which 40,000 cell/well HEK293E cells were seeded and incubated overnight in a 5% CO2 incubator at 37° C. After transfection, all culture supernatant was removed, 100 μL of Opti-MEM medium (evaluation basal medium) containing 0.5% FBS (Thermo Fisher Scientific), 1% non-essential amino acid solution (Thermo Fisher Scientific), and penicillin-streptomycin (Nacalai Tesque) was added, and incubation was performed at 37° C. for 4 hours, and thereby the cells were starved.
FBP-PAS dimer peptide or FBP monomer peptide at 10 μM was added to the evaluation basal medium containing 0 to 10 ng/mL bFGF, and 100 μL thereof was added to the cells. The cells were stimulated by culturing overnight in a 5% CO2 incubator at 37° C.
The signal intensities were detected using Dual-Luciferase Reporter Assay System (Promega). The medium supernatant in an amount of 100 μL was removed, 50 μL of Glo reagent was added, and the cells were lysed for 10 minutes at room temperature. The luminescence of Firefly luciferase emitted from the cell lysate solution was detected with a plate reader to quantify the activation of the FGFR-Erk-SRE pathway. Subsequently, 50 μL of Glo & Stop reagent solution was added, and after 10 minutes, the luminescence of the internal standard Renilla luciferase was detected to quantify the number of cells. The signal activity of each sample was quantified as SRE activity=(Firefly luciferase luminescence intensity)/(Renilla luciferase luminescence intensity). The relative signal activity values for the samples without addition of the evaluation compound were determined and used as relative receptor activity.
As shown in
(4-1) Outline of HGF-PAS Dimer Peptide Design
It is impossible to express peptide dimer molecules of Met-linked cyclic peptide aMD4 reported in K. Ito, et al. Nat. Commun. 6, 6373, 2015, dimerized by a PEG linker, as a single polypeptide chain in C. glutamicum for the following reasons.
(1) aMD4 is cyclized by an intramolecular thioether bond formed by the reaction of the chloroacetyl groups added to the N-terminus amino groups with the sulfhydryl groups of the cysteine-side chains in the sequence, but the thioether bond cannot express in C. glutamicum.
(2) Dimerization is achieved by binding the C-terminuses of the cyclic peptides to each other using a Bis-Maleimide-PEG linker, and cannot be expressed in C. glutamicum.
Therefore, the molecule was converted as follows to design an expressible form. Regarding (1) above, the thioether bond was converted into a disulfide bond by two cysteine-side chain sulfhydryl groups. The conversion to a disulfide bond lengthened the cyclized site by 2 atoms, but by deleting the residue next to cysteine on the N-terminus side (tyrosine in the case of aMD4), the cyclized site was designed to be shortened by one atom. The above (2) was addressed by using a PAS sequence instead of the PEG linker and further designing the peptide sequence to be “first disulfide conversion aMD4”-“PAS linker”-“second disulfide conversion aMD4” so that it could be expressed as a single polypeptide chain. That is, the C-terminus of the first disulfide conversion aMD4 and the N-terminus of the PAS linker, and the N-terminus of the second disulfide conversion aMD4 and the C-terminus of the PAS linker are bound by an amide bond, and can be expressed as a single polypeptide chain.
(4-2) Preparation of HGF-PAS Dimer Peptides
The prepared HGF-PAS dimer peptides are as follows.
(4-3) Expression of HGF-PAS Dimer Peptides
The expression of these HGF-PAS dimer peptides was examined using Corynex (registered trademark). Hereinafter, examples of expression examinations using Corynex (registered trademark) will be described.
(4-4) Construction of Each Secretory Expression Plasmid of PAS-aMD4-PEG11, PAS-aMD4dY-PEG11, and PAS-aMD4-PEG3 Using TorA Signal Sequence.
As the HGF-PAS dimer peptide, three types of amino acid sequences of the above (b) PAS-aMD4-PEG11 (which may be hereinafter referred to as “PAS-aMD4-PEG11”), (c) PAS-aMD4dY-PEG11 (which may be hereinafter referred to as “PAS-aMD4dY-PEG11”), and (d) PAS-aMD4-PEG3 (which may be hereinafter referred to as “PAS-aMD4-PEG3”) were designed, and the base sequences encoding these proteins were designed in consideration of the codon usage frequency of C. glutamicum. Furthermore, the following expression cassettes were designed to enable secretory expression by C. glutamicum.
PAS-aMD4-PEG11 was secretory-expressed as a fusion protein of PAS-aMD4-PEG11 and a signal peptide 39 amino acid residue of TorA derived from E. coli (hereinafter referred to as “TorAss-PAS-aMD4-PEG11”). The base sequence and amino acid sequence encoding the designed TorAss-PAS-aMD4-PEG11 are set forth in SEQ ID NOs: 50 and 51, respectively.
PAS-aMD4dY-PEG11 was secretory-expressed as a fusion protein of PAS-aMD4dY-PEG11 and a signal peptide 39 amino acid residue of TorA derived from E. coli (hereinafter referred to as “TorAss-PAS-aMD4dY-PEG11”). The base sequence and amino acid sequence encoding the designed TorAss-PAS-aMD4dY-PEG11 are set forth in SEQ ID NOs: 52 and 53, respectively.
PAS-aMD4-PEG3 was secretory-expressed as a fusion protein of PAS-aMD4-PEG3 and a signal peptide 39 amino acid residue of TorA derived from E. coli (hereinafter referred to as “TorAss-PAS-aMD4-PEG3”). The base sequence and amino acid sequence encoding the designed TorAss-PAS-aMD4-PEG3 are set forth in SEQ ID NOs: 54 and 55, respectively.
The promoter of the cspB gene derived from the C. glutamicum ATCC 13869 strain was linked upstream of the base sequences set forth in TorAss-PAS-aMD4-PEG11, TorAss-PAS-aMD4dY-PEG11, and TorAss-PAS-aMD4-PEG3, and furthermore, an expression cassette of each HGF-PAS dimer peptide having a KpnI site on the 5′-side and an ApaI site on the 3′-side was designed and totally synthesized. The totally synthesized DNA fragment (HGF-PAS dimer peptide expression cassette) was inserted into the KpnI-ApaI site of pPK10 described in Reference Example 1 to construct pPK10_TorAss-PAS-aMD4-PEG11, pPK10_TorAss-PAS-aMD4dY-PEG11, and pPK10_TorAss-PAS-aMD4-PEG3, a secretory expression plasmid for each HGF-PAS dimer peptide using the TorA signal sequence. As a result of determining the base sequence of the inserted fragment, it was confirmed that each HGF-PAS dimer peptide expression cassette as designed had been constructed. Base sequences were determined using BigDye (registered trademark) Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) and 3130 Genetic Analyzer (Applied Biosystems).
(4-5) Secretory Expression of Each HGF-PAS Dimer Peptide in C. glutamicum
The pPK10_TorAss-PAS-aMD4-PEG11, pPK10_TorAss-PAS-aMD4dY-PEG11, and pPK10_TorAss-PAS-aMD4-PEG3 constructed above were used to transform the C. glutamicum YDK0107 strain described in WO2016/171224 to obtain the YDK0107/pPK10_TorAss-PAS-aMD4-PEG11 strain, YDK0107/pPK10_TorAss-PAS-aMD4dY-PEG11 strain, and YDK0107/pPK10_TorAss-PAS-aMD4-PEG3 strain.
The obtained transformants were each cultured in MMTG liquid medium containing 25 mg/L kanamycin (glucose at 120 g, magnesium sulfate heptahydrate at 3 g, ammonium sulfate at 30 g, potassium dihydrogen phosphate at 1.5 g, iron heptahydrate at 0.03 g, manganese sulfate pentahydrate at 0.03 g, thiamine hydrochloride at 0.45 mg, biotin at 0.45 mg, DL-methionine at 0.15 g, soybean hydrochloric acid hydrolyzate (total nitrogen amount at 0.2 g), calcium carbonate at 50 g, adjusted to pH 7.0 with 1 L of water) at 30° C. for 72 hours.
After completion of the culture, 6.5 μL of the culture supernatant obtained by centrifuging each culture solution was subjected to reduced SDS-PAGE using NuPAGE (registered trademark) 12% Bis-Tirs Gel (Thermo Fisher Scientific), and then stained with Quick-CBB (Wako). As a result, a protein band presumed to be PAS-aMD4-PEG11 was detected in the culture supernatant of the YDK0107/pPK10_TorAss-PAS-aMD4-PEG11 strain (
(4-6) Construction of Each Secretory Expression Plasmid of AET-PAS-aMD4-PEG11, AET-PAS-aMD4dY-PEG11, and AET-PAS-aMD4-PEG3 Using CspB Signal Sequence
As the HGF-PAS dimer peptide, three types of amino acid sequences of the above (e) AET-PAS-aMD4-PEG11 (which may be hereinafter referred to as “AET-PAS-aMD4-PEG11”), (f) AET-PAS-aMD4dY-PEG11 (which may be hereinafter referred to as “AET-PAS-aMD4dY-PEG11”), and (g) AET-PAS-aMD4-PEG3 (which may be hereinafter referred to as “AET-PAS-aMD4-PEG3”) were designed, and the base sequences encoding these proteins were designed in consideration of the codon usage frequency of C. glutamicum. Furthermore, the following expression cassettes were designed to enable secretory expression by C. glutamicum.
AET-PAS-aMD4-PEG11 was secretory-expressed as a fusion protein of AET-PAS-aMD4-PEG11 and a signal peptide 30 amino acid residue of CspB derived from C. glutamicum ATCC 13869 strain (hereinafter referred to as “CspBss-AET-PAS-aMD4-PEG11”). The base sequence and amino acid sequence encoding the designed CspBss-AET-PAS-aMD4-PEG11 are set forth in SEQ ID NOs: 56 and 57, respectively.
AET-PAS-aMD4dY-PEG11 was secretory-expressed as a fusion protein of AET-PAS-aMD4dY-PEG11 and a signal peptide 30 amino acid residue of CspB derived from C. glutamicum ATCC 13869 strain (hereinafter referred to as “CspBss-AET-PAS-aMD4dY-PEG11”). The base sequence and amino acid sequence encoding the designed CspBss-AET-PAS-aMD4dY-PEG11 are set forth in SEQ ID NOs: 58 and 59, respectively.
AET-PAS-aMD4-PEG3 was secretory-expressed as a fusion protein of AET-PAS-aMD4-PEG3 and a signal peptide 30 amino acid residue of CspB derived from C. glutamicum ATCC 13869 strain (hereinafter referred to as “CspBss-AET-PAS-aMD4-PEG3”). The base sequence and amino acid sequence encoding the designed CspBss-AET-PAS-aMD4-PEG3 are set forth in SEQ ID NOs: 60 and 61, respectively.
The promoter of the cspB gene derived from the C. glutamicum ATCC 13869 strain was linked upstream of the base sequences set forth in AET-PAS-aMD4-PEG11, AET-PAS-aMD4dY-PEG11, and AET-PAS-aMD4-PEG3, and furthermore, an expression cassette of each HGF-PAS dimer peptide having a KpnI site on the 5′-side and a BamHI site on the 3′-side was designed and totally synthesized. The totally synthesized DNA fragment (HGF-PAS dimer peptide expression cassette) was inserted into the KpnI-BamHI site of pPK4 described in Japanese Patent Application Publication No. Hei 9-322774 to construct pPK4_CspBss-AET-PAS-aMD4-PEG11, pPK4_CspBss-AET-PAS-aMD4dY-PEG11, and pPK4_CspBss-AET-PAS-aMD4-PEG3, a secretory expression plasmid for each HGF-PAS dimer peptide using the CspB signal sequence. As a result of determining the base sequence of the inserted fragment, it was confirmed that each HGF-PAS dimer peptide expression cassette as designed had been constructed. Base sequences were determined using BigDye (registered trademark) Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) and 3130 Genetic Analyzer (Applied Biosystems).
(4-7) Secretory Expression of Each HGF-PAS Dimer Peptide in C. glutamicum
The pPK4_CspBss-AET-PAS-aMD4-PEG11, pPK4_CspBss-AET-PAS-aMD4dY-PEG11, and pPK4_CspBss-AET-PAS-aMD4-PEG3 constructed above were used to transform the C. glutamicum YDK010::phoS(W302C) strain described in WO2016/171224 to obtain the YDK010::phoS(W302C)/pPK4_CspBss-AET-PAS-aMD4-PEG11 strain, YDK010::phoS(W302C)/pPK4_CspBss-AET-PAS-aMD4dY-PEG11 strain, and YDK010::phoS(W302C)/pPK4_CspBss-AET-PAS-aMD4-PEG3 strain.
The obtained transformants were each cultured in MMTG liquid medium containing 25 mg/L kanamycin (glucose at 120 g, magnesium sulfate heptahydrate at 3 g, ammonium sulfate at 30 g, potassium dihydrogen phosphate at 1.5 g, iron heptahydrate at 0.03 g, manganese sulfate pentahydrate at 0.03 g, thiamine hydrochloride at 0.45 mg, biotin at 0.45 mg, DL-methionine at 0.15 g, soybean hydrochloric acid hydrolyzate (total nitrogen amount at 0.2 g), calcium carbonate at 50 g, adjusted to pH 7.0 with 1 L of water) at 30° C. for 72 hours.
After completion of the culture, 6.5 μL of the culture supernatant obtained by centrifuging each culture solution was subjected to reduced SDS-PAGE using NuPAGE (registered trademark) 12% Bis-Tirs Gel (Thermo Fisher Scientific), and then stained with Quick-CBB (Wako). As a result, a protein band presumed to be AET-PAS-aMD4-PEG11 was detected in the culture supernatant of the YDK010::phoS(W302C)/pPK4_CspBss-AET-PAS-aMD4-PEG11 strain (
(4-8) Purification of HGF-PAS Dimer Peptide
The HGF-PAS dimer peptides obtained above were purified using AKTA explorer (GE Healthcare) and Superdex 75 10/300 GL columns (GE Healthcare). The culture supernatant in an amount of 1 mL was injected into the AKTA explorer, and PBS (10 mM phosphate buffer, 140 mM NaCl, pH 7.4) was allowed to flow under the condition of a flow rate of 0.5 mL/min to fractionate the protein, thereby obtaining the desired HGF-PAS dimer peptide fraction.
AET-PAS-aMD4dY-PEG11, AET-PAS-aMD4-PEG11, and AET-PAS-aMD4-PEG3 were each mixed with α-Cyano-4-hydroxycinnamic Acid (CHCA), and MALDI-TOF-MS (Shimadzu, AXIMA-TOF 2) was used to measure the molecular weights.
As shown in
The Met activation ability of the HGF-PAS dimer peptide was evaluated by luciferase assay. To 25 μL of Opti-MEM medium (Thermo Fisher Scientific), 0.6 μL of Attractene Transfection Reagent (QIAGEN) was added, and the mixture was incubated at room temperature for 5 minutes. To the above mixed solution, a mixed solution of 25 μL of Opti-MEM and 1 μL of SRE reporter vector (QIAGEN) was added, and the mixture was incubated at room temperature for 20 minutes. This mixed solution was added to a 96-well plate, over which 40,000 cell/well HEK293E cells were seeded and incubated overnight in a 5% CO2 incubator at 37° C. After transfection, all culture supernatant was removed, 100 μL of Opti-MEM medium (evaluation basal medium) containing 0.5% FBS (Thermo Fisher Scientific), 1% non-essential amino acid solution (Thermo Fisher Scientific), and penicillin-streptomycin (Nacalai Tesque) was added, and incubation was performed at 37° C. for 4 hours, and thereby the cells were starved.
To the evaluation basal medium, 0 to 200 ng/mL HGF was added, or 0 to 800 ng/mL AET-PAS-aMD4dY-PEG11, AET-PAS-aMD4-PEG11, or AET-PAS-aMD4-PEG3 was added, or a culture supernatant containing PAS-aMD4dY-PEG11, PAS-aMD4-PEG11, or PAS-aMD4-PEG3 was added so as to be diluted 10-fold with respect to the medium, and the evaluation basal medium was added in an amount of 100 μL to the cells. The cells were stimulated by culturing overnight in a 5% CO2 incubator at 37° C.
The signal intensities were detected using Dual-Luciferase Reporter Assay System (Promega). The medium supernatant in an amount of 100 μL was removed, 50 μL of Glo reagent was added, and the cells were lysed for 10 minutes at room temperature. The luminescence of Firefly luciferase emitted from the cell lysate solution was detected with a plate reader to quantify the activation of the HGF-Erk-SRE pathway. Subsequently, 50 μL of Glo & Stop reagent solution was added, and after 10 minutes, the luminescence of the internal standard Renilla luciferase was detected to quantify the number of cells. The signal activity of each sample was quantified as SRE activity=(Firefly luciferase luminescence intensity)/(Renilla luciferase luminescence intensity). The relative signal activity values for the samples without addition of the evaluation compound were determined and used as relative receptor activity.
As shown in
The receptor tyrosine kinase (RTK) specificity of the HGF-PAS dimer peptide was evaluated using Proteome Profiler Human Phospho-RTK Array Kit (R&D Systems).
HEK293E cells confluent in a 10 cm cell culture dish were starved by culturing for 24 hours in D-MEM medium containing 0.5% FBS (Thermo Fisher Scientific) and penicillin-streptomycin (Nacalai Tesque). The starved HEK293E cells were stimulated with 200 ng/mL AET-PAS-aMD4dY-PEG11 for 10 minutes. As a positive control, 100 ng/mL HGF was similarly stimulated for 10 minutes. As a negative control, PBS was added and stimulated for 10 minutes (Mock group). After removing the medium and washing the cells once with PBS, the cells were lysed by adding 1 mL of Lysis buffer 17 containing a Protease inhibitor cocktail (Nacalai Tesque). The lysate solution was centrifuged at 14,000 G for 5 minutes to obtain the supernatant as a lysate.
The lysate was analyzed using Proteome Profiler Human Phospho-RTK Array Kit. Molecular Imager ChemiDoc XRS System (Bio-Rad) was used to detect chemiluminescence. As shown in
HGF has been reported to promote cell proliferation by activating Met (K. Ito, et al. Nat. Commun. 6, 6373, 2015). Therefore, HuCCT1 cell culture was used to evaluate whether the HGF-PAS dimer peptide had the same activity of promoting cell proliferation as HGF.
RPMI 1640 medium (Nacalai Tesque) containing 5% FBS was added to a 24-well cell culture plate, and HuCCT1 cells were seeded at 5,000 cell/well. HGF at 35 ng/mL or AET-PAS-aMD4dY-PEG11 at 40 ng/mL was added, and the cells were cultured at 37° C. and 5% CO2 for 5 days. The cells were detached with 0.25% Trypsin/EDTA (Thermo Fisher Scientific) and the number of cells was quantified with Countess Automated Cell Counter (Thermo Fisher Scientific) (N=3).
As shown in
HGF has been reported to promote cell migration ability by activating Met (K. Ito, et al. Nat. Commun. 6, 6373, 2015). Therefore, HuCCT1 cell culture was used to evaluate whether the HGF-PAS dimer peptide had the same activity of promoting cell migration as HGF.
To Transwell inserts for 24-well (pore size 3.0 m, Corning), 20,000 HuCCT1 cells suspended in low serum medium (RPMI 1640 medium with 0.5% FBS) were added. A low serum medium containing 100 ng/mL HGF or 200 ng/mL AET-PAS-aMD4dY-PEG11 was added to the lower layer. After culturing for 24 hours under the conditions of 37° C. and 5% CO2, the Transwell inserts were washed 3 times with PBS and cell-fixed and stained with methanol containing 0.5% Crystal Violet (Nacalai Tesque) for 10 minutes. Immobilized and stained Transwell inserts were washed with distilled water. The cells inside the inserts were removed with a scraper. The cells migrated to the outside of the inserts and stained were photographed in the bright field observation mode of a BZ-X microscope (Keyence).
The migration ability was calculated as (area of stained region)/(insert area) and as a relative value (Relative migration efficiency) to the value of the non-added group (Mock) (N=2).
When HGF or AET-PAS-aMD4dY-PEG11 was added and cultured, the proportion of the cells migrating to the lower part of the Transwell inserts increased, and therefore it was clarified that AET-PAS-aMD4dY-PEG11 promoted cell migration as in the case of HGF.
HGF has been reported to promote cell wound healing ability by activating Met (K. Ito, et al. Nat. Commun. 6, 6373, 2015). Therefore, HuCCT1 cell culture was used to evaluate whether the HGF-PAS dimer peptide would promote wound healing as HGF.
To 96-well cell culture plates, 50,000 HuCCT1 cells suspended in RPMI 1640 medium with 10% FBS were added per well and incubated overnight under the conditions of 37° C. and 5% CO2. Cells in the center of the culture wells were scraped using a 1000 μL Thermo Scientific ART chip (Thermo Fisher Scientific) and washed with low serum medium (RPMI 1640 medium with 0.5% FBS). Low serum medium containing 33 ng/mL HGF or 100 ng/mL AET-PAS-aMD4dY-PEG11 was added, and the cells were cultured under the conditions of 37° C. and 5% CO2. BioStudio-T (Nikon Corporation) was used for cell observation, and cells were automatically photographed every hour. The rate of wound healing (μm/h) was calculated as ((wound width 1 hour after wound creation)−(wound width 7 hours after wound creation))/6 (N=4).
It is known that HGF is allowed to act on HUVEC cells and HuCCT1 cells contained in collagen gel to form a tubular structure (K. Ito, et al. Nat. Commun. 6, 6373, 2015). It has also been reported that a Met full agonist having a function similar to that of HGF can form a tubular structure in the above cells, whereas a partial agonist having only a partial function cannot promote the formation of a tubular structure (W. Miao, et al. Int. J. Mol. Sci. 19, 3141, 2018). Therefore, it was decided to confirm whether the HGF-PAS dimer peptide was a full agonist or a partial agonist by using a tubular structure formation experiment using HuCCT1 cells.
To 8 equivalents of CellMatrix type IA (Nitta Gelatin), 1 equivalent of 10-fold concentrated D-MEM/F12 (Thermo Fisher Scientific) and 1 equivalent of reconstitution buffer (22 g/L sodium bicarbonate, 47.7 g/L HEPES, 0.05N sodium hydroxide aqueous solution) were mixed in order on ice. HuCCT1 cells were added at 25,000 cells per mL of the mixture and mixed on ice. To a 48-well cell culture plate, 400 μL of the above mixture was added, and the mixture was allowed to stand for 4 hours under the conditions of 37° C. and 5% CO2 for gelation. Onto the formed intracellular encapsulated collagen gel, 500 μL of RPMI 1640 medium containing 10% FBS was added. The cell-stimulating group was cultured by adding 35 ng/mL HGF or 40 ng/mL AET-PAS-aMD4dY-PEG11. The whole medium was replaced at a frequency not exceeding 3 days. On day 7 of culture, the morphology of the cells in the collagen gel was observed with an inverted microscope.
(12-1) Outline of HGF-PAS Heterodimer Peptide Design
The Met-linked cyclic peptides aMD4 and aMD5 reported in K. Ito, et al. Nat. Commun. 6, 6373, 2015 were expressed as heterodimeric molecules. In the dimer peptide synthesis method in K. Ito, et al. Nat. Commun. 6, 6373, 2015, it is difficult to selectively synthesize a dimer peptide having “aMD4”-“linker”-“aMD5”. That is, when two types of peptides are bound via a PEG molecule, four types of dimer peptides of “aMD4”-“linker”-“aMD4”, “aMD4”-“linker”-“aMD5”, “aMD5”-“linker”-“aMD4”, and “aMD5”-“linker”-“aMD5” are produced. Therefore, in this example, the following design enables the heterodimer peptide dimerized by the PAS linker to be expressed in C. glutamicum as one polypeptide chain.
(1) aMD4 and aMD5 are cyclized by an intramolecular thioether bond formed by the reaction of the chloroacetyl groups added to the N-terminus amino groups with the sulfhydryl groups of the cysteine-side chains in the sequence, and therefore cyclized by a disulfide bond due to the sulfhydryl groups of the two cysteine side chains.
(2) Dimerization is achieved by binding the C-terminuses of the cyclic peptides to each other using a Bis-Maleimide-PEG linker, and cannot be expressed in C. glutamicum, so that the C-terminus of aMD4 and the N-terminus of aMD5 are bound with a PAS linker peptide.
With the above design, the “aMD4”-“PAS linker”-“aMD5” peptide is selectively expressed.
(12-2) Preparation of HGF-PAS Heterodimer Peptide
The prepared HGF-PAS heterodimer peptide is as follows.
(12-3) Expression of HGF-PAS Heterodimer Peptide
Corynex (registered trademark) was used to examine the expression of HGF-PAS heterodimer peptide. Hereinafter, examples of expression examinations using Corynex (registered trademark) will be described.
(12-4) Construction of Secretory Expression Plasmid of AET-PAS-aMD4_aMD5-PEG11 Using CspB Signal Sequence
As the HGF-PAS heterodimer peptide, the amino acid sequence of the above (h) AET-PAS-aMD4_aMD5-PEG11 (which may be hereinafter referred to as “AET-PAS-aMD4_aMD5-PEG11”) was designed, and the base sequence encoding this protein was designed in consideration of the codon usage frequency of C. glutamicum. Furthermore, the following expression cassette was designed to enable secretion expression by C. glutamicum.
AET-PAS-aMD4_aMD5-PEG11 was secretory-expressed as a fusion protein of AET-PAS-aMD4_aMD5-PEG11 and a signal peptide 30 amino acid residue of CspB derived from C. glutamicum ATCC 13869 strain (hereinafter referred to as “CspBss-AET-PAS-aMD4_aMD5-PEG11”). The base sequence and amino acid sequence encoding the designed CspBss-AET-PAS-aMD4_aMD5-PEG11 are set forth in SEQ ID NOs: 63 and 64, respectively.
The promoter of the cspB gene derived from the C. glutamicum ATCC 13869 strain was linked upstream of the base sequence set forth in AET-PAS-aMD4_aMD5-PEG11, and furthermore, an expression cassette of HGF-PAS heterodimer peptide having a KpnI site on the 5′-side and an BamHI site on the 3′-side was designed and totally synthesized. The totally synthesized DNA fragment (HGF-PAS heterodimer peptide expression cassette) was inserted into the KpnI-BamHI site of pPK4 described in Japanese Patent Application Publication No. Hei 9-322774 to construct pPK4_CspBss-AET-PAS-aMD4_aMD5-PEG1, a secretory expression plasmid for the HGF-PAS heterodimer peptide using the CspB signal sequence. As a result of determining the base sequence of the inserted fragment, it was confirmed that the HGF-PAS heterodimer peptide expression cassette as designed had been constructed. Base sequences were determined using BigDye (registered trademark) Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) and 3130 Genetic Analyzer (Applied Biosystems).
(12-5) Secretory Expression of HGF-PAS Heterodimer Peptide in C. glutamicum
The pPK4_CspBss-AET-PAS-aMD4_aMD5-PEG11 constructed above was used to transform the C. glutamicum YDK010::phoS(W302C) strain described in WO2016/171224 to obtain the YDK010::phoS(W302C)/pPK4_CspBss-AET-PAS-aMD4_aMD5-PEG11 strain.
The obtained transformants were each cultured in MMTG liquid medium containing 25 mg/L kanamycin (glucose at 120 g, magnesium sulfate heptahydrate at 3 g, ammonium sulfate at 30 g, potassium dihydrogen phosphate at 1.5 g, iron heptahydrate at 0.03 g, manganese sulfate pentahydrate at 0.03 g, thiamine hydrochloride at 0.45 mg, biotin at 0.45 mg, DL-methionine at 0.15 g, soybean hydrochloric acid hydrolyzate (total nitrogen amount at 0.2 g), calcium carbonate at 50 g, adjusted to pH 7.0 with 1 L of water) at 30° C. for 72 hours.
After completion of the culture, 6.5 μL of the culture supernatant obtained by centrifuging each culture solution was subjected to reduced SDS-PAGE using NuPAGE (registered trademark) 12% Bis-Tirs Gel (Thermo Fisher Scientific), and then stained with Quick-CBB (Wako). As a result, a protein band presumed to be AET-PAS-aMD4_aMD5-PEG11 was detected in the culture supernatant of the YDK010::phoS(W302C)/pPK4_CspBss-AET-PAS-aMD4_aMD5-PEG11 strain (
AET-PAS-aMD4_aMD5-PEG11 peptide expression supernatant was mixed with α-Cyano-4-hydroxycinnamic Acid (CHCA), and MALDI-TOF-MS (Shimadzu, AXIMA-TOF 2) was used to measure the molecular weight.
As shown in
(14-1) Outline of HGF-PAS Dimer Peptide Linker Variant Design
AET-PAS-aMD4dY-PEG11 with HGF-like activity has a structure in which a PAS linker composed of 22 amino acids is linked between the first aMD4dY cyclic peptide (set forth in SEQ ID NO: 2) and the second aMD4dY cyclic peptide. By changing the length of this PAS linker, it is expected that the HGF-like activity will change. Therefore, a linker variant was designed in which the PAS linker portion was changed to a PAS repeat sequence from 8 amino acids to 200 amino acids.
In addition to the PAS linker, a GS linker, which is a repeating sequence of glycine and serin, is also known as a flexible linker. Therefore, the peptide sequence was designed to be a linker variant in which aMD4dY was bound to the N-terminus and C-terminus of the GS linker composed of a repeating sequence of 4 glycine residues and 1 serine residue (GGGGS), that is, a “first aMD4dY cyclic peptide”-“GS linker”-“second aMD4dY cyclic peptide”.
(14-2) Preparation of HGF-PAS Dimer Peptide Linker Variants
The prepared HGF-PAS dimer peptide linker variants are as follows.
(14-3) Expression of HGF-PAS Dimer Peptide Linker Variants
The expression of these HGF-PAS dimer peptide linker variants was examined using Corynex (registered trademark). Hereinafter, examples of expression examinations using Corynex (registered trademark) will be described.
(14-4) Construction of Each Secretory Expression Plasmid of AET-aMD4dY-PAS8, AET-aMD4dY-PAS49, AET-aMD4dY-PAS100, AET-aMD4dY-PAS200, AET-aMD4dY-GS15, and AET-aMD4dY-GS22 Using CspB Signal Sequence
As the HGF-PAS dimer peptide linker variant, six types of amino acid sequences of the above (i) AET-aMD4dY-PAS8 (which may be hereinafter referred to as “AET-aMD4dY-PAS8”), (j) AET-aMD4dY-PAS49 (which may be hereinafter referred to as “AET-aMD4dY-PAS49”), (k) AET-aMD4dY-PAS100 (which may be hereinafter referred to as “AET-aMD4dY-PAS100”), (1) AET-aMD4dY-PAS200 (which may be hereinafter referred to as “AET-aMD4dY-PAS200”), (m) AET-aMD4dY-GS15 (which may be hereinafter referred to as “AET-aMD4dY-GS15”), and (n) AET-aMD4dY-GS22 (which may be hereinafter referred to as “AET-aMD4dY-GS22”) were designed, and base sequences encoding these proteins were designed in consideration of the codon usage frequency of C. glutamicum. Furthermore, the following expression cassettes were designed to enable secretory expression by C. glutamicum.
AET-aMD4dY-PAS8 was secretory-expressed as a fusion protein of AET-aMD4dY-PAS8 and a signal peptide 30 amino acid residue of CspB derived from C. glutamicum ATCC 13869 strain (hereinafter referred to as “CspBss-AET-aMD4dY-PAS8”). The base sequence and amino acid sequence encoding the designed CspBss-AET-aMD4dY-PAS8 are set forth in SEQ ID NOs: 87 and 88, respectively.
AET-aMD4dY-PAS49 was secretory-expressed as a fusion protein of AET-aMD4dY-PAS49 and a signal peptide 30 amino acid residue of CspB derived from C. glutamicum ATCC 13869 strain (hereinafter referred to as “CspBss-AET-aMD4dY-PAS49”). The base sequence and amino acid sequence encoding the designed CspBss-AET-aMD4dY-PAS49 are set forth in SEQ ID NOs: 89 and 90, respectively.
AET-aMD4dY-PAS100 was secretory-expressed as a fusion protein of AET-aMD4dY-PAS100 and a signal peptide 30 amino acid residue of CspB derived from C. glutamicum ATCC 13869 strain (hereinafter referred to as “CspBss-AET-aMD4dY-PAS100”). The base sequence and amino acid sequence encoding the designed CspBss-AET-aMD4dY-PAS100 are set forth in SEQ ID NOs: 91 and 92, respectively.
AET-aMD4dY-PAS200 was secretory-expressed as a fusion protein of AET-aMD4dY-PAS200 and a signal peptide 30 amino acid residue of CspB derived from C. glutamicum ATCC 13869 strain (hereinafter referred to as “CspBss-AET-aMD4dY-PAS200”). The base sequence and amino acid sequence encoding the designed CspBss-AET-aMD4dY-PAS200 are set forth in SEQ ID NOs: 93 and 93, respectively.
AET-aMD4dY-GS15 was secretory-expressed as a fusion protein of AET-aMD4dY-GS15 and a signal peptide 30 amino acid residue of CspB derived from C. glutamicum ATCC 13869 strain (hereinafter referred to as “CspBss-AET-aMD4dY-GS15”). The base sequence and amino acid sequence encoding the designed CspBss-AET-aMD4dY-GS15 are set forth in SEQ ID NOs: 95 and 96, respectively.
AET-aMD4dY-GS22 was secretory-expressed as a fusion protein of AET-aMD4dY-GS22 and a signal peptide 30 amino acid residue of CspB derived from C. glutamicum ATCC 13869 strain (hereinafter referred to as “CspBss-AET-aMD4dY-GS22”). The base sequence and amino acid sequence encoding the designed CspBss-AET-aMD4dY-GS22 are set forth in SEQ ID NOs: 97 and 98, respectively.
The promoter of the cspB gene derived from the C. glutamicum ATCC 13869 strain was linked upstream of the base sequences set forth in CspBss-AET-aMD4dY-PAS8, CspBss-AET-aMD4dY-PAS49, CspBss-AET-aMD4dY-PAS100, CspBss-AET-aMD4dY-PAS200, CspBss-AET-aMD4dY-GS15, and CspBss-AET-aMD4dY-GS22, and furthermore, an expression cassette of each HGF-PAS dimer peptide linker variant having a KpnI site on the 5′-side and an BamHI site on the 3′-side was designed and totally synthesized. The totally synthesized DNA fragment (HGF-PAS dimer peptide linker variant expression cassette) was inserted into the KpnI-BamHI site of pPK4 described in Japanese Patent Application Publication No. Hei 9-322774 to construct pPK4_CspBss-AET-aMD4dY-PAS8, pPK4_CspBss-AET-aMD4dY-PAS49, pPK4_CspBss-AET-aMD4dY-PAS100, pPK4_CspBss-AET-aMD4dY-PAS200, pPK4_CspBss-AET-aMD4dY-GS15, and pPK4_CspBss-AET-aMD4dY-GS22, a secretory expression plasmid for each HGF-PAS dimer peptide linker variant using the CspB signal sequence. As a result of determining the base sequence of the inserted fragment, it was confirmed that each HGF-PAS dimer peptide linker variant expression cassette as designed had been constructed. Base sequences were determined using BigDye (registered trademark) Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) and 3500xL Genetic Analyzer (Applied Biosystems).
In addition, pPK4_CspBss-AET-PAS-aMD4dY-PEG11 was constructed in the same manner as above, and its construction was confirmed. AET-PAS-aMD4dY-PEG11 is from Example 4 and has a PAS linker composed of 22 amino acids.
(14-5) Secretory Expression of Each HGF-PAS Dimer Peptide in C. glutamicum
The pPK4_CspBss-AET-aMD4dY-PAS8, pPK4_CspBss-AET-aMD4dY-PAS49, pPK4_CspBss-AET-aMD4dY-PAS100, pPK4_CspBss-AET-aMD4dY-PAS200, pPK4_CspBss-AET-aMD4dY-GS15, and pPK4_CspBss-AET-aMD4dY-GS22 constructed above were used to transform the C. glutamicum YDK010::phoS(W302C) strain described in WO2016/171224 to obtain the YDK010::phoS(W302C)/pPK4_CspBss-AET-aMD4dY-PAS8 strain, YDK010::phoS(W302C)/pPK4_CspBss-AET-aMD4dY-PAS49 strain, YDK010::phoS(W302C)/pPK4_CspBss-AET-aMD4dY-PAS100 strain, YDK010::phoS(W302C)/pPK4_CspBss-AET-aMD4dY-PAS200 strain, YDK010::phoS(W302C)/pPK4_CspBss-AET-aMD4dY-GS15 strain, and YDK010::phoS(W302C)/pPK4_CspBss-AET-aMD4dY-GS22 strain.
The obtained transformants were each cultured in MMTG liquid medium containing 25 mg/L kanamycin (glucose at 120 g, magnesium sulfate heptahydrate at 3 g, ammonium sulfate at 30 g, potassium dihydrogen phosphate at 1.5 g, iron heptahydrate at 0.03 g, manganese sulfate pentahydrate at 0.03 g, thiamine hydrochloride at 0.45 mg, biotin at 0.45 mg, DL-methionine at 0.15 g, soybean hydrochloric acid hydrolyzate (total nitrogen amount at 0.2 g), calcium carbonate at 50 g, adjusted to pH 7.0 with 1 L of water) at 30° C. for 72 hours.
After completion of the culture, 6.5 μL of the culture supernatant obtained by centrifuging each culture solution was subjected to reduced SDS-PAGE using NuPAGE (registered trademark) 12% Bis-Tirs Gel (Thermo Fisher Scientific), and then stained with Quick-CBB (Wako). As a result, a protein band presumed to be AET-aMD4dY-PAS8 was detected in the culture supernatant of the YDK010::phoS(W302C)/pPK4_CspBss-AET-aMD4dY-PAS8 strain (
In addition, the YDK010::phoS(W302C)/pPK4_CspBss-AET-PAS-aMD4dY-PEG11 strain obtained by the same method as above was cultured in the same manner as above, and a protein band presumed to be AET-PAS-aMD4dY-PEG11 (hereinafter also referred to as “AET-aMD4dY-PAS22”) was detected in the culture supernatant (
When comparing 22 residues with the same linker length, AET-aMD4dY-PAS22 (
The cell filtrate of each HGF-PAS dimer peptide after culturing in Example 14 was subjected to molecular weight measurement using LC-MS (Waters, ACQUITY UPLC H-Class/SQD2). The analysis conditions are shown in Table 2.
As shown in
The Met activation ability of the HGF-PAS dimer peptide linker variant was evaluated by luciferase assay. To 25 μL of Opti-MEM medium (Thermo Fisher Scientific), 0.6 L of Attractene Transfection Reagent (QIAGEN) was added, and the mixture was incubated at room temperature for 5 minutes. To the above mixed solution, a mixed solution of 25 μL of Opti-MEM and 1 μL of SRE reporter vector (QIAGEN) was added, and the mixture was incubated at room temperature for 20 minutes. This mixed solution was added to a 96-well plate, over which 40,000 cell/well HEK293E cells were seeded and incubated overnight in a 5% CO2 incubator at 37° C. After transfection, all culture supernatant was removed, 100 μL of Opti-MEM medium (evaluation basal medium) containing 0.5% FBS (Thermo Fisher Scientific), 1% non-essential amino acid solution (Thermo Fisher Scientific), and penicillin-streptomycin (Nacalai Tesque) was added, and incubation was performed at 37° C. for 4 hours, and thereby the cells were starved.
To the evaluation basal medium, 0 to 100 ng/mL HGF was added, or a culture supernatant containing AET-aMD4dY-PAS8, AET-aMD4dY-PAS22 (the same molecule as AET-PAS-aMD4dY-PEG11), AET-aMD4dY-PAS49, AET-aMD4dY-PAS100, AET-aMD4dY-PAS200, AET-aMD4dY-GS15, or AET-aMD4dY-GS22 was added to the medium so as to be diluted at a predetermined ratio, and the evaluation basal medium was added in an amount of 100 μL to the cells. The cells were stimulated by culturing overnight in a 5% CO2 incubator at 37° C.
The signal intensities were detected using Dual-Luciferase Reporter Assay System (Promega). The medium supernatant in an amount of 100 μL was removed, 50 μL of Glo reagent was added, and the cells were lysed for 10 minutes at room temperature. The luminescence of Firefly luciferase emitted from the cell lysate solution was detected with a plate reader to quantify the activation of the HGF-Erk-SRE pathway. Subsequently, 50 μL of Glo & Stop reagent solution was added, and after 10 minutes, the luminescence of the internal standard Renilla luciferase was detected to quantify the number of cells. The signal activity of each sample was quantified as SRE activity=(Firefly luciferase luminescence intensity)/(Renilla luciferase luminescence intensity). The relative signal activity values for the samples without addition of the evaluation compound were determined and used as relative receptor activity.
As shown in
(17-1) Outline of Design
The HGF-PAS peptide with enhanced stability was designed as follows. As a method for enhancing the stability of peptides and proteins, a method for adding a long-chain PAS sequence has been reported (Published Japanese Translation of PCT International Application No. 2013-531480 and Published Japanese Translation of PCT International Application No. 2010-531139). As an HGF-PAS peptide with enhanced stability, a peptide was designed in which a PAS sequence composed of 200 amino acids (PAS200) was bound to the C-terminus of AET-aMD4dY-PAS22 (the same molecule as AET-PAS-aMD4dY-PEG11). That is, the peptide sequence was designed to be “first aMD4dY cyclic peptide”-“PAS linker”-“second aMD4dY cyclic peptide”-“long-chain PAS sequence (PAS200)”.
(17-2) Preparation of Stabilized HGF-PAS Dimer Peptide
The prepared stabilized HGF-PAS dimer peptide is as follows.
(17-3) Expression of Stabilized HGF-PAS Dimer Peptide
Corynex (registered trademark) was used to examine the expression of stabilized HGF-PAS dimer peptide. Hereinafter, examples of expression examinations using Corynex (registered trademark) will be described.
(17-4) Construction of Secretory Expression Plasmid of AET-aMD4dY-PAS22-PAS200 Using CspB Signal Sequence
As the stabilized HGF-PAS dimer peptide, the amino acid sequence of the above (a) AET-aMD4dY-PAS22-PAS200 (which may be hereinafter referred to as “AET-aMD4dY-PAS22-PAS200”) was designed, and the base sequence encoding this protein was designed in consideration of the codon usage frequency of C. glutamicum. Furthermore, the following expression cassette was designed to enable secretion expression by C. glutamicum.
AET-aMD4dY-PAS22-PAS200 was secretory-expressed as a fusion protein of AET-aMD4dY-PAS22-PAS200 and a signal peptide 30 amino acid residue of CspB derived from C. glutamicum ATCC 13869 strain (hereinafter referred to as “CspBss-AET-aMD4dY-PAS22-PAS200”). The base sequence and amino acid sequence encoding the designed CspBss-AET-aMD4dY-PAS22-PAS200 are set forth in SEQ ID NOs: 100 and 101, respectively.
The promoter of the cspB gene derived from the C. glutamicum ATCC 13869 strain was linked upstream of the base sequence set forth in CspBss-AET-aMD4dY-PAS22-PAS200, and furthermore, an expression cassette of stabilized HGF-PAS dimer peptide having a KpnI site on the 5′-side and an BamHI site on the 3′-side was designed and totally synthesized. The totally synthesized DNA fragment (stabilized HGF-PAS dimer peptide expression cassette) was inserted into the KpnI-BamHI site of pPK4 described in Japanese Patent Application Publication No. Hei 9-322774 to construct pPK4_CspBss-AET-aMD4dY-PAS22-PAS200, a secretory expression plasmid for the stabilized HGF-PAS dimer peptide using the CspB signal sequence. As a result of determining the base sequence of the inserted fragment, it was confirmed that the stabilized HGF-PAS dimer peptide expression cassette as designed had been constructed. Base sequences were determined using BigDye (registered trademark) Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) and 3500xL Genetic Analyzer (Applied Biosystems).
(17-5) Secretory Expression of Stabilized HGF-PAS Dimer Peptide in C. glutamicum
The pPK4_CspBss-AET-aMD4dY-PAS22-PAS200 constructed above was used to transform the C. glutamicum YDK010::phoS(W302C) strain described in WO2016/171224 to obtain the YDK010::phoS(W302C)/pPK4_CspBss-AET-aMD4dY-PAS22-PAS200 strain.
The obtained transformants were cultured in MMTG liquid medium containing 25 mg/L kanamycin (glucose at 120 g, magnesium sulfate heptahydrate at 3 g, ammonium sulfate at 30 g, potassium dihydrogen phosphate at 1.5 g, iron heptahydrate at 0.03 g, manganese sulfate pentahydrate at 0.03 g, thiamine hydrochloride at 0.45 mg, biotin at 0.45 mg, DL-methionine at 0.15 g, soybean hydrochloric acid hydrolyzate (total nitrogen amount at 0.2 g), calcium carbonate at 50 g, adjusted to pH 7.0 with 1 L of water) at 30° C. for 72 hours.
After completion of the culture, 6.5 μL of the culture supernatant obtained by centrifuging each culture solution was subjected to reduced SDS-PAGE using NuPAGE (registered trademark) 4 to 12% Bis-Tirs Gel (Thermo Fisher Scientific), and then stained with Quick-CBB (Wako). As a result, a protein band presumed to be AET-aMD4dY-PAS22-PAS200 was detected in the culture supernatant of the YDK010::phoS(W302C)/pPK4_CspBss-AET-aMD4dY-PAS22-PAS200 strain (
The cell filtrate of the stabilized HGF-PAS dimer peptide after culturing in Example 17 was subjected to molecular weight measurement using LC-MS (Waters, ACQUITY UPLC H-Class/SQD2). The analysis conditions are shown in Table 2. As shown in
The Met activation ability of the stabilized HGF-PAS dimer peptide was evaluated by luciferase assay. To 25 μL of Opti-MEM medium (Thermo Fisher Scientific), 0.6 L of Attractene Transfection Reagent (QIAGEN) was added, and the mixture was incubated at room temperature for 5 minutes. To the above mixed solution, a mixed solution of 25 μL of Opti-MEM and 1 μL of SRE reporter vector (QIAGEN) was added, and the mixture was incubated at room temperature for 20 minutes. This mixed solution was added to a 96-well plate, over which 40,000 cell/well HEK293E cells were seeded and incubated overnight in a 5% CO2 incubator at 37° C. After transfection, all culture supernatant was removed, 100 μL of Opti-MEM medium (evaluation basal medium) containing 0.5% FBS (Thermo Fisher Scientific), 1% non-essential amino acid solution (Thermo Fisher Scientific), and penicillin-streptomycin (Nacalai Tesque) was added, and incubation was performed at 37° C. for 4 hours, and thereby the cells were starved.
To the evaluation basal medium, 0 to 100 ng/mL HGF was added, or a culture supernatant containing AET-aMD4dY-PAS22-PAS200 was added to the medium so as to be diluted at a predetermined ratio, and the evaluation basal medium was added in an amount of 100 μL to the cells. The cells were stimulated by culturing overnight in a 5% CO2 incubator at 37° C.
The signal intensities were detected using Dual-Luciferase Reporter Assay System (Promega). The medium supernatant in an amount of 100 μL was removed, 50 μL of Glo reagent was added, and the cells were lysed for 10 minutes at room temperature. The luminescence of Firefly luciferase emitted from the cell lysate solution was detected with a plate reader to quantify the activation of the HGF-Erk-SRE pathway. Subsequently, 50 μL of Glo & Stop reagent solution was added, and after 10 minutes, the luminescence of the internal standard Renilla luciferase was detected to quantify the number of cells. The signal activity of each sample was quantified as SRE activity=(Firefly luciferase luminescence intensity)/(Renilla luciferase luminescence intensity). The relative signal activity values for the samples without addition of the evaluation compound were determined and used as relative receptor activity.
As shown in
(20-1) Outline of Design
Peginesatide has been reported as an erythropoietin mimetic peptide. Pedinesatide has a structure in which a lysine is added to the C-terminus of an erythropoietin receptor-binding peptide and ε-amino groups are bound to each other with a dicarboxylic acid linker linked by a long-chain PEG. However, expression of Peginesatide in C. glutamicum as a single polypeptide chain cannot be performed for the following reasons.
(1) Peginesatide contains unnatural amino acids, and peptides containing unnatural amino acids cannot be expressed in C. glutamicum.
(2) Peptides containing a dicarboxylic acid linker cannot be expressed in C. glutamicum.
(3) Dimerization is achieved by binding the C-terminuses of two cyclic peptide molecules with the ε-amino group of lysine, but a structure with C-terminuses bound to each other and a structure with the ε-amino group of lysine and another amino acid forming an amide bond cannot be expressed in C. glutamicum.
Therefore, the molecule was converted as follows to design an expressible form. The above (1) can be expressed by using an erythropoietin receptor-binding cyclic peptide (U.S. Pat. No. 5,773,569A) that does not contain an unnatural amino acid. The above (2) can be expressed by using a peptidic linker. Regarding (3) above, the N-terminus of one cyclic peptide and the C-terminus of the other peptide were bound to each other using a PAS sequence instead of the C-terminuses of the cyclic peptides. That is, the obstacles were dealt with by designing the peptide sequence to be “first erythropoietin receptor-binding cyclic peptide”-“PAS linker”-“second erythropoietin receptor-binding cyclic peptide”. That is, the C-terminus of the first erythropoietin receptor-binding cyclic peptide and the N-terminus of the PAS linker are linked by an amide bond to the N-terminus of the second erythropoietin receptor-binding cyclic peptide and the C-terminus of the PAS linker, respectively, and the peptide chain can be expressed as a single polypeptide chain.
(20-2) Preparation of EPO-PAS Dimer Peptides
The prepared EPO-PAS dimer peptides are as follows.
(20-3) Expression of EPO-PAS Dimer Peptides
The expression of these EPO-PAS dimer peptides was examined using Corynex (registered trademark). Hereinafter, examples of expression examinations using Corynex (registered trademark) will be described.
(20-4) Construction of EPO-PAS8 and EPO-PAS22 Secretory Expression Plasmids Using CspA Signal Sequence
As the EPO-PAS dimer peptide, two types of amino acid sequences of the above (p) EPO-PAS8 (which may be hereinafter referred to as “EPO-PAS8”) and (q) EPO-PAS22 (which may be hereinafter referred to as “EPO-PAS22”) were designed, and the base sequences encoding these proteins were designed in consideration of the codon usage frequency of C. glutamicum. Furthermore, the following expression cassettes were designed to enable secretory expression by C. glutamicum.
EPO-PAS8 was secretory-expressed as a fusion protein of EPO-PAS8 and a signal peptide 25 amino acid residue of CspA derived from C. ammoniagenes ATCC 6872 strain (hereinafter referred to as “CspAss-EPO-PAS8”). The base sequence and amino acid sequence encoding the designed CspAss-EPO-PAS8 are set forth in SEQ ID NOs: 106 and 107, respectively.
EPO-PAS22 was secretory-expressed as a fusion protein of EPO-PAS22 and a signal peptide 25 amino acid residue of CspA derived from C. ammoniagenes ATCC 6872 strain (hereinafter referred to as “CspAss-EPO-PAS22”). The base sequence and amino acid sequence encoding the designed CspAss-EPO-PAS22 are set forth in SEQ ID NOs: 108 and 109, respectively.
The promoter of the cspB gene derived from the C. glutamicum ATCC 13869 strain was linked upstream of the base sequences set forth in CspAss-EPO-PAS8 and CspAss-EPO-PAS22, and furthermore, an expression cassette of each EPO-PAS dimer peptide having a KpnI site on the 5′-side and an BamHI site on the 3′-side was designed and totally synthesized. The totally synthesized DNA fragment (EPO-PAS dimer peptide expression cassette) was inserted into the KpnI-BamHI site of pPK4 described in Japanese Patent Application Publication No. Hei 9-322774 to construct pPK4_CspAss-EPO-PAS8 and pPK4_CspAss-EPO-PAS22, a secretory expression plasmid for each EPO-PAS dimer peptide using the CspA signal sequence. As a result of determining the base sequence of the inserted fragment, it was confirmed that each EPO-PAS dimer peptide expression cassette as designed had been constructed. Base sequences were determined using BigDye (registered trademark) Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) and 3500xL Genetic Analyzer (Applied Biosystems).
(20-5) Construction of each secretory expression plasmid of AET-EPO-PAS8 and AET-EPO-PAS22 using CspB signal sequence
As the EPO-PAS dimer peptide, two types of amino acid sequences of the above (r) AET-EPO-PAS8 (which may be hereinafter referred to as “AET-EPO-PAS8”) and (s) AET-EPO-PAS22 (which may be hereinafter referred to as “AET-EPO-PAS22”) were designed, and the base sequences encoding these proteins were designed in consideration of the codon usage frequency of C. glutamicum. Furthermore, the following expression cassettes were designed to enable secretory expression by C. glutamicum.
AET-EPO-PAS8 was secretory-expressed as a fusion protein of AET-EPO-PAS8 and a signal peptide 30 amino acid residue of CspB derived from C. glutamicum ATCC 13869 strain (hereinafter referred to as “CspBss-AET-EPO-PAS8”). The base sequence and amino acid sequence encoding the designed CspBss-AET-EPO-PAS8 are set forth in SEQ ID NOs: 110 and 111, respectively.
AET-EPO-PAS22 was secretory-expressed as a fusion protein of AET-EPO-PAS22 and a signal peptide 30 amino acid residue of CspB derived from C. glutamicum ATCC 13869 strain (hereinafter referred to as “CspBss-AET-EPO-PAS22”). The base sequence and amino acid sequence encoding the designed CspBss-AET-EPO-PAS22 are set forth in SEQ ID NOs: 112 and 113, respectively.
The promoter of the cspB gene derived from the C. glutamicum ATCC 13869 strain was linked upstream of the base sequences set forth in CspBss-AET-EPO-PAS8 and CspBss-AET-EPO-PAS22, and furthermore, an expression cassette of each EPO-PAS dimer peptide having a KpnI site on the 5′-side and an BamHI site on the 3′-side was designed and totally synthesized. The totally synthesized DNA fragment (EPO-PAS dimer peptide expression cassette) was inserted into the KpnI-BamHI site of pPK4 described in Japanese Patent Application Publication No. Hei 9-322774 to construct pPK4_CspBss-AET-EPO-PAS8 and pPK4_CspBss-AET-EPO-PAS22, a secretory expression plasmid for each EPO-PAS dimer peptide using the CspB signal sequence. As a result of determining the base sequence of the inserted fragment, it was confirmed that each EPO-PAS dimer peptide expression cassette as designed had been constructed. Base sequences were determined using BigDye (registered trademark) Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) and 3500xL Genetic Analyzer (Applied Biosystems).
(20-6) Secretory Expression of Each EPO-PAS Dimer Peptide in C. glutamicum
The pPK4_CspAss-EPO-PAS8, pPK4_CspAss-EPO-PAS22, pPK4_CspBss-AET-EPO-PAS8, and pPK4_CspBss-AET-EPO-PAS22 constructed above were used to transform the C. glutamicum YDK0107 strain described in WO2016/171224 to obtain the YDK0107/pPK4_CspAss-EPO-PAS8 strain, YDK0107/pPK4_CspAss-EPO-PAS22 strain, YDK0107/pPK4_CspBss-AET-EPO-PAS8 strain, and YDK0107/pPK4_CspBss-AET-EPO-PAS22 strain.
The obtained transformants were each cultured in MMTG liquid medium containing 25 mg/L kanamycin (glucose at 120 g, magnesium sulfate heptahydrate at 3 g, ammonium sulfate at 30 g, potassium dihydrogen phosphate at 1.5 g, iron heptahydrate at 0.03 g, manganese sulfate pentahydrate at 0.03 g, thiamine hydrochloride at 0.45 mg, biotin at 0.45 mg, DL-methionine at 0.15 g, soybean hydrochloric acid hydrolyzate (total nitrogen amount at 0.2 g), calcium carbonate at 50 g, adjusted to pH 7.0 with 1 L of water) at 30° C. for 72 hours.
After completion of the culture, 6.5 μL of the culture supernatant obtained by centrifuging each culture solution was subjected to reduced SDS-PAGE using NuPAGE (registered trademark) 12% Bis-Tirs Gel (Thermo Fisher Scientific), and then stained with Quick-CBB (Wako). As a result, a protein band presumed to be EPO-PAS8 was detected in the culture supernatant of the YDK0107/pPK4_CspAss-EPO-PAS8 strain (
The cell filtrate of AET-EPO-PAS8 and AET-EPO-PAS22 after culturing in Example 20 was subjected to molecular weight measurement using LC-MS (Waters, ACQUITY UPLC/SQD2). The analysis conditions are shown in Table 2. As shown in
The EpoR activation ability of the EPO-PAS dimer peptide was evaluated using PathHunter (registered trademark) eXpress EpoR-JAK2 Functional Assay Kit (DiscoverX).
Cells for EPO activity evaluation included in PathHunter (registered trademark) eXpress EpoR-JAK2 Functional Assay Kit were seeded on a 96-well plate and cultured for 24 hours at 37° C. under 5% CO2. To the cells, 860 pg/L to 900 μg/L recombinant human erythropoietin (rhEPO, Peprotech), or a culture supernatant containing AET-EPO-PAS8 or AET-EPO-PAS22 diluted to a predetermined concentration (cultured as described in Example 20), or the monomer peptide EMP35 (GGLYACHMGPMTWVCQPLRG, synthesized by GenScript Japan) was added. As a negative control, the culture supernatant (
As shown in
(23-1) Outline of Design
Peptide dimers that bind to the thrombopoietin receptor c-Mpl cannot be expressed in C. glutamicum for the following reasons. Specifically, a peptide dimer molecule (AF13948) obtained by dimerizing the straight chain c-Mpl-binding peptide AF12505 reported in S. E. Cwirla, et al. Science, 276, 1696-1699, 1997 with the α- and ε-amino groups of lysine cannot be expressed in C. glutamicum as a single polypeptide chain for the following reasons.
(1) Dimerization is achieved by binding the C-terminuses of the straight chain peptides AF12505 to each other via the α- and ε-amino groups of lysine, and cannot be expressed in C. glutamicum. (2) The non-protein amino acid β-alanine is bound to the C-terminus of AF12505 bound to the α-amino group of lysine, and peptides containing non-protein amino acids cannot be expressed in C. glutamicum. Therefore, the molecule was converted as follows to design an expressible form. The obstacles were dealt with by using PAS sequences instead of lysine and β-alanine and further designing the peptide sequence to be “first AF12505”-“PAS linker”-“second AF12505” so that it could be expressed as a single polypeptide chain. Specifically, the C-terminal of the first AF12505 and the N-terminal of the PAS linker are linked by an amide bond, and the N-terminal of the second AF12505 and the C-terminal of the PAS linker are linked by an amide bond, so that they can be expressed as a single polypeptide chain.
In addition, the peptide reported in WO9640750, a cyclic c-Mpl binding peptide AF12285 with biotin added to the C-terminus and multimerized with streptavidin, cannot be expressed in C. glutamicum as a single polypeptide chain for the following reasons.
(1) Biotin is modified at the C-terminal of the cyclic peptide AF12285 via the ε-amino group of lysine. Peptides containing biotin cannot be expressed at C. glutamicum.
(2) The biotinylated cyclic peptide is multimerized with streptavidin. It is impossible to express streptavidin at the same time as a peptide in C. glutamicum. Therefore, the molecule was converted as follows to design an expressible form. The obstacles were dealt with by using PAS sequences instead of biotin-streptavidin multimerization and further designing the peptide sequence to be “first AF12285”-“PAS linker”-“second AF12285” so that it could be expressed as a single polypeptide chain. Specifically, the C-terminal of the first AF12505 and the N-terminal of the PAS linker are linked by an amide bond, and the N-terminal of the second AF12505 and the C-terminal of the PAS linker are linked by an amide bond, so that they can be expressed as a single polypeptide chain.
(23-2) Preparation of TPO-PAS Dimer Peptides
The prepared TPO-PAS dimer peptides are as follows.
(23-3) Expression of TPO-PAS Dimer Peptides
The expression of these TPO-PAS dimer peptides was examined using Corynex (registered trademark). Hereinafter, examples of expression examinations using Corynex (registered trademark) will be described.
(23-4) Construction of Secretory Expression Plasmid of TPO2-PAS8 Using CspA Signal Sequence
As the TPO-PAS dimer peptide, the amino acid sequence of the above (t) TPO2-PAS8 (which may be hereinafter referred to as “TPO2-PAS8”) was designed, and the base sequence encoding this protein was designed in consideration of the codon usage frequency of C. glutamicum. Furthermore, the following expression cassette was designed to enable secretion expression by C. glutamicum.
TPO2-PAS8 was secretory-expressed as a fusion protein of TPO2-PAS8 and a signal peptide 25 amino acid residue of CspA derived from C. ammoniagenes ATCC 6872 strain (hereinafter referred to as “CspAss-TPO2-PAS8”). The base sequence and amino acid sequence encoding the designed CspAss-TPO2-PAS8 are set forth in SEQ ID NOs: 117 and 118, respectively.
The promoter of the cspB gene derived from the C. glutamicum ATCC 13869 strain was linked upstream of the base sequence set forth in CspAss-TPO2-PAS8, and furthermore, an expression cassette of TPO-PAS dimer peptide having a KpnI site on the 5′-side and an BamHI site on the 3′-side was designed and totally synthesized. The totally synthesized DNA fragment (TPO-PAS dimer peptide expression cassette) was inserted into the KpnI-BamHI site of pPK4 described in Japanese Patent Application Publication No. Hei 9-322774 to construct pPK4_CspAss-TPO2-PAS8, a secretory expression plasmid for the TPO-PAS dimer peptide using the CspA signal sequence. As a result of determining the base sequence of the inserted fragment, it was confirmed that the TPO-PAS dimer peptide expression cassette as designed had been constructed. Base sequences were determined using BigDye (registered trademark) Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) and 3500xL Genetic Analyzer (Applied Biosystems).
(23-5) Construction of Each Secretory Expression Plasmid of AET-TPO1-PAS8 and AET-TPO2-PAS8 Using CspB Signal Sequence
As the TPO-PAS dimer peptide, two types of amino acid sequences of the above (u) AET-TPO1-PAS8 (which may be hereinafter referred to as “AET-TPO1-PAS8”) and (v) AET-TPO2-PAS8 (which may be hereinafter referred to as “AET-EPO2-PAS8”) were designed, and the base sequences encoding these proteins were designed in consideration of the codon usage frequency of C. glutamicum. Furthermore, the following expression cassettes were designed to enable secretory expression by C. glutamicum.
AET-TPO1-PAS8 was secretory-expressed as a fusion protein of AET-TPO1-PAS8 and a signal peptide 30 amino acid residue of CspB derived from C. glutamicum ATCC 13869 strain (hereinafter referred to as “CspBss-AET-TPO1-PAS8”). The base sequence and amino acid sequence encoding the designed CspBss-AET-TPO1-PAS8 are set forth in SEQ ID NOs: 119 and 120, respectively.
AET-TPO2-PAS8 was secretory-expressed as a fusion protein of AET-TPO2-PAS8 and a signal peptide 30 amino acid residue of CspB derived from C. glutamicum ATCC 13869 strain (hereinafter referred to as “CspBss-AET-TPO2-PAS8”). The base sequence and amino acid sequence encoding the designed CspBss-AET-TPO2-PAS8 are set forth in SEQ ID NOs: 121 and 122, respectively.
The promoter of the cspB gene derived from the C. glutamicum ATCC 13869 strain was linked upstream of the base sequences set forth in CspBss-AET-TPO1-PAS8 and CspBss-AET-TPO2-PAS8, and furthermore, an expression cassette of each TPO-PAS dimer peptide having a KpnI site on the 5′-side and an BamHI site on the 3′-side was designed and totally synthesized. The totally synthesized DNA fragment (TPO-PAS dimer peptide expression cassette) was inserted into the KpnI-BamHI site of pPK4 described in Japanese Patent Application Publication No. Hei 9-322774 to construct pPK4_CspBss-AET-TPO1-PAS8 and pPK4_CspBss-AET-TPO2-PAS8, a secretory expression plasmid for each TPO-PAS dimer peptide using the CspB signal sequence. As a result of determining the base sequence of the inserted fragment, it was confirmed that each TPO-PAS dimer peptide expression cassette as designed had been constructed. Base sequences were determined using BigDye (registered trademark) Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) and 3500xL Genetic Analyzer (Applied Biosystems).
(23-6) Secretory Expression of Each TPO-PAS Dimer Peptide in C. glutamicum
The pPK4_CspAss-TPO2-PAS8, pPK4_CspBss-AET-TPO1-PAS8, and pPK4_CspBss-AET-TPO2-PAS8 constructed above were used to transform the C. glutamicum YDK0107 strain described in WO2016/171224 to obtain the YDK0107/pPK4_CspAss-TPO2-PAS8 strain, YDK0107/pPK4_CspBss-AET-TPO1-PAS8 strain, and YDK0107/pPK4_CspBss-AET-TPO2-PAS8 strain.
The obtained transformants were each cultured in MMTG liquid medium containing 25 mg/L kanamycin (glucose at 120 g, magnesium sulfate heptahydrate at 3 g, ammonium sulfate at 30 g, potassium dihydrogen phosphate at 1.5 g, iron heptahydrate at 0.03 g, manganese sulfate pentahydrate at 0.03 g, thiamine hydrochloride at 0.45 mg, biotin at 0.45 mg, DL-methionine at 0.15 g, soybean hydrochloric acid hydrolyzate (total nitrogen amount at 0.2 g), calcium carbonate at 50 g, adjusted to pH 7.0 with 1 L of water) at 30° C. for 72 hours.
After completion of the culture, 6.5 μL of the culture supernatant obtained by centrifuging each culture solution was subjected to reduced SDS-PAGE using NuPAGE (registered trademark) 12% Bis-Tirs Gel (Thermo Fisher Scientific), and then stained with Quick-CBB (Wako). As a result, a protein band presumed to be AET-TPO1-PAS8 was detected in the culture supernatant of the YDK0107/pPK4_CspBss-AET-TPO1-PAS8 strain (
The cell filtrate of the TPO-PAS dimer peptide after culturing in Example 23 was subjected to molecular weight measurement using LC-MS (Waters, ACQUITY UPLC/SQD2). The analysis conditions are shown in Table 2. As shown in
The thrombopoietin-like activity of the TPO-PAS dimer peptide was evaluated by quantification of tyrosine phosphorylation levels in HEL cells, a human leukemia-derived blood cell line. 200,000 HEL cells were cultured in RPMI 1640 medium without FBS (Thermo Fisher Scientific) for 24 hours and starved. The cells were stimulated for 20 minutes in RPMI 1640 medium supplemented with 10 to 100 ng/mL recombinant human TPO (rhTPO, Peprotech) or a culture supernatant containing AET-TPO1-PAS8, TPO2-PAS8, or AET-TPO2-PAS8 at a predetermined dilution factor. As a negative control, PBS (Mock group) or a supernatant expressing no peptide (Empty group) by using an empty vector was added, and stimulation was performed for 20 minutes. After removing the medium and washing the cells once with PBS, the cells were lysed by adding 100 μL of Lysis buffer 17 (R&D Systems) supplemented with Protease inhibitor cocktail (Nacalai Tesque). The lysate solution was centrifuged at 14,000 G for 5 minutes to obtain the supernatant as lysate.
APVDF membrane (Immobilon-P membrane 0.45 m, Merck) was treated with methanol for 1 minute and then with ultrapure water for 5 minutes for hydrophilic treatment. The PVDF membrane was dried, and each cell lysate solution was spotted with a 1 μL pipette and dried. The PVDF membrane was blocked with PVDF Blocking Reagent for Can Get Signal (NOF) at room temperature for 1 hour, and then Can Get Signal Solution 2 (NOF), supplemented with anti-pY antibody-HGF conjugate (Cell Signaling Technology) at 1:5000, was added, followed by an antibody reaction at 4° C. for 24 hours. The membrane was washed 3 times with TBST buffer, Luminata Crescendo Western HRP Substrate (Merck) was added, and a chemiluminescence reaction was carried out. Chemiluminescence was detected using Amersham Imager 600 (GE Healthcare). The luminescence intensity of the detected dots was quantified by ImageJ.
As shown in
The signal characteristics of the TPO-PAS dimer peptide were evaluated using Proteome Profiler Human Phospho-Kinase Array Kit (R&D Systems).
1,000,000 HEL cells were cultured in RPMI 1640 medium without FBS (Thermo Fisher Scientific) for 24 hours and starved. The cells were stimulated for 20 minutes in RPMI 1640 medium supplemented with 100 ng/mL recombinant human TPO (rhTPO, Peprotech) or a culture supernatant containing TPO2-PAS8 at a dilution of 1/100 to 1/1000. As a negative control, PBS was added, and stimulation was performed for 20 minutes (Mock group). After removing the medium and washing the cells once with PBS, the cells were lysed by adding 200 μL of Lysis buffer 17 (R&D Systems) supplemented with Protease inhibitor cocktail (Nacalai Tesque). The lysate solution was centrifuged at 14,000 G for 5 minutes to obtain the supernatant as lysate.
The lysate was analyzed using Proteome Profiler Human Phospho-Kinase Array Kit. Amersham Imager 600 (GE Healthcare) was used to detect chemiluminescence. The chemiluminescence intensity of the dots was quantified using ImageJ. As shown in
(27-1) Outline of Design
It is impossible to express the VEGFR-binding cyclic peptides P-3 and P-4 reported in A. Shrivastava, et al. Protein Eng. Des. Select. 18, 417, 2005, dimerized by a glutarate linker, as a single polypeptide chain in C. glutamicum for the following reasons. Dimerization is achieved by binding the ε-amino groups of the lysine residues located at the C-terminus of each of the cyclic peptides P-3 and P-4 via glutaric acid, and cannot be expressed in C. glutamicum. Therefore, the molecule was converted as follows to design an expressible form. The obstacles were dealt with by using a PAS sequence instead of a glutarate linker and further designing the peptide sequence to be “first VEGFR-binding sequence (P-3)”-“PAS linker”-“second VEGFR-binding sequence (P-4)” so that it could be expressed as a single polypeptide chain. Specifically, the C-terminal of P-3 and the N-terminal of the PAS linker are linked by an amide bond, and the N-terminal of P-4 and the C-terminal of the PAS linker are linked by an amide bond, so that they can be expressed as a single polypeptide chain.
(27-2) Preparation of VEGFR_D2-PAS Heterodimer Peptide
The prepared VEGFR_D2-PAS heterodimer peptide is as follows.
(27-3) Expression of VEGFR_D2-PAS Heterodimer Peptide
Corynex (registered trademark) was used to examine the expression of VEGFR_D2-PAS heterodimer peptide. Hereinafter, examples of expression examinations using Corynex (registered trademark) will be described.
(27-4) Construction of AET-VEGFR_D2-PAS16 Secretory Expression Plasmid Using CspB Signal Sequence
As the VEGFR_D2-PAS heterodimer peptide, the amino acid sequence of the above (w) AET-VEGFR_D2-PAS16 (which may be hereinafter referred to as “AET-VEGFR_D2-PAS16”, and may be simply referred to as “VEGFR_D2-PAS16”) was designed, and the base sequence encoding this protein was designed in consideration of the codon usage frequency of C. glutamicum. Furthermore, the following expression cassette was designed to enable secretion expression by C. glutamicum.
AET-VEGFR_D2-PAS16 was secretory-expressed as a fusion protein of AET-VEGFR_D2-PAS16 and a signal peptide 30 amino acid residue of CspB derived from C. glutamicum ATCC 13869 strain (hereinafter referred to as “CspBss-VEGFR_D2-PAS16”). The base sequence and amino acid sequence encoding the designed CspBss-AET-VEGFR_D2-PAS16 are set forth in SEQ ID NOs: 124 and 125, respectively.
The promoter of the cspB gene derived from the C. glutamicum ATCC 13869 strain was linked upstream of the base sequence set forth in CspBss-AET-VEGFR_D2-PAS16, and furthermore, an expression cassette of VEGFR_D2-PAS heterodimer peptide having a KpnI site on the 5′-side and an BamHI site on the 3′-side was designed and totally synthesized. The totally synthesized DNA fragment (VEGFR_D2-PAS heterodimer peptide expression cassette) was inserted into the KpnI-BamHI site of pPK4 described in Japanese Patent Application Publication No. Hei 9-322774 to construct pPK4_CspBss-AET-VEGFR_D2-PAS16, a secretory expression plasmid for the VEGFR_D2-PAS heterodimer peptide using the CspB signal sequence. As a result of determining the base sequence of the inserted fragment, it was confirmed that the VEGFR_D2-PAS heterodimer peptide expression cassette as designed had been constructed. Base sequences were determined using BigDye (registered trademark) Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) and 3500xL Genetic Analyzer (Applied Biosystems).
(27-5) Secretory Expression of VEGFR_D2-PAS Heterodimer Peptide in C. glutamicum
The pPK4_CspBss-AET-VEGFR_D2-PAS16 constructed above was used to transform the C. glutamicum YDK0107 strain described in WO2016/171224 to obtain the YDK0107/pPK4_CspBss-AET-VEGFR_D2-PAS16 strain.
The obtained transformants were each cultured in MMTG liquid medium containing 25 mg/L kanamycin (glucose at 120 g, magnesium sulfate heptahydrate at 3 g, ammonium sulfate at 30 g, potassium dihydrogen phosphate at 1.5 g, iron heptahydrate at 0.03 g, manganese sulfate pentahydrate at 0.03 g, thiamine hydrochloride at 0.45 mg, biotin at 0.45 mg, DL-methionine at 0.15 g, soybean hydrochloric acid hydrolyzate (total nitrogen amount at 0.2 g), calcium carbonate at 50 g, adjusted to pH 7.0 with 1 L of water) at 30° C. for 72 hours.
After completion of the culture, 6.5 μL of the culture supernatant obtained by centrifuging the culture solution or the culture solution containing the cells and the culture supernatant uniformly without centrifugation was each subjected to reduced SDS-PAGE using NuPAGE (registered trademark) 12% Bis-Tirs Gel (Thermo Fisher Scientific), and then stained with Quick-CBB (Wako). As a result, a very small amount of a protein band presumed to be AET-VEGFR_D2-PAS16 was detected in the culture supernatant of the YDK0107/pPK4_CspBss-AET-VEGFR_D2-PAS16 strain (
From the above results, it was considered that after secretion, most of AET-VEGFR_D2-PAS16 was aggregated in the culture supernatant or adsorbed on the cell surface of the cultured cells.
(27-6) Solubilization of VEGFR_D2-PAS Heterodimer Peptide by Urea Treatment
To the precipitate fraction containing the cells obtained by centrifuging the culture solution of the YDK0107/pPK4_CspBss-AET-VEGFR_D2-PAS16 strain obtained above, an equal volume of 0.5 M Urea (50 mM Tris-HCl, pH 8.0) or 1.0 M Urea (50 mM Tris-HCl, pH 8.0) was added to the removed culture supernatant and mixed. 6.5 μL of the supernatant fraction obtained by centrifuging each Urea treatment solution or the mixture containing the cells and the supernatant uniformly without centrifugation was each subjected to reduced SDS-PAGE using NuPAGE (registered trademark) 12% Bis-Tirs Gel (Thermo Fisher Scientific), and then stained with Quick-CBB (Wako). As a result, in the 0.5 M Urea and 1.0 M Urea treatment samples, a protein band presumed to be AET-VEGFR_D2-PAS16 was extracted into the supernatant and obtained as a soluble fraction (
The solution obtained by washing the cells expressing the VEGFR_D2-PAS heterodimer after culturing in Example 27 with 8 M Urea was subjected to cell filtration and then molecular weight measurement using LC-MS (Waters, ACQUITY UPLC/SQD2). The analysis conditions are shown in Table 5.
As shown in
The VEGF inhibitory ability of the VEGFR_D2-PAS heterodimer peptide was evaluated by luciferase assay. 40,000 cell/well VEGFR/NFAT Reporter HEK293 cells (BPS Bioscience) were seeded and incubated overnight in a 5% CO2 incubator at 37° C. The cells were incubated overnight in Assay medium (MEM medium (Nacalai Tesque), 1×MEM Non-Essential Amino Acids Solution (Thermo Fisher Scientific), 1 mM Sodium Pyruvate (Nacalai Tesque), 1% Penicillin-Streptomycin (Sigma Aldrich), and 0.3% FBS (Thermo Fisher Scientific)) to starvation. To the Assay medium, 10 ng/mL human recombinant VEGF (R&D Systems) was added, and further, VEGFR_D2-PAS16 purified by HPLC, or a monomer peptide P3 (AGPTWCEDDWYYCWLFGT (SEQ ID NO: 71), synthesized by GenScript Japan) or Pm4 (VCWEDSWGGEVCWLFGT (SEQ ID NO: 72), synthesized by GenScript Japan) was added at a predetermined dilution factor, and 100 μL of the Assay medium was added to the cells. The cells were stimulated by culturing in a 5% CO2 incubator at 37° C. for 4 hours.
One-Glo Luciferase Assay System (Promega) was used to detect the signal intensity. Medium supernatant in an amount of 50 μL was removed, 50 μL of One-Glo reagent was added, and the cells were lysed for 10 minutes at room temperature. The luminescence emitted from the cell lysate solution was detected with a Nivo plate reader (Perkin Elmer) to quantify the activation of the VEGFR-NFAT pathway, and the relative signal activity value for the sample without addition of evaluation compound was determined and used as relative receptor activity.
As shown in
(30-1) Outline of Linker Variant Design
The erythropoietin mimetic peptides AET-EPO-PAS8 and AET-EPO-PAS22 have a structure in which a PAS linker composed of 8 amino acids or 22 amino acids is linked between the first erythropoietin receptor-binding cyclic peptide and the second erythropoietin receptor-binding cyclic peptide. By changing the length of this PAS linker, it is expected that the erythropoietin receptor binding activity will change. Therefore, a linker variant was designed in which the PAS linker portion was changed to a PAS repeat sequence of 49 amino acids or 100 amino acids.
In addition to the PAS linker, a GS linker, which is a repeating sequence of glycine and serin, is also known as a flexible linker. Therefore, the peptide sequence was designed to be a linker variant in which an EPO cyclic peptide was bound to the N-terminus and C-terminus of the GS linker composed of a repeating sequence of 4 glycine residues and 1 serine residue (GGGGS), that is, a “first erythropoietin receptor-binding cyclic peptide”-“GS linker”-“second erythropoietin receptor-binding cyclic peptide”.
(30-2) Preparation of EPO-PAS Dimer Peptide Linker Variants
The prepared EPO-PAS dimer peptide linker variants are as follows.
(30-3) Expression of EPO-PAS Dimer Peptide Linker Variant
The expression of these EPO-PAS dimer peptide linker variants was examined using Corynex (registered trademark). Hereinafter, examples of expression examinations using Corynex (registered trademark) will be described.
(30-4) Construction of Each Secretory Expression Plasmid of AET-EPO-PAS49, AET-EPO-PAS49-b, AET-EPO-PAS100, AET-EPO-PAS100-b, AET-EPO-GS8, and AET-EPO-GS22 Using CspB Signal Sequence
As the EPO-PAS dimer peptide linker variant, six types of amino acid sequences of the above (x) AET-EPO-PAS49 (which may be hereinafter referred to as “AET-EPO-PAS49”), (y) AET-EPO-PAS49-b (which may be hereinafter referred to as “AET-EPO-PAS49-b”), (z) AET-EPO-PAS100 (which may be hereinafter referred to as “AET-EPO-PAS100”), (A) AET-EPO-PAS100-b (which may be hereinafter referred to as “AET-EPO-PAS100-b”), (B) AET-EPO-GS8 (which may be hereinafter referred to as “AET-EPO-GS8”), and (C) AET-EPO-GS22 (which may be hereinafter referred to as “AET-EPO-GS22”) were designed, and base sequences encoding these proteins were designed in consideration of the codon usage frequency of C. glutamicum. Furthermore, the following expression cassettes were designed to enable secretory expression by C. glutamicum.
AET-EPO-PAS49 was secretory-expressed as a fusion protein of AET-EPO-PAS49 and a signal peptide 30 amino acid residue of CspB derived from C. glutamicum ATCC 13869 strain (hereinafter referred to as “CspBss-AET-EPO-PAS49”). The base sequence and amino acid sequence encoding the designed CspBss-AET-EPO-PAS49 are set forth in SEQ ID NOs: 132 and 133, respectively.
AET-EPO-PAS49-b was secretory-expressed as a fusion protein of AET-EPO-PAS49-b and a signal peptide 30 amino acid residue of CspB derived from C. glutamicum ATCC 13869 strain (hereinafter referred to as “CspBss-AET-EPO-PAS49-b”). The base sequence and amino acid sequence encoding the designed CspBss-AET-EPO-PAS49-b are set forth in SEQ ID NOs: 134 and 135, respectively.
AET-EPO-PAS100 was secretory-expressed as a fusion protein of AET-EPO-PAS100 and a signal peptide 30 amino acid residue of CspB derived from C. glutamicum ATCC 13869 strain (hereinafter referred to as “CspBss-AET-EPO-PAS100”). The base sequence and amino acid sequence encoding the designed CspBss-AET-EPO-PAS100 are set forth in SEQ ID NOs: 136 and 137, respectively.
AET-EPO-PAS100-b was secretory-expressed as a fusion protein of AET-EPO-PAS100-b and a signal peptide 30 amino acid residue of CspB derived from C. glutamicum ATCC 13869 strain (hereinafter referred to as “CspBss-AET-EPO-PAS100-b”). The base sequence and amino acid sequence encoding the designed CspBss-AET-EPO-PAS100-b are set forth in SEQ ID NOs: 138 and 139, respectively.
AET-EPO-GS8 was secretory-expressed as a fusion protein of AET-EPO-GS8 and a signal peptide 30 amino acid residue of CspB derived from C. glutamicum ATCC 13869 strain (hereinafter referred to as “CspBss-AET-EPO-GS8”). The base sequence and amino acid sequence encoding the designed CspBss-AET-EPO-GS8 are set forth in SEQ ID NOs: 140 and 141, respectively.
AET-EPO-GS22 was secretory-expressed as a fusion protein of AET-EPO-GS22 and a signal peptide 30 amino acid residue of CspB derived from C. glutamicum ATCC 13869 strain (hereinafter referred to as “CspBss-AET-EPO-GS22”). The base sequence and amino acid sequence encoding the designed CspBss-AET-EPO-GS22 are set forth in SEQ ID NOs: 142 and 143, respectively.
The promoter of the cspB gene derived from the C. glutamicum ATCC 13869 strain was linked upstream of the base sequences set forth in CspBss-AET-EPO-PAS49, CspBss-AET-EPO-PAS49-b, CspBss-AET-EPO-PAS100, CspBss-AET-EPO-PAS100-b, CspBss-AET-EPO-GS8, and CspBss-AET-EPO-GS22, and furthermore, an expression cassette of each EPO-PAS dimer peptide linker variant having a KpnI site on the 5′-side and an BamHI site on the 3′-side was designed and totally synthesized. The totally synthesized DNA fragment (EPO-PAS dimer peptide linker variant expression cassette) was inserted into the KpnI-BamHI site of pPK4 described in Japanese Patent Application Publication No. Hei 9-322774 to construct pPK4_CspBss-AET-EPO-PAS49, pPK4_CspBss-AET-EPO-PAS49-b, pPK4_CspBss-AET-EPO-PAS100, pPK4_CspBss-AET-EPO-PAS100-b, pPK4_CspBss-AET-EPO-GS8, and pPK4_CspBss-AET-EPO-GS22, a secretory expression plasmid for each EPO-PAS dimer peptide linker variant using the CspB signal sequence. As a result of determining the base sequence of the inserted fragment, it was confirmed that each EPO-PAS dimer peptide linker variant expression cassette as designed had been constructed. Base sequences were determined using BigDye (registered trademark) Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) and 3500xL Genetic Analyzer (Applied Biosystems).
(30-5) Secretory Expression of Each EPO-PAS Dimer Peptide in C. glutamicum
The pPK4_CspBss-AET-EPO-PAS49, pPK4_CspBss-AET-EPO-PAS49-b, pPK4_CspBss-AET-EPO-PAS100, pPK4_CspBss-AET-EPO-PAS100-b, pPK4_CspBss-AET-EPO-GS8, and pPK4_CspBss-AET-EPO-GS22 constructed above were used to transform the C. glutamicum YDK0107 strain described in WO2016/171224 to obtain the YDK0107/pPK4_CspBss-AET-EPO-PAS49 strain, YDK0107/pPK4_CspBss-AET-EPO-PAS49-b strain, YDK0107/pPK4_CspBss-AET-EPO-PAS100 strain, YDK0107/pPK4_CspBss-AET-EPO-PAS100-b strain, YDK0107/pPK4_CspBss-AET-EPO-GS8 strain, and YDK0107/pPK4_CspBss-AET-EPO-GS22 strain.
The obtained transformants were each cultured in MMTG liquid medium containing 25 mg/L kanamycin (glucose at 120 g, magnesium sulfate heptahydrate at 3 g, ammonium sulfate at 30 g, potassium dihydrogen phosphate at 1.5 g, iron heptahydrate at 0.03 g, manganese sulfate pentahydrate at 0.03 g, thiamine hydrochloride at 0.45 mg, biotin at 0.45 mg, DL-methionine at 0.15 g, soybean hydrochloric acid hydrolyzate (total nitrogen amount at 0.2 g), calcium carbonate at 50 g, adjusted to pH 7.0 with 1 L of water) at 30° C. for 72 hours.
After completion of the culture, 6.5 μL of the culture supernatant obtained by centrifuging each culture solution was subjected to reduced SDS-PAGE using NuPAGE (registered trademark) 12% Bis-Tirs Gel (Thermo Fisher Scientific), and then stained with Quick-CBB (Wako). As a result, a protein band presumed to be AET-EPO-PAS49 was detected in the culture supernatant of the YDK0107/pPK4_CspBss-AET-EPO-PAS49 strain (
The cell filtrate of the EPO-PAS dimer peptide linker variant after culturing in Example 30 was subjected to molecular weight measurement using LC-MS (Waters, ACQUITY UPLC/SQD2). The analysis conditions are shown in Table 2. As shown in
The EpoR activation ability of the EPO-PAS dimer peptide linker variant was evaluated using PathHunter (registered trademark) eXpress EpoR-JAK2 Functional Assay Kit (DiscoverX).
Cells for EPO activity evaluation included in PathHunter (registered trademark) eXpress EpoR-JAK2 Functional Assay Kit were seeded on a 96-well plate and cultured for 24 hours at 37° C. under 5% CO2. To the cells, a culture supernatant containing AET-EPO-PAS8, AET-EPO-GS8, AET-EPO-PAS22, or AET-EPO-GS22 diluted to a predetermined concentration (cultured as described in Example 20 or 30), or the monomer peptide EMP35 (GGLYACHMGPMTWVCQPLRG, synthesized by GenScript Japan) was added. As a negative control, the culture supernatant (
As shown in
(33-1) Outline of Design
The EPO-PAS peptide with enhanced stability was designed as follows. As a method for enhancing the stability of peptides and proteins, a method for adding a long-chain PAS sequence has been reported (Published Japanese Translation of PCT International Application No. 2013-531480 and Published Japanese Translation of PCT International Application No. 2010-531139). As an EPO-PAS peptide with enhanced stability, a peptide was designed in which a PAS sequence composed of 200 amino acids (PAS200) or a PAS sequence composed of 600 amino acids (PAS600) was bound to the C-terminus of AET-EPO-PAS22. That is, the peptide sequence was designed to be “first erythropoietin receptor-binding cyclic peptide”-“PAS linker”-“second erythropoietin receptor-binding cyclic peptide”-“long-chain PAS sequence (PAS200 or PAS600)”.
(33-2) Preparation of Stabilized EPO-PAS Dimer Peptides
The prepared stabilized EPO-PAS dimer peptides are as follows.
(33-3) Expression of Stabilized EPO-PAS Dimer Peptides
Corynex (registered trademark) was used to examine the expression of stabilized EPO-PAS dimer peptide. Hereinafter, examples of expression examinations using Corynex (registered trademark) will be described.
(33-4) Construction of AET-EPO-PAS22-PAS200 Secretory Expression Plasmid Using CspB Signal Sequence
As the stabilized EPO-PAS dimer peptide, the amino acid sequences of the above (D) AET-EPO-PAS22-PAS200 (which may be hereinafter referred to as “AET-EPO-PAS22-PAS200”) and (E)AET-EPO-PAS22-PAS600 (which may be hereinafter referred to as “AET-EPO-PAS22-PAS600”) were designed, and the base sequences encoding these proteins were designed in consideration of the codon usage frequency of C. glutamicum. Furthermore, the following expression cassette was designed to enable secretion expression by C. glutamicum.
AET-EPO-PAS22-PAS200 was secretory-expressed as a fusion protein of AET-EPO-PAS22-PAS200 and a signal peptide 30 amino acid residue of CspB derived from C. glutamicum ATCC 13869 strain (hereinafter referred to as “CspBss-AET-EPO-PAS22-PAS200”). The base sequence and amino acid sequence encoding the designed CspBss-AET-EPO-PAS22-PAS200 are set forth in SEQ ID NOs: 146 and 147, respectively.
AET-EPO-PAS22-PAS600 was secretory-expressed as a fusion protein of AET-EPO-PAS22-PAS600 and a signal peptide 30 amino acid residue of CspB derived from C. glutamicum ATCC 13869 strain (hereinafter referred to as “CspBss-AET-EPO-PAS22-PAS600”). The base sequence and amino acid sequence encoding the designed CspBss-AET-EPO-PAS22-PAS600 are set forth in SEQ ID NOs: 148 and 149, respectively.
The promoter of the cspB gene derived from the C. glutamicum ATCC 13869 strain was linked upstream of the base sequences set forth in CspBss-AET-EPO-PAS22-PAS200 and CspBss-AET-EPO-PAS22-PAS600, and furthermore, an expression cassette of each stabilized EPO-PAS dimer peptide having a KpnI site on the 5′-side and an BamHI site on the 3′-side was designed and totally synthesized. The totally synthesized DNA fragment (stabilized EPO-PAS dimer peptide expression cassette) was inserted into the KpnI-BamHI site of pPK4 described in Japanese Patent Application Publication No. Hei 9-322774 to construct pPK4_CspBss-AET-EPO-PAS22-PAS200 and pPK4_CspBss-AET-EPO-PAS22-PAS600, a secretory expression plasmid for each stabilized EPO-PAS dimer peptide using the CspB signal sequence. As a result of determining the base sequence of the inserted fragment, it was confirmed that the stabilized EPO-PAS dimer peptide expression cassette as designed had been constructed. Base sequences were determined using BigDye (registered trademark) Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) and 3500xL Genetic Analyzer (Applied Biosystems).
(33-5) Secretory Expression of Stabilized EPO-PAS Dimer Peptide in C. glutamicum
The pPK4_CspBss-AET-EPO-PAS22-PAS200 and pPK4_CspBss-AET-EPO-PAS22-PAS600 constructed above were used to transform the C. glutamicum YDK0107 strain described in WO2016/171224 to obtain the YDK0107/pPK4_CspBss-AET-EPO-PAS22-PAS200 strain and YDK0107/pPK4_CspBss-AET-EPO-PAS22-PAS600 strain.
The obtained transformants were each cultured in MMTG liquid medium containing 25 mg/L kanamycin (glucose at 120 g, magnesium sulfate heptahydrate at 3 g, ammonium sulfate at 30 g, potassium dihydrogen phosphate at 1.5 g, iron heptahydrate at 0.03 g, manganese sulfate pentahydrate at 0.03 g, thiamine hydrochloride at 0.45 mg, biotin at 0.45 mg, DL-methionine at 0.15 g, soybean hydrochloric acid hydrolyzate (total nitrogen amount at 0.2 g), calcium carbonate at 50 g, adjusted to pH 7.0 with 1 L of water) at 30° C. for 72 hours.
After completion of the culture, 6.5 μL of the culture supernatant obtained by centrifuging each culture solution was subjected to reduced SDS-PAGE using NuPAGE (registered trademark) 4 to 12% Bis-Tirs Gel (Thermo Fisher Scientific), and then stained with Quick-CBB (Wako). As a result, a protein band presumed to be AET-EPO-PAS22-PAS200 was detected in the culture supernatant of the YDK0107/pPK4_CspBss-AET-EPO-PAS22-PAS200 strain (
The cell filtrate of each stabilized EPO-PAS dimer peptide after culturing in Example 33 was subjected to molecular weight measurement using LC-MS (Waters, ACQUITY UPLC/SQD2). The analysis conditions are shown in Table 2. As shown in
The EpoR activation ability of the stabilized EPO-PAS dimer peptide was evaluated using PathHunter (registered trademark) eXpress EpoR-JAK2 Functional Assay Kit (DiscoverX).
Cells for EPO activity evaluation included in PathHunter (registered trademark) eXpress EpoR-JAK2 Functional Assay Kit were seeded on a 96-well plate and cultured for 24 hours at 37° C. under 5% CO2. To the cells, a culture supernatant containing 14.2 μg/L to 220 pg/L AET-EPO-PAS22, AET-EPO-PAS22-PAS200, or AET-EPO-PAS22-PAS600 (cultured as described in Example 20 or 33) was added. As a negative control, the culture supernatant (
As shown in
(36-1) Construction of Gene Construct of Cell-Free Expression Dimer Peptides
The following were designed as cell-free expression dimer peptides.
Base sequence encoding the amino acid sequences of the above dimer peptides were designed. Furthermore, 5′-sides were added with T7 promoter sequences and ribosome binding sequences required for cell-free expression, and their 3′-sides were added with stop codons and untranslated regions. The corresponding cell-free expression base sequences are shown below. These DNA sequences were totally synthesized and cloned into the pEX-K4J2 vector by Eurofins Genomics.
(36-2) Cell-Free Expression of Dimer Peptides
The genes of the dimer peptides constructed above were amplified by PCR. PCR was performed using the primers of the sequences shown below and KOD-Plus-Ver. 2 (Toyobo) as the PCR enzyme.
Next, the peptide dimers were expressed by a cell-free expression system based on the gene fragments amplified by PCR. PUREfrex 2.0 (GeneFrontier) was used for cell-free expression.
For cell-free expression with PUREfrex 2.0, to the gene fragments amplified by 2 nM PCR, 10 μL of Solution I, 1 μL of Solution II, 2 μL of Solution III, and 7 μL of water were added, and the mixture was incubated at 37° C. for 6 hours to carry out a translation reaction.
(36-3) Molecular Weight Analysis of Cell-Free Expression Dimer Peptides
A solution, obtained by expressing HGF-PAS dimer peptides (MAET-aMD4-PAS22, MAET-aMD4dY-PAS8, MAET-aMD4dY-PAS22), EPO-PAS dimer peptides (MAET-EPO-PAS8, MAET-EPO-PAS49-b, MAET-EPO-PAS100-b), and a VEGFR_D2-PAS dimer peptide (MAET-VEGFR_D2-PAS16) in a cell-free expression system, was mixed with α-Cyano-4-hydroxycinnamic Acid (CHCA), and subjected to molecular weight measurement with MALDI-TOF-MS (Shimadzu, AXIMA TOF 2).
As shown in
The Met activation ability of the cell-free expression HGF-PAS dimer peptides was evaluated by luciferase assay. To 25 μL of Opti-MEM medium (Thermo Fisher Scientific), 0.6 μL of Attractene Transfection Reagent (QIAGEN) was added, and the mixture was incubated at room temperature for 5 minutes. To the above mixed solution, a mixed solution of 25 μL of Opti-MEM and 1 μL of SRE reporter vector (QIAGEN) was added, and the mixture was incubated at room temperature for 20 minutes. This mixed solution was added to a 96-well plate, over which 40,000 cell/well HEK293E cells were seeded and incubated overnight in a 5% CO2 incubator at 37° C. After transfection, all culture supernatant was removed, 100 μL of Opti-MEM medium (evaluation basal medium) containing 0.5% FBS (Thermo Fisher Scientific), 1% non-essential amino acid solution (Thermo Fisher Scientific), and penicillin-streptomycin (Nacalai Tesque) was added, and incubation was performed at 37° C. for 4 hours, and thereby the cells were starved.
To the evaluation basal medium, 0 to 100 ng/mL HGF was added, or a cell-free translation solution with translated AET-aMD4dY-PAS22 was added to the medium so as to be diluted at a predetermined ratio, or a cell-free translation solution with untranslated peptide was added to dilute at the same ratio, and the evaluation basal medium was added in an amount of 100 L to the cells. The cells were stimulated by culturing overnight in a 5% CO2 incubator at 37° C.
The signal intensities were detected using Dual-Luciferase Reporter Assay System (Promega). The medium supernatant in an amount of 100 μL was removed, 50 μL of Glo reagent was added, and the cells were lysed for 10 minutes at room temperature. The luminescence of Firefly luciferase emitted from the cell lysate solution was detected with a plate reader to quantify the activation of the HGF-Erk-SRE pathway. Subsequently, 50 μL of Glo & Stop reagent solution was added, and after 10 minutes, the luminescence of the internal standard Renilla luciferase was detected to quantify the number of cells. The signal activity of each sample was quantified as SRE activity=(Firefly luciferase luminescence intensity)/(Renilla luciferase luminescence intensity). The relative signal activity values for the samples without addition of the evaluation compound were determined and used as relative receptor activity.
As shown in
The EpoR activation ability of the EPO-PAS dimer peptide linker variant was evaluated using PathHunter (registered trademark) eXpress EpoR-JAK2 Functional Assay Kit (DiscoverX).
Cells for EPO activity evaluation included in PathHunter (registered trademark) eXpress EpoR-JAK2 Functional Assay Kit were seeded on a 96-well plate and cultured for 24 hours at 37° C. under 5% CO2. To the cells, a cell-free translation solution with translated AET-EPO-PAS8, AET-EPO-PAS49-b, or AET-EPO-PAS100-b diluted to a predetermined concentration was added. As a negative control, a cell-free translation solution with untranslated peptide, diluted at the same ratio as the cell-free translation solution with translated AET-EPO-PAS8, AET-EPO-PAS49, or AET-EPO-PAS100, was added. The prepared Substrate Reagent was added to the cells stimulated at room temperature for 3 hours, and the cells were incubated for 60 minutes. The chemiluminescence intensity was quantified with a Nivo plate reader (Perkin Elmer).
As shown in
The VEGF inhibitory ability of the cell-free expressed VEGFR_D2-PAS heterodimer peptide was evaluated by luciferase assay. 40,000 cell/well VEGFR/NFAT Reporter HEK293 cells (BPS Bioscience) were seeded and incubated overnight in a 5% CO2 incubator at 37° C. The cells were incubated overnight in Assay medium (MEM medium (Nacalai Tesque), 1×MEM Non-Essential Amino Acids Solution (Thermo Fisher Scientific), 1 mM Sodium Pyruvate (Nacalai Tesque), 1% Penicillin-Streptomycin (Sigma Aldrich), and 0.3% FBS (Thermo Fisher Scientific)) to starvation. To the Assay medium, 100 μL of 10 ng/mL human recombinant VEGF (R&D Systems) was added, and further, MAET-VEGFR_D2-PAS16, MAET-VEGFR_D2-PAS49-b, MAET-VEGFR_D2-PAS100-b, or a cell-free expression solution containing MAET-VEGFR_D2-GS16, or a cell-free expression solution with unexpressed peptide was added at a predetermined dilution factor, and 100 μL of the Assay medium was added to the cells. The cells were stimulated by culturing in a 5% CO2 incubator at 37° C. for 4 hours.
One-Glo Luciferase Assay System (Promega) was used to detect the signal intensity. Medium supernatant in an amount of 50 μL was removed, 50 μL of One-Glo reagent was added, and the cells were lysed for 10 minutes at room temperature. The luminescence emitted from the cell lysate solution was detected with a Nivo plate reader (Perkin Elmer) to quantify the activation of the VEGFR-NFAT pathway, and the relative signal activity value for the sample without addition of evaluation compound was determined and used as relative receptor activity.
As shown in
(40-1) Outline of Design
The HGF-PAS trimer peptide was designed as follows. A peptide was designed in which an aMD4dY sequence was further bound to the C-terminus of AET-aMD4dY-PAS22 mentioned above via a PAS linker. That is, the peptide sequence was designed to be “first aMD4dY cyclic peptide”-“PAS linker”-“second aMD4dY cyclic peptide”-“PAS linker”-“third aMD4dY cyclic peptide”.
(40-2) Preparation of HGF-PAS Trimer Peptide
The prepared HGF-PAS trimer peptide is as follows.
(40-3) Expression of HGF-PAS Trimer Peptide
Corynex (registered trademark) was used to examine the expression of stabilized HGF-PAS trimer peptide. Hereinafter, examples of expression examinations using Corynex (registered trademark) will be described.
(40-4) Construction of AET-aMD4dY-PAS22-Trimer Secretory Expression Plasmid Using CspB Signal Sequence
As the stabilized HGF-PAS dimer peptide, the amino acid sequence of the above (P) AET-aMD4dY-PAS22-Trimer was designed, and the base sequence encoding this protein was designed in consideration of the codon usage frequency of C. glutamicum. Furthermore, the following expression cassette was designed to enable secretion expression by C. glutamicum.
AET-aMD4dY-PAS22-Trimer was secretory-expressed as a fusion protein of AET-aMD4dY-PAS22-Trimer and a signal peptide 30 amino acid residue of CspB derived from C. glutamicum ATCC 13869 strain (hereinafter referred to as “CspBss-AET-aMD4dY-PAS22-Trimer”). The base sequence and amino acid sequence encoding the designed CspBss-AET-aMD4dY-PAS22-Trimer are set forth in SEQ ID NOs: 173 and 174, respectively.
The promoter of the cspB gene derived from the C. glutamicum ATCC 13869 strain was linked upstream of the base sequence set forth in CspBss-AET-aMD4dY-PAS22-Trimer, and furthermore, an expression cassette of HGF-PAS trimer peptide having a KpnI site on the 5′-side and an BamHI site on the 3′-side was designed and totally synthesized. The totally synthesized DNA fragment (HGF-PAS trimer peptide expression cassette) was inserted into the KpnI-BamHI site of pPK4 described in Japanese Patent Application Publication No. Hei 9-322774 to construct pPK4_CspBss-AET-aMD4dY-PAS22-Trimer, a secretory expression plasmid for the HGF-PAS trimer peptide using the CspB signal sequence. As a result of determining the base sequence of the inserted fragment, it was confirmed that the HGF-PAS trimer peptide expression cassette as designed had been constructed. Base sequences were determined using BigDye (registered trademark) Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) and 3500xL Genetic Analyzer (Applied Biosystems).
(40-5) Secretory Expression of HGF-PAS Trimer Peptide in C. glutamicum
The pPK4_CspBss-AET-aMD4dY-PAS22-Trimer constructed above was used to transform the C. glutamicum YDK010::phoS(W302C) strain described in WO2016/171224 to obtain the YDK010::phoS(W302C)/pPK4_CspBss-AET-aMD4dY-PAS22-Trimer strain.
The obtained transformants were each cultured in MMTG liquid medium containing 25 mg/L kanamycin (glucose at 120 g, magnesium sulfate heptahydrate at 3 g, ammonium sulfate at 30 g, potassium dihydrogen phosphate at 1.5 g, iron heptahydrate at 0.03 g, manganese sulfate pentahydrate at 0.03 g, thiamine hydrochloride at 0.45 mg, biotin at 0.45 mg, DL-methionine at 0.15 g, soybean hydrochloric acid hydrolyzate (total nitrogen amount at 0.2 g), calcium carbonate at 50 g, adjusted to pH 7.0 with 1 L of water) at 30° C. for 72 hours.
After completion of the culture, 6.5 μL of the culture supernatant obtained by centrifuging each culture solution was subjected to reduced SDS-PAGE using NuPAGE (registered trademark) 12% Bis-Tirs Gel (Thermo Fisher Scientific), and then stained with Quick-CBB (Wako). As a result, a protein band presumed to be AET-aMD4dY-PAS22-Trimer was detected in the culture supernatant of the YDK010::phoS(W302C)/pPK4_CspBss-AET-aMD4dY-PAS22-Trimer strain (
In addition, the YDK010::phoS(W302C)/pPK4_CspBss-AET-aMD4dY-PAS22 strain obtained by the same method as above was cultured in the same manner as above, and a protein band presumed to be AET-aMD4dY-PAS22 was detected in the culture supernatant (
The cell filtrate of AET-aMD4dY-PAS22-Trimer after culturing in Example 40 was subjected to molecular weight measurement using LC-MS (Waters, ACQUITY UPLC/SQD2). The analysis conditions are shown in Table 2. As shown in
The Met activation ability of the HGF-PAS trimer peptide was evaluated by luciferase assay. To 25 μL of Opti-MEM medium (Thermo Fisher Scientific), 0.6 μL of Attractene Transfection Reagent (QIAGEN) was added, and the mixture was incubated at room temperature for 5 minutes. To the above mixed solution, a mixed solution of 25 μL of Opti-MEM and 1 μL of SRE reporter vector (QIAGEN) was added, and the mixture was incubated at room temperature for 20 minutes. This mixed solution was added to a 96-well plate, over which 40,000 cell/well HEK293E cells were seeded and incubated overnight in a 5% CO2 incubator at 37° C. After transfection, all culture supernatant was removed, 100 μL of Opti-MEM medium (evaluation basal medium) containing 0.5% FBS (Thermo Fisher Scientific), 1% non-essential amino acid solution (Thermo Fisher Scientific), and penicillin-streptomycin (Nacalai Tesque) was added, and incubation was performed at 37° C. for 4 hours, and thereby the cells were starved.
To the evaluation basal medium, 0 to 100 ng/mL HGF was added, or a culture supernatant containing AET-aMD4dY-PAS22 or AET-aMD4dY-PAS22-Trimer was added to the medium so as to be diluted at a predetermined ratio, and the evaluation basal medium was added in an amount of 100 μL to the cells. The cells were stimulated by culturing overnight in a 5% CO2 incubator at 37° C.
The signal intensities were detected using Dual-Luciferase Reporter Assay System (Promega). The medium supernatant in an amount of 100 μL was removed, 50 μL of Glo reagent was added, and the cells were lysed for 10 minutes at room temperature. The luminescence of Firefly luciferase emitted from the cell lysate solution was detected with a plate reader to quantify the activation of the HGF-Erk-SRE pathway. Subsequently, 50 μL of Glo & Stop reagent solution was added, and after 10 minutes, the luminescence of the internal standard Renilla luciferase was detected to quantify the number of cells. The signal activity of each sample was quantified as SRE activity=(Firefly luciferase luminescence intensity)/(Renilla luciferase luminescence intensity). The relative signal activity values for the samples without addition of the evaluation compound were determined and used as relative receptor activity.
As shown in
The Met activation ability of HGF-PAS dimer peptide and monomer peptide was compared by luciferase assay. To 25 μL of Opti-MEM medium (Thermo Fisher Scientific), 0.6 L of Attractene Transfection Reagent (QIAGEN) was added, and the mixture was incubated at room temperature for 5 minutes. To the above mixed solution, a mixed solution of 25 μL of Opti-MEM and 1 μL of SRE reporter vector (QIAGEN) was added, and the mixture was incubated at room temperature for 20 minutes. This mixed solution was added to a 96-well plate, over which 40,000 cell/well HEK293E cells were seeded and incubated overnight in a 5% CO2 incubator at 37° C. After transfection, all culture supernatant was removed, 100 μL of Opti-MEM medium (evaluation basal medium) containing 0.5% FBS (Thermo Fisher Scientific), 1% non-essential amino acid solution (Thermo Fisher Scientific), and penicillin-streptomycin (Nacalai Tesque) was added, and incubation was performed at 37° C. for 4 hours, and thereby the cells were starved.
To the evaluation basal medium, 0 to 100 ng/mL HGF was added, or a AET-aMD4dY-PAS22 or aMD4dY monomer peptide (CRQFNRRTHEVWNLDC (SEQ ID NO: 2), synthesized by GenScript Japan) was added at a predetermined concentration, and added in an amount of 100 μL to the cells. The cells were stimulated by culturing overnight in a 5% CO2 incubator at 37° C.
The signal intensities were detected using Dual-Luciferase Reporter Assay System (Promega). The medium supernatant in an amount of 100 μL was removed, 50 μL of Glo reagent was added, and the cells were lysed for 10 minutes at room temperature. The luminescence of Firefly luciferase emitted from the cell lysate solution was detected with a plate reader to quantify the activation of the HGF-Erk-SRE pathway. Subsequently, 50 μL of Glo & Stop reagent solution was added, and after 10 minutes, the luminescence of the internal standard Renilla luciferase was detected to quantify the number of cells. The signal activity of each sample was quantified as SRE activity=(Firefly luciferase luminescence intensity)/(Renilla luciferase luminescence intensity). The relative signal activity values for the samples without addition of the evaluation compound were determined and used as relative receptor activity.
As shown in
(44-1) Outline of Linker Variant Design
AET-VEGFR_D2-PAS16 has a structure in which a PAS linker composed of 16 amino acids is linked between the first VEGFR-binding sequence (P-3) and the second VEGFR-binding sequence (P-4). By changing the length of this PAS linker, it is expected that the VEGFR-binding activity will change. Therefore, a linker variant was designed in which the PAS linker portion was changed to a PAS repeat sequence of 49 amino acids or 100 amino acids.
In addition to the PAS linker, a GS linker, which is a repeating sequence of glycine and serin, is also known as a flexible linker. Therefore, the peptide sequence was designed to be a linker variant in which a VEGFR-binding cyclic peptide was bound to the N-terminus and C-terminus of the GS linker composed of a repeating sequence of 4 glycine residues and 1 serine residue (GGGGS), that is, a “first VEGFR-binding sequence (P-3)”-“GS linker”-“second VEGFR-binding sequence (P-4)”. That is, the C-terminus of P-3 and the N-terminus of the PAS linker are linked by an amide bond to the N-terminus of P-4 and the C-terminus of the PAS linker, respectively, and the peptide chain can be expressed as a single polypeptide chain.
(44-2) Preparation of VEGFR_D2-PAS Heterodimer Peptide Linker Variants
The prepared VEGFR_D2-PAS heterodimer peptide linker variants are as follows.
(44-3) Expression of VEGFR_D2-PAS Heterodimer Peptide Linker Variants
Corynex (registered trademark) was used to examine the expression of VEGFR_D2-PAS heterodimer peptide linker variants. Hereinafter, examples of expression examinations using Corynex (registered trademark) will be described.
(44-4) Construction of Each Secretory Expression Plasmid of AET-VEGFR_D2-PAS49, AET-VEGFR_D2-PAS49-b, AET-VEGFR_D2-PAS100, AET-VEGFR_D2-PAS100-b, and AET-VEGFR_D2-GS16 Using CspB Signal Sequence
As the VEGFR_D2-PAS heterodimer peptide linker variant, five types of amino acid sequences of the above (Q) AET-VEGFR_D2-PAS49 (which may be hereinafter referred to as “AET-VEGFR_D2-PAS49”, and may be simply referred to as “VEGFR_D2-PAS49”), (R) AET-VEGFR_D2-PAS49-b (which may be hereinafter referred to as “AET-VEGFR_D2-PAS49-b”, and may be simply referred to as “VEGFR_D2-PAS49-b”), (S) AET-VEGFR_D2-PAS100 (which may be hereinafter referred to as “AET-VEGFR_D2-PAS100”, and may be simply referred to as “VEGFR_D2-PAS100”), (T) AET-VEGFR_D2-PAS100-b (which may be hereinafter referred to as “AET-VEGFR_D2-PAS100-b”, and may be simply referred to as “VEGFR_D2-PAS100-b”), and (U) AET-VEGFR_D2-GS16 (which may be hereinafter referred to as “AET-VEGFR_D2-GS16”, and may be simply referred to as “VEGFR_D2-GS16”) were designed, and the base sequences encoding these proteins were designed in consideration of the codon usage frequency of C. glutamicum. Furthermore, the following expression cassettes were designed to enable secretory expression by C. glutamicum.
VEGFR_D2-PAS49 was secretory-expressed as a fusion protein of VEGFR_D2-PAS49 and a signal peptide 30 amino acid residue of CspB derived from C. glutamicum ATCC 13869 strain (hereinafter referred to as “CspBss-VEGFR_D2-PAS49”). The base sequence and amino acid sequence encoding the designed CspBss-VEGFR_D2-PAS49 are set forth in SEQ ID NOs: 180 and 181, respectively.
VEGFR_D2-PAS49-b was secretory-expressed as a fusion protein of VEGFR_D2-PAS49-b and a signal peptide 30 amino acid residue of CspB derived from C. glutamicum ATCC 13869 strain (hereinafter referred to as “CspBss-VEGFR_D2-PAS49-b”). The base sequence and amino acid sequence encoding the designed CspBss-VEGFR_D2-PAS49-b are set forth in SEQ ID NOs: 182 and 183, respectively.
VEGFR_D2-PAS100 was secretory-expressed as a fusion protein of VEGFR_D2-PAS100 and a signal peptide 30 amino acid residue of CspB derived from C. glutamicum ATCC 13869 strain (hereinafter referred to as “CspBss-VEGFR_D2-PAS100”). The base sequence and amino acid sequence encoding the designed CspBss-VEGFR_D2-PAS100 are set forth in SEQ ID NOs: 184 and 185, respectively.
VEGFR_D2-PAS100-b was secretory-expressed as a fusion protein of VEGFR_D2-PAS100-b and a signal peptide 30 amino acid residue of CspB derived from C. glutamicum ATCC 13869 strain (hereinafter referred to as “CspBss-VEGFR_D2-PAS100-b”). The base sequence and amino acid sequence encoding the designed CspBss-VEGFR_D2-PAS100-b are set forth in SEQ ID NOs: 186 and 187, respectively.
VEGFR_D2-GS16 was secretory-expressed as a fusion protein of VEGFR_D2-GS16 and a signal peptide 30 amino acid residue of CspB derived from C. glutamicum ATCC 13869 strain (hereinafter referred to as “CspBss-VEGFR_D2-GS16”). The base sequence and amino acid sequence encoding the designed CspBss-VEGFR_D2-GS16 are set forth in SEQ ID NOs: 188 and 189, respectively.
The promoter of the cspB gene derived from the C. glutamicum ATCC 13869 strain was linked upstream of the base sequences set forth in CspBss-VEGFR_D2-PAS49, CspBss-VEGFR_D2-PAS49-b, CspBss-VEGFR_D2-PAS100, CspBss-VEGFR_D2-PAS100-b, and CspBss-VEGFR_D2-GS16, and furthermore, an expression cassette of each VEGFR_D2-PAS heterodimer peptide linker variant having a KpnI site on the 5′-side and an BamHI site on the 3′-side was designed and totally synthesized. The totally synthesized DNA fragment (VEGFR_D2-PAS heterodimer peptide linker variant expression cassette) was inserted into the KpnI-BamHI site of pPK4 described in Japanese Patent Application Publication No. Hei 9-322774 to construct pPK4_CspBss-VEGFR_D2-PAS49, pPK4_CspBss-VEGFR_D2-PAS49-b, pPK4_CspBss-VEGFR_D2-PAS100, pPK4_CspBss-VEGFR_D2-PAS100-b, and pPK4_CspBss-VEGFR_D2-GS16, a secretory expression plasmid for each VEGFR_D2-PAS heterodimer peptide linker variant using the CspB signal sequence. As a result of determining the base sequence of the inserted fragment, it was confirmed that each VEGFR_D2-PAS heterodimer peptide linker variant expression cassette as designed had been constructed. Base sequences were determined using BigDye (registered trademark) Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) and 3500xL Genetic Analyzer (Applied Biosystems).
(44-5) Secretory Expression of Each VEGFR_D2-PAS Heterodimer Peptide Linker Variant in C. glutamicum
The pPK4_CspBss-VEGFR_D2-PAS49, pPK4_CspBss-VEGFR_D2-PAS49-b, pPK4_CspBss-VEGFR_D2-PAS100, pPK4_CspBss-VEGFR_D2-PAS100-b, and pPK4_CspBss-VEGFR_D2-GS16 constructed above were used to transform the C. glutamicum YDK0107 strain described in WO2016/171224 to obtain the YDK0107/pPK4_CspBss-VEGFR_D2-PAS49 strain, YDK0107/pPK4_CspBss-VEGFR_D2-PAS49-b strain, YDK0107/pPK4_CspBss-VEGFR_D2-PAS100 strain, YDK0107/pPK4_CspBss-VEGFR_D2-PAS100-b strain, and YDK0107/pPK4_CspBss-VEGFR_D2-GS16 strain.
The obtained transformants were each cultured in MMTG liquid medium containing 25 mg/L kanamycin (glucose at 120 g, magnesium sulfate heptahydrate at 3 g, ammonium sulfate at 30 g, potassium dihydrogen phosphate at 1.5 g, iron heptahydrate at 0.03 g, manganese sulfate pentahydrate at 0.03 g, thiamine hydrochloride at 0.45 mg, biotin at 0.45 mg, DL-methionine at 0.15 g, soybean hydrochloric acid hydrolyzate (total nitrogen amount at 0.2 g), calcium carbonate at 50 g, adjusted to pH 7.0 with 1 L of water) at 30° C. for 72 hours.
After completion of the culture, 6.5 μL of the culture supernatant obtained by centrifuging each culture solution was subjected to reduced SDS-PAGE using NuPAGE (registered trademark) 12% Bis-Tirs Gel (Thermo Fisher Scientific), and then stained with Quick-CBB (Wako). As a result, a protein band presumed to be VEGFR_D2-PAS49 was detected in the culture supernatant of the YDK0107/pPK4_CspBss-VEGFR_D2-PAS49 strain (
The cell filtrate with expressed VEGFR_D2-PAS heterodimer variant after culturing in Example 44 was subjected to cell filtration and then molecular weight measurement using LC-MS (Waters, ACQUITY UPLC/SQD2). The analysis conditions are shown in Table 5. As shown in
The VEGF inhibitory ability of the VEGFR_D2-PAS heterodimer peptide linker variant was evaluated by luciferase assay. 40,000 cell/well VEGFR/NFAT Reporter HEK293 cells (BPS Bioscience) were seeded and incubated overnight in a 5% CO2 incubator at 37° C. The cells were incubated overnight in Assay medium (MEM medium (Nacalai Tesque), 1×MEM Non-Essential Amino Acids Solution (Thermo Fisher Scientific), 1 mM Sodium Pyruvate (Nacalai Tesque), 1% Penicillin-Streptomycin (Sigma Aldrich), and 0.3% FBS (Thermo Fisher Scientific)) to starvation. To the Assay medium, 10 ng/mL human recombinant VEGF (R&D Systems) was added, and further, a culture supernatant containing VEGFR_D2-PAS16, VEGFR_D2-PAS49, or VEGFR_D2-PAS100 at a predetermined concentration was added, and 100 μL of the Assay medium was added to the cells. The cells were stimulated by culturing in a 5% CO2 incubator at 37° C. for 4 hours. Note that VEGFR_D2-PAS16 was obtained according to the method described in Example 27.
One-Glo Luciferase Assay System (Promega) was used to detect the signal intensity. Medium supernatant in an amount of 50 μL was removed, 50 μL of One-Glo reagent was added, and the cells were lysed for 10 minutes at room temperature. The luminescence emitted from the cell lysate solution was detected with a Nivo plate reader (Perkin Elmer) to quantify the activation of the VEGFR-NFAT pathway, and the relative signal activity value for the sample without addition of evaluation compound was determined and used as relative receptor activity.
The evaluation results are shown in
(47-1) Outline of Linker Variant Design
TPO2-PAS8, which has thrombopoietin-like activity, has a structure in which a PAS linker composed of 8 amino acids is linked between the first AF12285 peptide and the second AF12285 peptide. By changing the length of this PAS linker, it is expected that the thrombopoietin-like activity will change. Therefore, a linker variant was designed in which the PAS linker portion was changed to a PAS repeat sequence of 49 amino acids or 100 amino acids.
In addition to the PAS linker, a GS linker, which is a repeating sequence of glycine and serin, is also known as a flexible linker. Therefore, the peptide sequence was designed to be a linker variant in which EPO cyclic peptide was bound to the N-terminus and C-terminus of the GS linker composed of a repeating sequence of 4 glycine residues and 1 serine residue (GGGGS), that is, a “first AF12285 peptide”-“GS linker”-“first AF12285 peptide”.
(47-2) Preparation of TPO-PAS Dimer Peptide Linker Variant
The prepared TPO-PAS dimer peptide linker variants are as follows.
(47-3) Expression of TPO-PAS Dimer Peptide Linker Variants
Corynex (registered trademark) was used to examine the expression of these TPO-PAS dimer peptide linker variants. Hereinafter, examples of expression examinations using Corynex (registered trademark) will be described.
(47-4) Construction of Each Secretory Expression Plasmid of TPO2-PAS49, TPO2-PAS49-b, TPO2-PAS100, TPO2-PAS100-b, and TPO2-GS8 Using CspA Signal Sequence.
As the TPO-PAS dimer peptide linker variant, five types of amino acid sequences of the above (V) TPO2-PAS49 (which may be hereinafter referred to as “TPO2-PAS49”), (W) TPO2-PAS49-b (which may be hereinafter referred to as “TPO2-PAS49-b”), (X) TPO2-PAS100 (which may be hereinafter referred to as “TPO2-PAS100”), (Y) TPO2-PAS100-b (which may be hereinafter referred to as “TPO2-PAS100-b”), and (Z) TPO2-GS8 (which may be hereinafter referred to as “TPO2-GS8”) were designed, and the base sequences encoding these proteins were designed in consideration of the codon usage frequency of C. glutamicum. Furthermore, the following expression cassettes were designed to enable secretory expression by C. glutamicum.
TPO2-PAS49 was secretory-expressed as a fusion protein of TPO2-PAS49 and a signal peptide 25 amino acid residue of CspA derived from C. ammoniagenes ATCC 6872 strain (hereinafter referred to as “CspAss-TPO2-PAS49”). The base sequence and amino acid sequence encoding the designed CspAss-TPO2-PAS49 are set forth in SEQ ID NOs: 195 and 196, respectively.
TPO2-PAS49-b was secretory-expressed as a fusion protein of TPO2-PAS49-b and a signal peptide 25 amino acid residue of CspA derived from C. ammoniagenes ATCC 6872 strain (hereinafter referred to as “CspAss-TPO2-PAS49-b”). The base sequence and amino acid sequence encoding the designed CspAss-TPO2-PAS49-b are set forth in SEQ ID NOs: 197 and 198, respectively.
TPO2-PAS100 was secretory-expressed as a fusion protein of TPO2-PAS100 and a signal peptide 25 amino acid residue of CspA derived from C. ammoniagenes ATCC 6872 strain (hereinafter referred to as “CspAss-TPO2-PAS100”). The base sequence and amino acid sequence encoding the designed CspAss-TPO2-PAS100 are set forth in SEQ ID NOs: 199 and 200, respectively.
TPO2-PAS100-b was secretory-expressed as a fusion protein of TPO2-PAS100-b and a signal peptide 25 amino acid residue of CspA derived from C. ammoniagenes ATCC 6872 strain (hereinafter referred to as “CspAss-TPO2-PAS100-b”). The base sequence and amino acid sequence encoding the designed CspAss-TPO2-PAS100-b are set forth in SEQ ID NOs: 201 and 202, respectively.
TPO2-GS8 was secretory-expressed as a fusion protein of TPO2-GS8 and a signal peptide 25 amino acid residue of CspA derived from C. ammoniagenes ATCC 6872 strain (hereinafter referred to as “CspAss-TPO2-GS8”). The base sequence and amino acid sequence encoding the designed CspAss-TPO2-GS8 are set forth in SEQ ID NOs: 203 and 204, respectively.
The promoter of the cspB gene derived from the C. glutamicum ATCC 13869 strain was linked upstream of the base sequences set forth in CspAss-TPO2-PAS49, CspAss-TPO2-PAS49-b, CspAss-TPO2-PAS100, CspAss-TPO2-PAS100-b, and CspAss-TPO2-GS8, and furthermore, an expression cassette of each TPO-PAS dimer peptide linker variant having a KpnI site on the 5′-side and an BamHI site on the 3′-side was designed and totally synthesized. The totally synthesized DNA fragment (TPO-PAS dimer peptide linker variant expression cassette) was inserted into the KpnI-BamHI site of pPK4 described in Japanese Patent Application Publication No. Hei 9-322774 to construct pPK4_CspAss-TPO2-PAS49, pPK4_CspAss-TPO2-PAS49-b, pPK4_CspAss-TPO2-PAS100, pPK4_CspAss-TPO2-PAS100-b, and pPK4_CspAss-TPO2-GS8, a secretory expression plasmid for each TPO-PAS dimer peptide linker variant using the CspA signal sequence. As a result of determining the base sequence of the inserted fragment, it was confirmed that each TPO-PAS dimer peptide linker variant expression cassette as designed had been constructed. Base sequences were determined using BigDye (registered trademark) Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) and 3500xL Genetic Analyzer (Applied Biosystems).
(47-5) Secretory Expression of Each TPO-PAS Dimer Peptide Linker Variant in C. glutamicum
The pPK4_CspAss-TPO2-PAS49, pPK4_CspAss-TPO2-PAS49-b, pPK4_CspAss-TPO2-PAS100, pPK4_CspAss-TPO2-PAS100-b, and pPK4_CspAss-TPO2-GS8 constructed above were used to transform the C. glutamicum YDK0107 strain described in WO2016/171224 to obtain the YDK0107/pPK4_CspAss-TPO2-PAS49 strain, YDK0107/pPK4_CspAss-TPO2-PAS49-b strain, YDK0107/pPK4_CspAss-TPO2-PAS100 strain, YDK0107/pPK4_CspAss-TPO2-PAS100-b strain, and YDK0107/pPK4_CspAss-TPO2-GS8 strain.
The obtained transformants were each cultured in MMTG liquid medium containing 25 mg/L kanamycin (glucose at 120 g, magnesium sulfate heptahydrate at 3 g, ammonium sulfate at 30 g, potassium dihydrogen phosphate at 1.5 g, iron heptahydrate at 0.03 g, manganese sulfate pentahydrate at 0.03 g, thiamine hydrochloride at 0.45 mg, biotin at 0.45 mg, DL-methionine at 0.15 g, soybean hydrochloric acid hydrolyzate (total nitrogen amount at 0.2 g), calcium carbonate at 50 g, adjusted to pH 7.0 with 1 L of water) at 30° C. for 72 hours.
After completion of the culture, 6.5 μL of the culture supernatant obtained by centrifuging each culture solution was subjected to reduced SDS-PAGE using NuPAGE (registered trademark) 12% Bis-Tirs Gel (Thermo Fisher Scientific), and then stained with Quick-CBB (Wako). As a result, a protein band presumed to be TPO2-PAS49 was detected in the culture supernatant of the YDK0107/pPK4_CspAss-TPO2-PAS49 strain (
The cell filtrate of the TPO-PAS dimer peptide linker variant after culturing in Example 47 was subjected to molecular weight measurement using LC-MS (Waters, ACQUITY UPLC/SQD2). The analysis conditions are shown in Table 2. As shown in
The thrombopoietin-like activity of the TPO-PAS dimer peptide variant was evaluated by quantification of CREB phosphorylation levels in HEL cells, a human leukemia-derived blood cell line. 200,000 HEL cells were cultured in RPMI 1640 medium without FBS (Thermo Fisher Scientific) for 24 hours and starved. The cells were stimulated for 20 minutes in RPMI 1640 medium supplemented with 100 ng/mL recombinant human TPO (rhTPO, Peprotech) or a culture supernatant containing each dimer peptide of TPO2-PAS8, TPO2-PAS49, TPO2-PAS100, or TPO2-GS8 diluted to a final concentration of 20-40 ng/mL. As a negative control, PBS was added, and stimulation was performed for 20 minutes (Mock group). After removing the medium and washing the cells once with PBS, the cells were lysed by adding 100 μL of Lysis buffer 17 (R&D Systems) supplemented with Protease inhibitor cocktail (Nacalai Tesque). The lysate solution was centrifuged at 14,000 G for 5 minutes to obtain the supernatant as lysate. Note that TPO2-PAS8 was obtained according to the method described in Example 23.
Phospho-CREB (Ser133) and Total CREB ELISA kit (RayBio) were used to quantify phosphorylated CREB (pCREB) levels in the lysates. Each lysate was diluted 25-fold with Assay Diluent, and 100 μL each was added to CREB Pan CREB Microplate, and shaken overnight at 4° C. After washing the Microplate 3 times with a washing buffer, 100 μL of Phospho Detection Antibody CREB (Ser133) was added, and the mixture was allowed to stand at 37° C. for 30 minutes for an antigen-antibody reaction. Furthermore, after washing the Microplate 3 times with a washing buffer, 100 μL of 100 μL anti-rabbit antibody HRP conjugate was added, and the mixture was allowed to stand at 37° C. for 30 minutes for an antigen-antibody reaction. After further washing the Microplate 3 times with a washing buffer, 100 μL of TMB solution was added, and a color reaction was carried out at room temperature for 30 minutes. Phosphorylation levels were quantified by adding 50 μL of Stop solution and measuring the absorbance at a wavelength of 450 nm on a microplate.
| Number | Date | Country | Kind |
|---|---|---|---|
| 2019-221040 | Dec 2019 | JP | national |
This application is a Continuation of, and claims priority under 35 U.S.C. § 120 to, International Application No. PCT/JP2020/045327, filed Dec. 4, 2020, and claims priority therethrough under 35 U.S.C. § 119 to Japanese Patent Application No. 2019-221040, filed Dec. 6, 2019, the entireties of which are incorporated by reference herein. Also, the Sequence Listing filed electronically herewith is hereby incorporated by reference (File name: 2022-06-03T_US-641_Seq_List; File size: 175 KB; Date recorded: Jun. 3, 2022).
| Number | Date | Country | |
|---|---|---|---|
| Parent | PCT/JP2020/045327 | Dec 2020 | US |
| Child | 17831877 | US |
